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HbA1c 
 
History of HbA1c 
Since the major medical achievement of discovering insulin in the 1920’s, 
diabetes mellitus (DM) has become a chronic disease with its well-known 
long-term complications. Glycemic control could initially only be 
estimated by measuring glucosuria and by asking the patient for symptoms 
suggestive of hyperglycemia. These assessments were very inaccurate and 
the achieved glycemic control therefore often far from optimal. The 
assessment of glycemic control was only marginally improved with 
laboratory measurements of (random) blood glucose levels. 
 
In the late 1960s, an unusual component of human hemoglobin A (HbA) 
was noted to be increased in patients with DM1 and in the 1970s, this same 
Hemoglobin A1c (HbA1c) was shown to decrease as glycemic control 
improved, and the potential of HbA1c as a clinical and research tool was 
recognized.2 
 
Clinical utility of HbA1c 
In 1993 the Diabetes Complications and Control Trial (DCCT) 
demonstrated the close relationship between HbA1c and the occurrence of 
diabetic complications in patients with type 1 diabetes mellitus (T1DM).3 
With this trial the role of HbA1c in the management of DM was firmly 
established. The United Kingdom Prospective Diabetes Study (UKPDS) 
confirmed that this relationship also existed in patients with type 2 
diabetes (T2DM).4,5 The HbA1c measurement is now the standard tool to 
monitor longer term glycemic control in patients with DM. More recently, 
the measurement of HbA1c level was proposed as a potential tool to 
diagnose DM (see also below).6 
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Chemistry of Glycated Hemoglobin and HbA1c   
 
About 40 % of the human blood consists of erythrocytes. The major 
function of erythrocytes is to transport hemoglobin, which in turn carries 
oxygen from the lungs to the tissues. Normal adult hemoglobin is an 
associated tetramer in which each of the alfa chain (α-chain) and non-alfa 
(β-, γ- and δ-chains) globin’s is bound to a heme (Fig. 1).  
 
Hemoglobin in a healthy person consists predominantly of HbA (adult 
hemoglobin, 97% of the total, α2β2), HbA2 (normal variant of 
hemoglobin, 2.5 %, α2δ2) and HbF (fetal hemoglobin, 0.5%, α2γ2) (Fig 
2).  
 
About 6% of total HbA is termed HbA1 (HbA to which sugar bind). In 
1958, Allen et al. reported that with cation-exchange chromatography 
human hemoglobin could be separated into at least three minor 
components that had more negative charges than HbA1.  
 
These minor hemoglobins, or also called “fast hemoglobins” (because they 
migrate more rapidly than HbA in an electrical field), were all named 
HbA1, which in turn is made up of HbA1a, HbA1b and HbA1c. (Fig 2) 
HbA1c is the major fraction, constituting approximately 80% of HbA1.7  
 
These fractions are defined by their electrophoretic and chromatographic 
properties, which differ slightly from those of the major component HbA0, 
despite the amino acid sequences of HbA1 and HbA0 being identical. 
HbA1c is the most abundant of these fractions and in health comprises 
approximately 5% of the total HbA fraction.  
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Figure 1: A molecule of hemoglobin is composed of 4 amino acid chains 
(proteins): 2 α-chains (red) and 2 β-chains (blue). Each chain also has an 
iron-containing heme group (green). Glucose will bond to certain 
positively charged chemical groups on the hemoglobin. HbA1c is defined 
as hemoglobin with glucose bound at the beginning (N-terminal) of the β-
chain. The total glycated hemoglobin will include HbA1c plus all the other 
hemoglobins that have glucose bound to lysine side chains and/or the N-
terminal of the α-chain. Generally about half of the glucose is bound to the 
HbA1c position with the other half bound at 3 or 4 other sites (lysines). 
Hemoglobin image courtesy of Wikimedia Commons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Human Hemoglobin consists predominantly of HbA, HbA2 and 
HbF. 
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Glycated hemoglobin (GHb) is derived from the nonenzymatic addition of 
glucose to valine and lysine residues on the α- and β-beta chains of the 
hemoglobin molecule. Structural and chemical investigations elucidated 
that glucose, in the open chain format, binds to the N‐terminal to form an 
aldimine (Schiff base) before undergoing an Amadori rearrangement to 
form a more stable ketoamine (Fig 3). This is a post-translational and non‐
enzymatic process that occurs continuously during the 120-day life span of 
the erythrocyte.8 
 
 
Figure 3. Formation of glycated hemoglobin A1c (HbA1c). HbA1c is an 
Amadori product and is formed through the intermediate Schiff base 
step.10 
 
Hemoglobin sub fractions, formed by glycation of α- and β-chains in HbA, 
are collectively named the glycohemoglobins. HbA1c is a specific GHb 
that results from the attachment of glucose to the N-terminal valine of the 
hemoglobin β-chain. Total GHb includes all glycated fractions, comprising 
HbA1c as well as hemoglobin glycated at sites other than the N-terminus of 
the β-chain (e.g., epsilon amino groups on lysine residues). The actual 
extent of glycation and the relative involvement of the α- and β-chains still 
remain unclear.9 The value of total GHb is due to inclusion of all glycated 
sites approximately 50% higher than that of HbA1c alone. 
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A broad range of assay methods has being developed since HbA1c was 
described in the late 1960’s. Two main difficulties regarding the accurate 
measurement of HbA1c are the large number of variant hemoglobins and 
glycohemoglobins, and the fact that HbA1c is not a stand-alone analyte 
because its quantity is related to the total hemoglobin concentration. As a 
result of this latter, HbA1c should be expressed as a ratio, i.e. HbA1c/total 
hemoglobin, and this dual measurement causes dual uncertainty in the 
outcome of the test.  
 
As the measurement of  glycated HbA1c is expressed as percentage of total 
HbA, even small deviations in the measurement may lead to a large 
change in this percentage. Depending on the measurement method used, 
the concentration of HbA1c is approximately 4–6% in healthy individuals 
without diabetes. 
 
In vitro and in vivo studies have demonstrated that the cumulative amount 
of HbA1c in an erythrocyte is directly proportional to the time-averaged 
concentration of glucose within the erythrocyte.8,11-13 Given this 
relationship, it stands to reason that brief periods of high blood glucose are 
unlikely to have a significant impact on hemoglobin glycation. 
 
The concentration of HbA1c depends on both the concentration of glucose 
in the blood and the lifespan of the erythrocyte. Because erythrocytes are 
in the circulation for approximately 4 months, HbA1c represents the 
integrated glucose concentration over the preceding 2 to 3 months.	  
 
Tahara et al. analyzed the relationship between HbA1c and the preceding 
plasma glucose levels.14 They showed that the rate of contribution of the 
preceding plasma glucose level to HbA1c depends on their time interval. In 
other words, the HbA1c level should be considered to reflect the weighted 
mean plasma glucose level in the preceding period. Their results showed 
that 50% of the HbA1c was determined by the plasma glucose level during 
the preceding 1-month period, while 25% of its level was determined by 
the plasma glucose level during the 1-month period before this month, and 
the remaining 25% was determined by the plasma glucose level during the 
2-month period before these 2 months. Thus, HbA1c levels reflect the 
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weighted mean plasma glucose level over the preceding 4 months, with 
more recent values providing a larger contribution than earlier values. 
 
Measurement methods for Glycated Hemoglobin  
Currently there are more than 15 different methods for measuring GHb. 
These methods measure GHb based on its physical, chemical, or antibody 
recognized characteristics. At the end of the DCCT in 1993, these methods 
measured either HbA1c, HbA1 (HbA1a + HbA1b + HbA1c), or total GHb. 
The different GHb assays available to the routine clinical laboratory can be 
divided into two major categories: those based on charge differences 
between GHb and non-GHb (cation-exchange chromatography, 
electrophoresis, and isoelectric focusing) and those based on structural 
characteristics of glycol-groups on hemoglobin (affinity chromatography 
and immunoassay).15-17 (Table 1) The advantages and disadvantages of 
various HbA1c assay methods are summarised in Table 2. 
 
Table 1: Assay methods for glycated hemoglobin and serum proteins 
 
Methods based on charge difference 
 Cation-exchange chromography 
 High Performance Liquid Chromatography  
 Isoelectric focusing 
 Agar gel electrophoresis 
Methods based on structural characteristics 
 Affinity chromatography 
 Immunoassay-based methods for HbA1c 
Methods measuring total GHb 
 Weak-acid hydrolysis 
 Affinity chromatography 
Assays for glycated serum proteins 
 Fructosamine assay 
 Affinity chromatography  
 
Most methods quantify HbA1c, defined as HbA with glucose attached to 
the NH2-terminal valine of one or both β–chains. Other methods (boronate 
affinity) quantify “total glycated hemoglobin,” which includes both HbA1c 
and other GHb adducts (e.g., glucose-lysine adducts and glucose β-chain 
NH2-terminal valine adducts). 
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The results of these different assays show excellent correlations and there 
are no convincing data to show that any one method or analyte is clinically 
superior to the other. However, the reported GHb results from the same 
blood sample could differ considerably among methods unless they are 
standardized to a common reference. Indeed, without standardization, the 
same blood sample could be read as 7% in one laboratory and 9% in 
another. 
 
In 1996, the National Glycohemoglobin Standardization Program (NGSP) 
was initiated to standardize GHb test results among laboratories to DCCT-
equivalent values. The rationale for standardizing GHb test results to 
DCCT aligned values was to provide comparability between laboratories 
and to align the data to the DCCT that had determined the relationship 
between HbA1c and long-term outcome risks in patients with DM.3,18 
 
The NGSP Laboratory Network includes a variety of assay methods, each 
calibrated to the DCCT reference. The DCCT reference is a HPLC cation-
exchange method that quantifies HbA1c and is a National Committee for 
Clinical Laboratory Standards (NCCLS)-designed comparison method. 
The assay method has been used since 1978 and has demonstrated good 
long-term precision (between-run coefficient of variation (CVs) 
consistently < 3%) The laboratories in the network interact with 
manufacturers of GHb methods to assist them first in calibrating their 
methods and then in providing comparison data for certification of 
traceability to the DCCT. Certification is valid for one year. 
(www.ngsp.org) 
 
Interferences from hemoglobin variants and adducts are summarized by 
Bry et al.19 and on the NGSP Web site at www.ngsp.org.19-22 Laboratories 
should use GHb assay methods with an inter-assay CV of < 4% (ideally < 
3%) and determine its own reference interval following NCCLS 
guidelines. Each method has certain advantages and disadvantages (Table 
2) for the clinical laboratory, and choosing a method can be difficult; none 
should be considered the “best” method. Laboratories have the 
responsibility to provide clinicians with information about their assay 
method. Such information should include the following: type of assay 
method, reference values, potential assay interferences, and assay 
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performance (e.g., some measure of assay imprecision, such as CV). 
Guidelines and recommendations for laboratory analysis in the diagnosis 
and management for DM are published elsewhere.9  
 
Table 2 Advantages and disadvantages of various HbA1c assay methods 
 
Method Advantages Disadvantages 
 
Ion 
Exchange 
Chromato 
graphy  
 
 
HbA1c has lower isoelectric point 
and migrates faster than other Hb 
components.  
 
Can inspect chromograms for Hb 
variants. 
 
Measurements with great 
precision.  
 
Variable interference 
from Hb-pathies, HbF 
and carbamylated Hb but 
the current ion exchange 
assays correct for HbF 
and carbamylated Hb 
does not interfere. 
Boronate  
Affinity  
 
Glucose binds to m-
aminophenylboronic acid.  
 
Minimal interference from Hb-
pathies, HbF and carbamylated 
Hb.  
Measures not only 
glycation of N- terminal 
valine on β-chain, but 
also β-chains glycated at 
other sites and glycated 
α-chains. 
Immuno 
assays  
Antibody binds to glucose and 
between 4- 10 N-terminal amino 
acids on β-chain.  
 
Not affected by HbE, HbD or 
carbamylated Hb. 
 
Relatively easy to implement 
under many different formats.  
May be affected by 
Hb-pathies with 
altered amino acids 
on binding sites.  
 
Some interference 
with HbF. 
 
Conditions that interfere with the measurement of HbA1c 
Hemoglobinopathies are well known conditions that can interfere with 
HbA1c measurement.20,23 Because the HbA1c test assumes a normal 
erythrocyte life span and Hb binding kinetics with glucose, 
hemoglobinopathies can affect the reliability of the test in different ways, 
including:  
1) altering the normal process of glycation of HbA to HbA1c 
2) an abnormal chromatography peak makes the measurement of HbA1c 
unreliable, and 
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3) red blood cells are more prone to hemolysis, thereby decreasing the 
time for glycosylation to occur and producing a falsely low HbA1c result.24 
 
Therefore, as an example HbAS can interfere with the HbA1c measurement 
in different directions. As stated above, several laboratory methods are 
available for HbA1c measurement. Depending on which laboratory method 
is used, the HbA1c value of a person with HbAS may be either falsely high 
or falsely low.23 The NGSP provides a table on its website 
(www.ngsp.org), describing the effects of frequently encountered Hb 
variants and derivatives on GHb measurement for more than 20 assay 
methods. Each laboratory method for HbA1c determination is based on the 
physical, chemical, or antibody-recognized properties of the normal (HbA) 
hemoglobin molecule.19 Individuals with HbAS have approximately half 
normal (HbA) and half sickle cell (HbS) hemoglobin, with each type 
contributing to GHb contents of any one erythrocyte.25 The abnormal 
hemoglobin also make erythrocytes more vulnerable to hemolysis, thereby 
decreasing erythrocyte lifespan and the time available for glycosylation to 
occur.26  
 
Health care providers should not use the HbA1c test for patients with a 
disease condition such as HbSS, HbCC, or HbSC. Even if an assay does 
not interfere with their variant, these patients may suffer from anemia, 
increased erythrocyte turnover, and transfusion requirements, which can 
adversely affect HbA1c as a marker of long-term glycemic control. 
 
But also conditions that influence erythrocyte lifespan and turnover as 
evidenced by reticulocytosis, hemolytic anemia, treatment of iron 
deficiency anemia, acute or chronic blood loss and or transfusions, chronic 
renal or liver disease, high dose vitamin C or erythropoietin treatment can 
falsely lower the HbA1c test result. During pregnancy enhanced 
erythropoiesis and hemodilution result in apparently lower HbA1c levels. 
Table 3 A summarizes conditions affecting HbA1c levels. Table 3 B show 
the mechanisms leading to altered HbA1c levels.  
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Table 3 A: Summary of conditions affecting HbA1c levels  
• Increased measured levels 
o Negatively charged hemoglobin variants 
o Uremia (carbamylation of Hb) 
o Alcoholism 
o Lead Poisoning 
o Elevated triglycerides 
o Iron deficiency anemia 
o Post-splenectomy 
o Hyperbilirubinemia 
o Opiate addiction 
o Chronic aspirin therapy 
• Decreased measured levels 
o Positively charged hemoglobin variants 
o Hemolytic anemia’s 
o Treatment of iron deficiency anemia 
o Treatment with erythropoietin 
o High dose Vitamin C 
o Acute or chronic blood loss 
o Pregnancy 
 
 
HbA1c and Mean Blood Glucose relationship 
The relationship between HbA1c and glycemia has been explored in 
several studies. These support the use of HbA1c as a measure of average 
glucose levels over the preceding 2 to 3 months.2,28-34 More recently the 
suggestion was made to express HbA1c as a mean blood glucose (MBG) 
equivalent, representing average glycemia. This would allow patients to 
equate the test to their own self-monitored blood glucose (SMBG) 
records35,36 As a result, both HbA1c and blood glucose targets are now used 
in routine management of patients with T1DM and T2DM.37  
 
New measurement method; IFCC-HbA1c  
Until recently the HbA1c assay failed to have a gold standard reference 
value. Therefore, it was very important to develop and further validate the 
HbA1c measurement method and to standardize this method worldwide. 
The NGSP created a primarily US focused standardization method to 
ensure cross-lab comparability. The different assays had a wide range of 
reference values making it difficult to compare the values between clinics 
and laboratories. The International Federation of Clinical Chemistry 
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(IFCC) Working Group on HbA1c Standardization developed a new 
reference method, that is very accurate and specific, but labor and resource 
intensive.38 This reference method is now the anchor for the HbA1c assay. 
 
Table 3 B Mechanisms leading to altered HbA1c levels* (Gallagher et al27) 
1. Erythropoiesis 
Increased HbA1c: iron - vitamin B12 deficiency, decreased erythropoiesis. 
Decreased HbA1c: administration of erythropoietin, iron, vitamin B12, 
reticulocytosis, chronic liver disease. 
2. Altered Hemoglobin 
Genetic or chemical alterations in Hb: Hb-pathies, HbF, methemoglobin, 
may increase or decrease HbA1c. 
3. Glycation 
Increased HbA1c: alcoholism, chronic renal failure, decreased intra- 
erythrocyte pH. 
Decreased HbA1c: aspirin, vitamin C/E, certain Hb-pathies, increased 
intra-erythrocyte pH. 
Variable HbA1c: genetic determinants. 
4. Erythrocyte destruction 
Increased HbA1c: increased erythrocyte life span: splenectomy. 
Decreased A1c: decreased erythrocyte life span: Hb-pathies, splenomegaly, 
rheumatoid arthritis or drugs (antiretroviral, ribavirin and dapsone). 
5. Assays 
Increased HbA1c: hyperbilirubinemia, carbamylated Hb, alcoholism, large 
doses of aspirin, chronic opiate use. 
Decreased HbA1c: hypertriglyceridemia. 
Variable HbA1c: hemoglobinopathies.  
* Some of the above interfering factors are “invisible” in certain of the available 
assays. 
 
Development of IFCC-HbA1c measurement method 
The IFCC reference method has three steps. In the first step, Hb from 
washed and lysed erythrocytes is cleaved into peptides by the proteolytic 
enzyme endoproteinase Guc-C. The resulting glycated and non-glycated 
N-terminal hexapeptides of the β-chain are then separated from the crude 
peptide mixture by reverse-phase High Performance Liquid 
Chromatography (HPLC). In the third and final step, the glycated and 
nonglycated hexapeptides are quantified by mass spectrometry or by 
capillary electrophoresis with ultraviolet detection. The percentage of 
HbA1c is determined by the ratio of glycated to non glycated β-N-terminal 
hexapeptides of Hb (HbA1c IFCC units in mmol HbA per mol Hb).38 
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The analytical performance of the reference method has been evaluated by 
an international network of reference laboratories comprising laboratories 
from Europe, Japan and the USA. Due to the higher specificity of the 
reference method, relative to the DCCT standardized values, the values in 
the diabetic range would be 1 to 2 % lower than those generated with the 
current reference DCCT method. The new IFCC-HbA1c reference values 
for non–diabetic patients will be 1.3 to 1.5 % lower than the NGSP values. 
The normal range would thus be approximately 2.5 to 4.7% rather than the 
present 4 to 6%. The new reference method has been approved by the 
member societies of the IFCC and Laboratory Medicine and is the anchor 
for standardization of HbA1c routine assays worldwide.36 
 
Even though some countries report HbA1c in IFCC numbers and units 
(mmol/mol) and others, including the U.S., will continue to report in 
NGSP/DCCT numbers and units (%), there is an established linear 
relationship between them allowing conversion from one to the other using 
a published master equation: 
 
NGSP DCCT-HbA1c (%) = (0.0915 x IFCC-HbA1c (mmol/mol)) + 2.15  
IFCC-HbA1c (mmol/mol) = [10.93 x DCCT-HbA1c (%)] – 23.5   
 
 
Introduction of the IFCC-HbA1c 
Several scenarios and ways to express the new values have been 
considered. Changing the HbA1c reference range could cause confusion for 
health-care professionals and patients, given the decades-long effort to 
educate people about the importance of measuring HbA1c and the goal of 
maintaining HbA1c at less than 7%. As the reference values, expressed, as 
percentage glycated Hb, are lower than those currently used, the 
introduction of this new method, could affect glycemic control in patients 
and therefore its introduction should be carefully planned and 
communicated. This was demonstrated in a Swedish study. When Sweden 
changed their HbA1c method to an assay with a lower reference range 
glycemic control worsened temporarily in patients with T1DM in the 
subsequent 3 years.39 The likely explanation is that patients need to get 
used to and feel comfortable with new numerical target values, in 
particular when these values are lower. 
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There is another, potential controversy that may arise from altering HbA1c 
measurement methods, especially if HbA1c should be used for diagnostic 
purposes. Indeed, now that DM is on the political agenda, being a 
pandemic disease imposing considerable burden on societies and 
individuals, altering diagnostic criteria may confuse policy makers and 
interfere with negotiations of organisations such as WHO and 
International Diabetes Federation (IDF) to allocate resources. 
 
Another cause for confusion is the similarity of the numbers in countries 
using SI units. HbA1c is expressed as a percentage of glycated hemoglobin, 
while the day-to-day monitoring of glycemic control is based on glucose 
levels expressed as mmol/L or mg/dL. This is problematic, especially 
when the numbers are similar (when glucose is measured in mmol/l). 
Therefore reporting overall glycemic control and long-term management 
goals as estimated average glucose (eAG), i.e. in the same units as plasma 
glucose, would eliminate these potential sources of confusion. 
 
Use of HbA1c in the diagnosis of Diabetes Mellitus 
Recently, an international expert committee6 recommended using HbA1c 
also as indicator for the diagnosis of diabetes. This committee, with 
members appointed by the American Diabetes Association (ADA), the 
European Association of the study of Diabetes (EASD), and the IDF, 
pointed out that HbA1c: is better standardized compared to glucose 
measurements; is a better index of overall glycemic exposure and risk for 
long-term complications; has substantially less biologic variability and 
pre-analytic instability; needs no fasting or timed samples; is relatively 
unaffected by acute (e.g. stress or illness related) perturbations in glucose 
levels; and is already used to guide management and adjust therapy. But, 
they also recognize the limitations of HbA1c as the recommended means of 
diagnosing diabetes, e.g. higher costs of the assay compared to glucose 
measurements, the inference of some hemoglobin traits (such as HbS, HbC 
and HbF) with some HbA1c assay methods, the influence of any condition 
that changes red cell turnover (such a hemolytic anemia and chronic 
malaria) on HbA1c levels and the effect of age and ethnicity on HbA1c 
levels. Despite these limitations, the committee stated that the ultimate 
goal of identifying individuals at risk for diabetes complications would be 
accomplished with an HbA1c diagnostic level of 6.5%. 
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Diagnosis should be confirmed with a repeat HbA1c test, unless clinical 
symptoms and plasma glucose levels ≥ 11.1mmol/l (200 mg/dl) are present 
in which case further testing is not required. Levels of HbA1c just below 
6.5% may indicate the presence of intermediate hyperglycemia. The 
precise lower cut-off point for this has yet to be defined, although the 
ADA has suggested 5.7 – 6.4% as the high risk range.40  
 
While recognizing the continuum of risk that may be captured by the 
HbA1c assay, the International Expert Committee recommended that 
persons with an HbA1c level between 6.0 and 6.5% were at particularly 
high risk and might be considered for diabetes prevention interventions. 
 
The diagnosis of DM in an asymptomatic person should not be made on 
the basis of a single abnormal plasma glucose or HbA1c value. At least one 
additional HbA1c or plasma glucose test result with a value in the diabetic 
range is required, either fasting, from a random (casual) sample, or from 
the oral glucose tolerance test (OGTT). The diagnosis should be made by 
the best technology available, avoiding blood glucose monitoring meters 
and single-use HbA1c test kits (except where this is the only option 
available or where there is a stringent quality assurance program in place). 
 
It is advisable to use one test or the other but if both glucose and HbA1c are 
measured and both are “diagnostic” then the diagnosis is made. If only one 
is abnormal then a second test, using the same method, is required to 
confirm the diagnosis. 
 
More and more asymptomatic subjects are being detected as a result of 
screening programs so that diagnostic certainty is paramount. If such tests 
fail to confirm the diagnosis of diabetes, it will usually be advisable to 
maintain surveillance with periodic re–testing until the glycemic status 
becomes clear.  
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Background of the present thesis 
 
Until recently the HbA1c assay failed to have a gold standard reference 
value. After the development of the new very accurate and specific IFCC-
HbA1c reference measurement method, which is now the anchor for the 
HbA1c assay worldwide, the introduction of this test with the new 
reference values became very important. An international trial, the A1c 
Derived Average Glucose study (ADAG) was performed, which formed 
the basis of this PhD project and is described in Chapter 2. The ADAG 
study was commenced to gain a better understanding of the relationship 
between HbA1c and average blood glucose and to investigate whether 
HbA1c could be expressed as eAG. Older studies examining this 
relationship have been limited, including relatively small homogeneous 
cohorts of patients, usually with T1DM.2,28-32 Moreover, almost all of the 
prior studies have relied on infrequent measures of capillary glucose 
levels, calling into question the validity of their assessment of chronic 
glycemia.	  	  
 
While awaiting the ADAG study results a consensus statement of the 
IFCC, IDF, EASD and ADA regarding the worldwide standardization of 
the HbA1c was made.41 HbA1c results should be standardized worldwide, 
and the IFCC reference system for HbA1c represents the only valid anchor 
to implement standardization of the measurement. The premises of the 
ADAG study were that if its results would fulfill the a priori specified 
criteria, the HbA1c assay results will be reported worldwide in the near 
future in IFCC units (mmol HbA/mol Hb) and derived NGSP units (%), 
using the IFCC-NGSP master equation. Also an estimated average plasma 
glucose (eAG) value will be reported as an interpretation of the HbA1c 
result and all clinical guidelines should be expressed in the respective 
units.41  
 
HbA1c measurement methods used in the ADAG study 
Owing to the impact of the outcome of the ADAG study it was very 
important to determine HbA1c values with a minimum of uncertainty and 
as close as possible to the IFCC primary reference method, which is the 
only valid anchor of HbA1c standardization. The HbA1c results used in the 
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ADAG study, approximately 2300 samples were analyzed and determined 
with the lowest uncertainty technically feasible by using four certified 
IFCC secondary reference methods and additional off-line calibration with 
IFCC secondary reference material. 
 
Factors that may affect the relationship between HbA1c 
and MBG 
It is not clear if factors like diabetes type, gender, smoking, ethnicity and 
age influence the relationship between HbA1c and MBG. In the ADAG 
study we analysed these factors and we describe the results in Chapter 2.  
 
 
Glucose Variability  
 
Patients with similar mean glucose or HbA1c values can have markedly 
different daily glucose profiles, with differences both in number and 
duration of glucose excursions. Hyperglycemia is thought to induce 
oxidative stress and interfere with normal endothelial function by 
overproduction of reactive oxygen species, which results in diabetic 
complications through several molecular mechanisms.42,43 In addition, 
glucose variability (GV) might contribute to these processes as well.  
 
Since the publication of the results of the DCCT in the early 1990’s3,18 the 
topic of GV as a contributor to diabetic complications has been debated. It 
was suggested that GV might explain the difference in micro vascular 
outcome between the intensively and conventionally treated T1DM with 
the same mean HbA1c throughout the trial.44 Although this hypothesis was 
refuted recently by the statisticians of the DCCT/Epidemiology of 
Diabetes Interventions and Complications (EDIC)45 themselves, 
subsequent hypotheses on the relation of GV to oxidative stress in T2DM 
patients and to mortality in patients with stress hyperglycemia have been 
postulated.  
 
Especially in T2DM, postprandial hyperglycemia contributes to individual 
GV. Recent studies have suggested that postprandial glucose may be a 
marker of cardiovascular disease risk.46-48 The positive relationship 
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between postprandial hyperglycemia and cardiovascular risk supports the 
possibility that GV may be related to cardiovascular risk as well.49 
 
Recent evidence suggests that also hypoglycemia may play an important 
role in the vascular complications of diabetes.50 Hypoglycemia also causes 
oxidative stress51, inflammation52, and endothelial dysfunction.53 Oxidative 
stress is considered the key player in the pathogenesis of diabetes 
complications.54,55 During hyperglycemia, oxidative stress is produced at 
the mitochondrial level54, similarly as in hypoglycemia.51 Therefore, 
oxidative stress might be considered the common factor linking 
hyperglycemia, hypoglycemia, and the vascular complications of diabetes. 
Consistent with this hypothesis is the evidence that hyperglycemia56 and 
hypoglycemia both produce endothelial dysfunction and inflammation 
through the generation of oxidative stress.53 Endothelial dysfunction and 
inflammation are well-recognized pathogenic factors for vascular disease, 
particularly in diabetes.57 There is, however, evidence in animal studies 
and in vitro, that free radical production rises, not only during 
hypoglycemia but particularly during glucose reperfusion after 
hypoglycemia.58 Until now, little attention has been given to studying the 
effects of recovery from hypoglycemia. Ceriello’s study suggested that 
when hyperglycemia follows hypoglycemia, an ischemia–reperfusion-like 
effect is produced. This study shows that the way in which recovery from 
hypoglycemia takes place in people with T1DM could play an important 
role in favoring the appearance of endothelial dysfunction, oxidative 
stress, and inflammation, widely recognized cardiovascular risk factors.59  
 
The potential contribution of GV or postprandial hyperglycemia to the 
glycation process is still unclear. Fasting and postprandial glucose (PPG) 
excursions both contribute to the MBG and therefore to the HbA1c.60 The 
question is whether the PPG and GV, apart from the contribution to MBG, 
also affect the glycation process and therefore may affect the relationship 
between MBG and HbA1c. 
 
 
 
 
CHAPTER 1  
  28 
How to measure Glucose Variability 
 
Self-Monitoring of Blood Glucose 
There are different methods for approximating GV. In general patients 
monitor their diabetes control with SMBG. The variation of SMBG levels 
can then be calculated, and expressed as e.g. Standard Deviation (SD) of 
all blood glucose values, the Magnitude of the Amplitude of Glycemic 
Excursions (MAGE) as described by Service et all61 Calculation of this 
parameter, which is independent of mean glycemia, is of particular interest 
since the greater the MAGE the higher the glycemic instability. Another 
parameters is the Mean Of Daily Differences (MODD) value, that was 
derived by Molnar et al. in 1972 in order to illustrate inter-day variation of 
blood glucose levels.62 A high MODD score is indicative of a large 
glycemic difference between days. The different GV measures are 
summarised in Table 4. 
 
Continuous Glucose Monitoring System 
The continuous glucose monitoring system (CGMS) is a recent addition to 
the arsenal of diabetes management. The CGMS consists of a tiny glucose-
sensing device called a "sensor" that is inserted just under the skin of the 
abdomen. Using a glucose-oxidase reaction, the sensor measures the level 
of glucose in the tissue every 10 seconds and sends the information via a 
wire to a cell phone-sized device called a "monitor" that is usually 
attached to a belt. The system automatically records an average glucose  
value every five minutes for up to 72 hours.  
 
CGMS offers the opportunity to calculate MBG but also MAGE and 
overall hyperglycemia, expressed as the Area Under the glucose Curve 
above a certain threshold of for example 180 mg/dl (AUC > 180) or Area 
Under the Curve post prandial 2-hour (AUCpp 2-h) and the PPG 
increment 2-hour (PPG increment 2-h) such as described by Monnier et 
al.63 
 
McDonnell has proposed an approach to the analysis of CGM data that is 
based on relevant hierarchical clinical questions: How representative are 
the data? What is the percentage of time spent in major glycemic 
excursions? How variable or labile is the glycemic control? In order to 
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provide answers to these questions they have explored the use of several 
algorithms in CGMS data obtained from groups with and without diabetes. 
As part of this new approach, they have developed a novel algorithm; the 
Continuous Overlapping Net Glycemic Action (CONGA), to assess 
glycemic variation. The CONGA is defined as the standard deviation of 
the differences, and measures the overall intra-day variation of glucose 
recordings.64  
 
The major limitation of SMBG is the low number of assessments. This 
will likely underestimate the real number of glycemic excursions. CGM 
can provide a more complete view of glycemic excursions, including the 
duration of the excursion, as calculated by the AUC, and the mean 
amplitude for the excursion. Therefore, the influence of GV on HbA1c and 
on the HbA1c-MBG relationship can be assessed much more precisely with 
CGM than with SMBG. In Chapter 3 we examined the association of 
several GV indices and the HbA1c-MBG relationship. 
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Table 4: The different measures of glucose variability. 
 
Measures of glucose variability Illustrates 
Indicator of 
Measured 
from 
SD Standard 
Deviation of all 
blood glucose 
values 
Amplitudes of 
glucose excursions 
SMBG and/or 
CGMS 
MAGE Magnitude of the 
Amplitude of 
Glycemic 
Excursions 
Intra-day glucose 
variability 
(Capturing only 
major fluctuations) 
SMBG and/or 
CGMS 
MODD Mean Of Daily 
Differences  
Inter-day variation 
of blood glucose 
levels 
SMBG and/or 
CGMS 
CONGA The Continuous 
Overlapping Net 
Glycemic Action 
The overall intra-
day variation of 
glucose recordings 
CGMS 
AUC > 180 Area Under the 
Curve 
Overall 
hyperglyemia above 
a certain threshold 
(180 mg/dl) 
CGMS 
AUCpp Area Under the 
Curve post 
prandial 2-hour 
Total area under the 
curve from the pre-
prandial value till 2 
hours after a meal 
CGMS 
PPG 
increment 
2-h 
Mean Post 
Prandial 
incremental 
Glucose in a 2-
hour window 
Postprandial 
increment 
calculated from the 
pre-prandial glucose 
level to the highest 
peak after a meal in 
a 2-hour period 
CGMS 
 
 
High and low glycators 
 
One of the potential biologic explanations for the variance in the HbA1c-
MBG relationship, other then measure error/imprecision, is the existence 
of so-called fast and slow glycators, as suggested by Hempe32 and by 
earlier smaller studies in both non-diabetic65-67 and diabetic subjects.68,69  
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Probably there are other factors than MBG that could influence the 
glycation process. Other non-glycation factors studied so far, that may 
influence the rate of glycation, include differences in glycolytic enzyme 
activity, which might facilitate the glycation of hemoglobin65,68-70 or 
enhance deglycation of hemoglobin.71,72 Furthermore, polymorphism of 
various enzymes, as for example fructosamine 3-kinase, which reverses 
the Amadori reaction of nonenzymatic glycation, may play a role.72-74 
There are studies to suggest that genetically determined mechanisms exist 
that act in the intracellular erythrocyte compartment to determine HbA1c 
levels.75,76 This could occur through the modification of glycation or 
deglycation or intra–cellular glucose concentration.  
 
It is also well known for example, that higher erythrocyte turnover rates 
can indirectly reduce HbA1c levels by reducing the amount of time 
erythrocytes have to accumulate stable HbA1c.77,78 Heritable differences in 
erythrocyte lifespan may possibly contribute as well.79 
Other biological processes that could have a more direct effect on HbA1c 
synthesis include factors that regulate intracellular glucose concentrations 
(e.g. glucose transport by the glucose transporter GLUT1 or glycolytic 
enzyme activity) or factors that influence non enzymatic glycation (e.g. 
intracellular pH or 2,3 diphosphoglycerate concentration)65,68,69 Glucose 
entry into erythrocytes is mediated by GLUT1, as is the preponderance of 
glucose entry into endothelial cells, the major target tissue of diabetes 
complications, implying that processes related to GLUT1-mediated 
transport could be a candidate.80 The rate of production of GHb, especially 
HbA1c, is catalysed specifically by 2,3-diphosphoglycerate.81,82, 65  
 
It is not known if there are other glycemic and non-glycemic factors that 
could influence the HbA1c-MBG relationship. In Chapter 4 we describe 
our hypothesis and results searching for factors that could influence this 
relationship.   
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Other markers of glycemic control 
 
1,5 AnhydroGlucitol 
The currently available markers for monitoring glycemic control, 
including HbA1c and fructosamine, only reflect average glucose, missing 
hyperglycemic excursions that may be balanced out by hypoglycemic 
episodes. A considerable number of patients who are otherwise in good 
control, as measured by HbA1c criteria, may still have significant 
postprandial hyperglycemia.83 Therefore, an alternative marker, that 
robustly reflects postprandial glucose excursions, responds rapidly and 
significantly to changes in glycemia, is metabolically stable, demonstrates 
low biological variability, and can be easily measured, would be a useful 
tool in the management of patients with DM. 
 
1,5 AnhydroGlucitol (1,5AG), the 1-deoxy form of glucose, has been 
recently proposed as a marker conforming to these criteria.84 1,5AG is a 
naturally occurring substance that above the threshold of a plasma glucose 
value around 10 mmol/l is renally cleared from the body. Levels of 1,5AG 
have been correlated with day-to-day glucose fluctuations, such that high 
values are associated with lower glucose excursions. During 
normoglycemia, 1,5AG is maintained at constant steady-state levels due to 
a lack of metabolism85,86 and large body pool compared with the amount of 
intake.86  
 
The characteristics of the 1,5AG assay suggest that it may be 
complementary to HbA1c with specific relevance to assessing postprandial 
hyperglycemia in well-controlled patients with a HbA1c between 6 and 8%. 
If 1,5AG levels fall, greater attention to glucose monitoring is required to 
correct the glycemic excursions that would underlie such changes. 
However, 1,5AG will not identify episodes of hyperglycemia at high 
HbA1c levels, since in these circumstances the 1,5AG levels will be (too) 
low and unresponsive to glycemic variability. It appears therefore that the 
level of 1,5AG depends on the total duration of hyperglycemic episodes, 
but only in patients with moderate to good glycemic control. In Chapter 5 
we examined whether 1,5AG levels are able to detect GV including 
overall (postprandial) hyperglycemic episodes at predefined HbA1c ranges.  
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Fructosamine 
Many proteins have been shown to be subject to glycation. Armbruster 
reviewed fructosamine and its potential usage in 1987.87 Fructosamine is 
the common name for glycated albumin or glycated proteins. The reaction 
of amino acids and reducing sugars to form stable ketoamine adducts was 
first described by Maillard. Albumin was found to be glycated at multiple 
sites and primarily at the epsilon-amino groups of lysine residues, as is 
also the case with hemoglobin.88 Glycation of albumin and other plasma 
proteins was found to be increased in DM and to correlate with HbA1c 
values. Hence fructosamine can also be used in monitoring the average 
concentration of blood glucose within the past two weeks.89-91 The 
fructosamine concentration is not influenced by hemoglobin abnormalities.  
 
In vitro studies have shown that the amount of fructosamine formed is 
related directly to the albumin concentration, and by protein turnover. 
Fructosamine is unfortunately not an adequate alternative to HbA1c for 
assessing glycemic control in patients with renal failure, as high urate 
levels, which could interfere with the HbA1c assay, can also interfere with 
the fructosamine assay.92 Patients on hemodialysis treatment have a high 
protein turnover rate that can confound results.93,94,95 
 
Fructosamine testing has been available since the 1980’s as a glycemic 
control-monitoring tool. The test for serum fructosamine is simpler and 
less costly than that for HbA1c, but at present is less frequently used. The 
level of fructosamine correlates well with fasting glucose and with HbA1c 
levels.96 This correlation is strengthened when the fructosamine level takes 
into account the serum albumin concentration.97 For several years, there 
was a home fructosamine meter that allowed patients to monitor their own 
fructosamine weekly, but it was taken off the market by the manufacturer 
because of inaccurate readings. 
 
Although the HbA1c test is more commonly used today, the ADA 
recognizes both tests as being a useful tool in monitoring diabetes control. 
The ADA has stated that fructosamine testing may be useful in persons 
where an HbA1c test may not produce reliable results. These situations 
include:  
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1) The evaluation of changes in diabetic treatment, since the effects of 
adjustment can be evaluated after a couple of weeks rather than months,  
2) In pregnancy, since the glucose and insulin needs of the mother and 
fetus change rapidly during gestation,  
3) Any condition that affects the average age of red blood cells, such as 
hemolytic anemia, sickle cell anemia, or blood loss. Fructosamine is not 
affected by such conditions, and may be a better choice for monitoring 
glucose control. 
 
Fructosamine results should be considered a part of the overall context of 
the patient’s total clinical findings and not as an absolute determination for 
how well a patient is managing their diabetes. That is, results should be 
compared with daily blood glucose monitoring, and other health 
information.  
 
False, low fructosamine results may be seen with decreased protein levels 
or increased protein loss, or, when there is a change in the type of protein 
produced by the body.  Also, just as can be true with the HbA1c test, 
persons whose blood glucose levels erratically fluctuate from high to low 
(brittle diabetes) may appear to have near normal, or even normal levels, 
of fructosamine, when in fact their glucose control is not adequate. 
 
Further, because of lack of standardization and concern with 
reproducibility, fructosamine is not recommended for routine use or as a 
replacement or supplement for HbA1c when the HbA1c appears to be 
providing an accurate representation of glycemic control.  
 
In Table 5 the comparison of blood glucose and fructosamine levels are 
shown. If a patient's fructosamine test results conflict with SBGM, the 
fructosamine test might not be an accurate reflection of overall blood 
glucose control. 
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Table 5: Comparison of blood glucose and fructosamine levels. 
 
Approximate Comparison of Blood Glucose 
 and 
Fructosamine Levels 
Glucose 
(mg/dl) 
Glucose 
(mmol/l) 
Fructosamine 
(µmol) 
90 5 212.5 
120 6.7 250 
150 8.3 287.5 
180 10 325 
210 11.7 362.5 
240 13.3 400 
270 15 437.5 
300 16.7 475 
330 18.3 512.5 
360 20 550 
390 21.7 587.5 
Normal HbA1c Range 4-6% 
 
As with HbA1c, certain conditions can impact the results of a fructosamine 
test. Fructosamine results may be falsely lowered by: 
. Malnutrition (nutritional deficiencies of iron, folate, 
vitamin B12, or vitamin B6) 
. Severe burns or other reason for loss of protein 
. Hyperthyroidism  
. Hemolysis (RBC destruction) 
. Nephrotic syndrome 
. Liver disease (cirrhosis or hepatitis) 
. Erratic fluctuations in blood glucose (sugar) levels 
Conversely, the following can cause a fructosamine test to yield falsely 
higher results: 
• Elevated serum albumin 
• Elevated IgA levels 
• Occasionally, the medication Isoniazid (sometimes used to 
treat tuberculosis) 
Factors that may have an effect on test results: 
. a high amount of fat in the blood (lipemia) 
. high levels of ascorbic acid (vitamin C) 
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Associations between various indices of real-life 
glycemic profiles and HbA1c 
 
New treatment regimens and guidelines increasingly focus on postprandial 
hyperglycemia as an additional target beyond average glucose control.98 
Reviewing the literature, studies targeting PPG control use various 
methods to quantify PPG, overall hyperglycemia or GV.99 Postprandial 
increments are thought to be the predominant contributors to overall 
hyperglycemia in patients with good to moderate glycemic control (HbA1c 
below 8.5 %).60 This observation has been used to highlight the need to 
measure and treat PPG in order to reach the stringent target levels of 
HbA1c.100,101 
 
In view of this, our aim in Chapter 6 was to examine the relationship 
among the most commonly used indices of PPG, overall hyperglycemia, 
GV, nocturnal glycemia, and HbA1c using glucose measures obtained 
during everyday activities from the ADAG study. Additionally, we studied 
which blood glucose value(s) of the day provide the strongest prediction of 
MBG, as measured by HbA1c, especially focusing on pre- and postprandial 
glucose contributions to the MBG levels. 
 
 
Real-life glycemic profiles in non-diabetic 
individuals  
 
Current understanding of normoglycemia is largely based on studies of 
populations without diabetes, often with small numbers of glucose 
measurements per individual. This results in limited insight into the 
glucose patterns in real-life in healthy individuals. In Chapter 7 we 
present glucose profiles of individuals without diabetes as related to the 
thresholds for impaired glucose tolerance and diabetes.  
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Associations between different indices of 
glycemia and Cardio Vascular Disease risk 
factors  
 
The role of postprandial hyperglycemia and GV in relation to the risk of 
cardiovascular disease (CVD) is heavily debated102,46,103,104 Treatment 
regimens and guidelines have increasingly focused on the control of PPG 
concentration as an additional target beyond average glucose (HbA1c) 
control. Much of the evidence is based on single 2 hour glucose value after 
oral glucose tolerance testing105,106 Direct evidence for an additional effect 
of controlling PPG excursions, over and above an effect on reduced 
average glucose levels, on relevant diabetic endpoints is limited. In 
Chapter 8 we examined the association between different indices of 
glycemia, monitored intensively during daily life activities, and metabolic 
CVD risk factors. 
 
 
Aims and Outline 
 
The aims of the studies described in this thesis are: 
 
1. to study the relationship between HbA1c and mean blood glucose, and to 
explore the potential confounders affecting/influencing this relationship 
(Chapter 2).  
2. to investigate the influence of glucose variability on HbA1c levels and on 
the relationship between MBG and HbA1c (Chapter 3). 
3. to explore whether non-glycemic factors can explain the variability in the 
MBG-HbA1c relationship (Chapter 4). 
4. to investigate to what extent the relationship between 1,5AG and measures 
of glucose variability are influenced by HbA1c level (Chapter 5). 
5. to study the relationships among common indices of postprandial 
glycemia, overall hyperglycemia, glucose variability, and HbA1c using 
detailed glucose measures obtained during everyday life and to study 
which blood glucose values of the day provide the strongest prediction of 
HbA1c (Chapter 6). 
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6. to investigate real-life glycemic profiles in non-diabetic individuals 
(Chapter 7). 
7. to examine HbA1c associations between measures of glucose 
control/variability and cardiovascular disease risk factors in persons with 
diabetes (Chapter 8). 
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ABSTRACT 
 
OBJECTIVE 
The A1C assay, expressed as the percent of hemoglobin that is glycated, 
measures chronic glycemia and is widely used to judge the adequacy of 
diabetes treatment and adjust therapy. Day-to-day management is guided 
by self-monitoring of capillary glucose concentrations (milligrams per 
decilitre or millimoles per liter). We sought to define the mathematical 
relationship between A1C and average glucose (AG) levels and determine 
whether A1C could be expressed and reported as AG in the same units as 
used in self-monitoring. 
RESEARCH DESIGN AND METHODS 
A total of 507 subjects, including 268 patients with type 1 diabetes, 159 
with type 2 diabetes, and 80 nondiabetic subjects from 10 international 
centers, was included in the analyses. A1C levels obtained at the end of 3 
months and measured in a central laboratory were compared with the AG 
levels during the previous 3 months. AG was calculated by combining 
weighted results from at least 2 days of continuous glucose monitoring 
performed four times, with seven-point daily self-monitoring of capillary 
(fingerstick) glucose performed at least 3 days per week. 
RESULTS 
Approximately 2700 glucose values were obtained by each subject during 
3 months. Linear regression analysis between the A1C and AG values 
provided the tightest correlations (AGmg/dl = 28.7 × A1C − 46.7, R2 = 
0.84, P < 0.0001), allowing calculation of an estimated average glucose 
(eAG) for A1C values. The linear regression equations did not differ 
significantly across subgroups based on age, sex, diabetes type, 
race/ethnicity, or smoking status. 
CONCLUSIONS 
A1C levels can be expressed as eAG for most patients with type 1 and 
type 2 diabetes. 
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The A1C assay is widely accepted and used as the most reliable means of 
assessing chronic glycemia (1–3). Its close association with risk for long-
term complications, established in epidemiologic studies and clinical trials 
(4–6), has lead to the establishment of specific A1C targets for diabetes 
care with the goal of preventing or delaying the development of long-term 
complications (2,7–9). Diabetes treatment is adjusted based on the A1C 
results, expressed as the percentage of hemoglobin that is glycated. The 
vast majority of assays have been standardized worldwide, through the 
National Glycohemoglobin Standardization Program (10), to the assay 
used in the Diabetes Control and Complications Trial (DCCT), which 
established the relationship between A1C levels and risk for long-term 
diabetes complications (4,5). 
A new, more stable and specific method of standardization of the A1C 
assay, which is not intended for use in routine assays, has been developed 
and proposed to be used for global standardization by the International 
Federation of Clinical Chemists (11,12). However, the new method results 
in values that are 1.5–2.0 percentage points lower than current National 
Glycohemoglobin Standardization Program values (13), potentially 
causing confusion for patients and health care providers. Moreover, the 
International Federation of Clinical Chemists results would be expressed 
in new units (millimoles per mole), which would add to the confusion. 
Chronic glycemia (A1C) is usually expressed as a percentage of 
hemoglobin that is glycated, whereas the day-to-day monitoring and 
therapy of diabetes are based on acute glucose levels expressed as 
milligrams per deciliter or millimoles per liter. This discrepancy has 
always been problematic. If we could reliably report chronic metabolic 
control and long-term management goals as average glucose (AG), i.e., in 
the same units of measurement as acute glycemia, it would eliminate these 
potential sources of confusion. 
The relationship between A1C and chronic glycemia has been explored in 
several studies that have supported the association of A1C with AG levels 
over the preceding 5–12 weeks (14–21). However, the older studies have 
been limited, including relatively small homogeneous cohorts of patients, 
usually with type 1 diabetes (14–19). Moreover, almost all of the prior 
studies have relied on infrequent measures of capillary glucose levels, 
calling into question the validity of their assessment of chronic glycemia. 
We performed an international multicenter study to examine the 
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relationship between average glucose, assessed as completely as possible 
with a combination of continuous glucose monitoring and frequent 
fingerstick capillary glucose testing, and A1C levels over time to estimate 
the relationship between the two. 
 
RESEARCH DESIGN AND METHODS— 
Study subjects were recruited at 11 centers in the U.S., Europe, Africa, and 
Asia according to the consensus protocol. Type 1 and type 2 diabetic and 
nondiabetic volunteers were between the ages of 18 and 70 years and were 
judged as likely to be able to complete the protocol, including performance 
of the self-monitoring by fingerstick and continuous glucose monitoring. 
To be eligible, nondiabetic subjects had to have no history of diabetes, a 
plasma glucose level <97 mg/dl (5.4 mmol/l) after an overnight fast, and 
an A1C level <6.5%. The diabetic subjects had to have stable glycemic 
control as evidenced by two A1C values within 1 percentage point of each 
other in the 6 months before recruitment. Any conditions that might result 
in a major change in glycemia, such as diseases that might require steroid 
therapy or plans for pregnancy during the study period, were exclusionary. 
Similarly, any conditions or treatments that might interfere with the 
measurement of A1C by any of the study methods, such as 
hemoglobinopathies (22), or that might interfere with the putative 
relationship between A1C and AG values, including anemia (hematocrit 
<39% in men and <36% in women), high erythrocyte turnover as 
evidenced by reticulocytosis, blood loss and/or transfusions, chronic renal 
or liver disease, or high-dose vitamin C or erythropoetin treatment, were 
grounds for exclusion. The study was approved by the human studies 
committees at the participating institutions, and informed consent was 
obtained from all participants. 
 
Measures of glycemia 
Measures of glycemia included continuous interstitial glucose monitoring 
(CGM) (CGMS; Medtronic Minimed, Northridge, CA), which measures 
glucose levels every 5 min and was performed for at least 2 days at 
baseline and then every 4 weeks during the next 12 weeks. For calibration 
purposes and as an independent measure of glycemia, subjects performed 
eight-point (premeal, 90 min postmeal, prebed, and at 3:00 A.M.) self-
monitoring of capillary glucose with the HemoCue blood glucose meter 
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(Hemocue Glucose 201 Plus; Hemocue, Ángelholm, Sweden) during the 2 
days of CGM. As a third and independent measure of glycemia, subjects 
were asked to perform seven-point (same as the eight-point profile above 
without the 3:00 A.M. measurement) fingerstick capillary glucose 
monitoring (OneTouch Ultra; Lifescan, Milipitas, CA) for at least 3 days 
per week, at times when CGM was not being performed, for the duration 
of the study. The results from the CGM and fingerstick monitoring were 
downloaded from their respective meters and exported to the data 
coordinating center. To be acceptable for analysis, the CGM data had to 
include at least one successful 24-h profile out of the 2–3 days of 
monitoring with no gaps >120 min and a mean absolute difference 
compared with the Hemocue calibration results <18%, as recommended by 
the manufacturer. 
Blood samples for A1C were obtained at baseline and monthly for 3 
months. The blood samples were frozen at −80° C and were sent on dry 
ice by overnight shipment to the central laboratory. Samples were 
analyzed with four different DCCT-aligned assays, including a high-
performance liquid chromatography assay (Tosoh G7; Tosoh Bioscience, 
Tokyo, Japan), two immunoassays (Roche A1C and Roche Tina-quant; 
Roche Diagnostics), and an affinity assay (Primus Ultra-2; Primus 
Diagnostics, Kansas City, MO). The mean A1C value was used. The 
laboratory assays were approved by the National Glycohemoglobin Study 
Program (10) and have intra- and interassay coefficients of variation 
<2.5% for low and high values. The assays were highly intercorrelated 
with R2 values of 0.99 and slopes of ∼1.0 and intercepts between 0.01 and 
0.18. Any samples that demonstrated “aging peaks” on high-performance 
liquid chromatography, evidence of degradation during storage and/or 
shipment, were considered unacceptable for analysis. One center in Asia 
was unable to store samples acceptably, resulting in samples that could not 
be assayed for A1C. The center was eliminated from the study. 
 
Diabetes management 
The study was observational in design. Diabetes management was left to 
the patients and their usual health care providers and was adjusted based 
on their fingerstick self-monitoring results. CGM results were reviewed by 
the study staff at the time they were downloaded. Participants were usually 
masked to the CGM results during the study; unmasking was required if 
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otherwise undetected frequent or prolonged periods of hypoglycemia were 
observed, in which case, the health care provider was alerted so that 
treatment could be adjusted. 
 
Statistical analysis 
We calculated an arithmetic mean glucose (AG) for each subject by 
combining the CGM measurement of interstitial glucose levels, corrected 
by a factor of 1.05 to be equivalent to capillary glucose levels in our study, 
and the Lifescan fingerstick measurements of capillary glucose. Because 
glucose levels were measured much more frequently on the CGM days (n 
∼ 288 per day) than during the Lifescan days (n ∼ 7), the results were 
weighted so that each measurement was proportional to the inverse of the 
total number of measurements taken in the same day. Therefore, equal 
weight was attached to each day during which glucose levels were 
measured. Subjects with fewer than 7 days of CGM during the study were 
excluded from analysis. We applied linear and quadratic regression models 
to estimate the relationship between A1C and AG. The quadratic model 
did not provide a significant improvement over the linear regression model 
(P = 0.82). An exponential model was considered but not used, since the 
paucity of data in the higher A1C range led to highly variable estimates. 
Prediction intervals were calculated to represent the range of predicted AG 
at given A1C levels (23). To correct for heteroschedasticity, we fit a model 
where the variance of AG is an increasing function of A1C. As a result, 
the 90% prediction intervals for AG given A1C is given by 
 
The mathematical details of the Bayesian method are given in online 
appendix 1, available at http://dx.doi.org/10.2337/dc08-0545. 
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min and a mean absolute difference
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tion results!18%, as recommended by
the manufacturer.
Blood samples for A1C were obtained
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and were sent on dry ice by overnight
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ples were analyzed with four different
DCCT-aligned assays, including a high-
performance liquid chromatography as-
say (Tosoh G7; Tosoh Bioscience, Tokyo,
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and Roche Tina-quant; Roche Diagnos-
tics), and an affinity assay (Primus Ul-
tra-2; Primus Diagnostics, Kansas City,
MO). The mean A1C value was used. The
laboratory assays were approved by the
National Glycohemoglobin Study Pro-
gram (10) and have intra- and interassay
coefficients of variation !2.5% for low
and high values. The assays were highly
intercorrelated with R2 values of 0.99 and
slopes of $1.0 and intercepts between
0.01 and 0.18. Any samples that demon-
strated “aging peaks” on high-perfor-
mance liquid chromatography, evidence
of degradation during storage and/or
shipment, were considered unacceptable
for analysis. One center in Asia was un-
able to store samples acceptably, resulting
in samples that could not be assayed for
A1C. The center was eliminated from the
study.
Diabetes management
The study was observational in design.
Diabetes management was left to the pa-
tients and their usual health care provid-
ers and was adjusted based on their
fingerstick self-monitoring results. CGM
results were reviewed by the study staff at
the time they were downloaded. Partici-
pants were usually masked to the CGM
results during the study; unmasking was
required if otherwise undetected frequent
or prolonged periods of hypoglycemia
were observed, in which case, the health
care provider was alerted so that treat-
ment could be adjusted.
Statistical analysis
Wecalculated an arithmeticmean glucose
(AG) for each subject by combining the
CGM measurement of interstitial glucose
levels, corrected by a factor of 1.05 to be
equivalent to capillary glucose levels in
our study, and the Lifescan fingerstick
measurements of capillary glucose. Be-
cause glucose levels were measured much
more frequently on the CGM days (n $
288 per day) than during the Lifescan
days (n$ 7), t e results w re weighted so
that ach measurement was proportional
to the inverse of the total number of mea-
surements taken in the same day. There-
fore, equal weight was attached to each
day during which glucose levels were
measured. Subjects with fewer than 7
days of CGM during the study were ex-
cluded from analysis. We applied linear
and quadratic regression models to esti-
mate the relationship between A1C and
AG. The quadratic model did not pr vide
a significant i provemen over the linear
r ression model (P % 0.82). A expo-
nential model was considered but not
used, since the paucity of data in the
higher A1C range led to highly variable
estimates. Prediction intervals were calcu-
lated to represent the range of predicted
AG at given A1C levels (23). To correct
for heteroschedasticity, we fit a model
where the variance of AG is an increas-
ing function of A1C. As a result, the
90% prediction intervals for AG given
A1C is given by
a ! b " A1C & tn#1,1#a/ 2
" !1 ! 1n!'1(A1C)'2/ 2,
where n% 507 and * % 0.1, which leads
to tn#1,1#*/ 2 # 1.648 and !1! 1m " 1.
The mathematical details of the
Bayesian method are given in online ap-
pendix 1, available at http://dx.doi.org/
10.2337/dc08-0545.
For the overall study results to be
considered acceptable, it was decided a
priori that $90% of the individual pa-
tients’ calculated AG would have to fall
within &15% of the study-wide calcu-
lated AG.
We examined the influence of factors
such as age, sex, race (Caucasian, African
or African American, or Hispanic), and
smoking history on the relationship be-
tween A1C andAG through amultivariate
regression model. We compared the
slopes and intercepts of the regression
equations for the individual subgroups
and calculated the SDs of the prediction
error for each. Age was divided by tertiles
separately for type 1 (!40, 40–50, "50
years) and type 2 diabetes (!50, 50–60,
"60 years).
RESULTS— Between April 2006 and
August 2007, 661 patients were recruited
from 10 clinical centers: 6 in the U.S., 3 in
Europe, and 1 in Cameroon. A total of
A1C assay and estimated average glucose values
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For the overall study results to be considered acceptable, it was decided a 
priori that ≥90% of the individual patients’ calculated AG would have to 
fall within ±15% of the study-wide calculated AG. 
We examined the influence of factors such as age, sex, race (Caucasian, 
African or African American, or Hispanic), and smoking history on the 
relationship between A1C and AG through a multivariate regression 
model. We compared the slopes and intercepts of the regression equations 
for the individual subgroups and calculated the SDs of the prediction error 
for each. Age was divided by tertiles separately for type 1 (<40, 40–50, 
>50 years) and type 2 diabetes (<50, 50–60, >60 years). 
 
 
RESULTS— 
Between April 2006 and August 2007, 661 patients were recruited from 10 
clinical centers: 6 in the U.S., 3 in Europe, and 1 in Cameroon. A total of 
335 participants had type 1 diabetes, 236 had type 2 diabetes, and 90 were 
nondiabetic (Table 1). The participants were distributed by baseline A1C 
in three groups, with 18% with A1C >8.5%, 44% between 6.6 and 8.5%, 
and 38% between 4 and 6.5%. The lowest A1C group consisted of 63% 
diabetic patients and 37% nondiabetic participants. 
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Table 1 Baseline characteristics 
 
 
Of 661 subjects who completed screening visits, 154 (23%) were not 
included in the final analyses for the following reasons: 91 (15%) did not 
complete the study or were excluded before study end because of 
conditions that were predefined (such as sickle cell trait [n = 5] or anemia 
[n = 5]), were identified during screening, or developed during the study; 
11 (2%) did not have adequate CGM; and 52 (8%) did not have samples 
that could be evaluated for A1C for technical reasons, including sample 
degradation because of storage or shipment problems. 
A total of 507 subjects completed the study and had adequate glucose-
monitoring and A1C samples to be included in the analyses (Table 1). The 
CGM and the Lifescan fingerstick capillary-monitoring data included 
∼2500 and 230 measurements per subject, respectively, for a total of 
∼2,700 glucose tests during the 3-month period. The median number of 
days of CGM was 13 and of fingerstick capillary monitoring was 39; 36% 
of the seven-point profiles were complete, with the mean number of tests 
being 5.1 per day. The correlation of the CGM and simultaneous Hemocue 
measurements not used for calibrating CGM was excellent, with the 95% 
limit of the overall average CGMS minus average Hemocue equaling 
−30.6 to 30.6 mg/dl (−1.7 to 1.7 mmol/l). 
For measuring the steady-state correlation between AG and A1C, the 
study was designed to include subjects with relatively stable glycemia. 
A1C values were generally stable, with 96% of the subjects maintaining 
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A1C within 1 percentage point of their baseline value over the course of 
the study. 
The relationship between the A1C level at the end of the 3-month study 
period and the calculated AG during the preceding 3 months, expressed as 
the simple linear regression AGmg/dl = 28.7 × A1C − 46.7 (AGmmol/l = 
1.59 × A1C − 2.59), R2 = 0.84, P < 0.0001, is shown in Fig. 1. The 
correlation has an SD of prediction error of 15.7 mg/dl (0.87 mmol/l). 
Based on the model described in the statistical analysis section, the 
estimated values are as follows: α = −41.4, 95% CI −48.8 to −33.5; β = 
27.9, 26.7–29.0; β1 = 4.81, 2.18–15.33; β2 = 2.03, 1.42–2.59. This leads to 
an estimated error SD of 13.4, 15.7, and 18.0 mg/dl when A1C is 6, 7, and 
8%, respectively. The Bayesian model–suggested regression line differs 
<2 mg/dl from a simple linear regression line in the A1C range of 4–10%, 
which includes 98.5% of our samples; the prediction intervals widen (P < 
0.05) as A1C values increase to 12%, but the difference between the 
Bayesian and simple linear regression is still <5 mg/dl. A Bland-Altman 
type of analysis examining the difference between the estimated glucose 
and observed glucose over the range of glucose values is shown in online 
appendix 2. The 90% prediction limits for the AG, based on the varying 
SD model, were very close to the preset limits of ±15% of the predicted 
mean over the full range of A1C; 89.95% of the samples fell within 15% 
of the calculated AG. 
 
The translation of A1C to estimated AG (eAG) based on the linear 
regression is shown in Table 2, for conventional and SI units, and with the 
95% prediction limits. Of note, the regression equation for A1C and AG 
using only the CGM results to calculate AG was AGCGM = 28.0 × A1C − 
36.9 (R2 = 0.82, P < 0.0001); the regression using only the seven-point 
fingerstick profiles to calculate AG was AG7-POINT = 29.1 × A1C − 50.7 
(R2 = 0.82, P < 0.0001). The difference in the regressions was not 
statistically significant for slope and intercept combined (P = 0.11). 
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Figure 1 Linear regression of A1C at the end of month 3 and calculated 
AG during the preceding 3 months. Calculated AGmg/dl = 28.7 × A1C − 
46.7 (AGmmol = 1.59 × A1C − 2.59) (R2 = 0.84, P < 0.0001). 
 
Table 2 Estimated average glucose 
 mg/dl* mmol/l† 
A1C (%)   
5 97 (76–120) 5.4 (4.2–6.7) 
6 126 (100–152) 7.0 (5.5–8.5) 
7 154 (123–185) 8.6 (6.8–10.3) 
8 183 (147–217) 10.2 (8.1–12.1) 
9 212 (170–249) 11.8 (9.4–13.9) 
10 240 (193–282) 13.4 (10.7–15.7) 
11 269 (217–314) 14.9 (12.0–17.5) 
12 298 (240–347) 16.5 (13.3–19.3) 
Data in parentheses are 95% CIs. 
* Linear regression eAG(mg/dl) = 28.7 × A1C − 46.7.  
† Linear regression eAG(mmol/l) = 1.59 × A1C − 2.59.  
 
 
The relationship between A1C and AG was the same when only the 
diabetic subjects were included (linear regression eAG = 28.3 × A1C − 
43.9 [R2 = 0.79, P < 0.0001]) as that for the whole cohort. A comparison 
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of the regression equations within the specified subgroups is shown in 
Table 3. There were no significant differences in the slope or intercept for 
the regression equations for any of the subgroup comparisons, and the SDs 
of the prediction error were all close to the 15.7 mg/dl (0.87 mmol/l) value 
for the entire study cohort. 
 
 
Table 3 Comparison of regression equations between A1C and eAG for 
subgroups 
 
 Comparison Difference 
in slope 
Difference  
in intercept 
P* 
Sex Male vs. Female 0.17 ± 1.14 0.57 ± 7.94 0.91 
DM type Type 1 vs. Type 2 −1.46 ± 1.61 9.35 ± 11.21 0.41 
Age T1DM 1st vs. 2nd tertile −1.03 ± 2.27 −5.61 ± 16.56 0.71 
 1st vs. 3rd tertile 1.53 ± 2.37 −6.99 ± 17.59 0.18 
 2nd vs. 3rd tertile 0.50 ± 2.47 −1.38 ± 18.29 0.69 
Age T2DM 1st vs. 2nd tertile −7.40 ± 3.67 52.00 ± 24.43 0.08 
 1st vs. 3rd tertile −1.57 ± 3.36 11.59 ± 22.31 0.84 
 2nd vs. 3rd tertile 5.83 ± 3.07 −40.41 ± 21.45 0.17 
Ethnicity Caucasian vs. 
African/African-
American 
3.87 ± 1.85 23.35 ± 12.48 0.07 
 Caucasian vs. 
Hispanic 
−1.80 ± 3.12 5.89 ± 20.51 0.81 
 Hispanic vs. 
African/African-
American 
−2.06 ± 3.49 17.46 ± 22.94 0.43 
Smoking Never vs. current 2.62 ± 1.48 −16.76 ± 10.93 0.14 
Data are means ± SE. 
* χ2 test with 2 d.f. comparing the intercept and slope simultaneously.  
 
 
CONCLUSIONS— 
The results of the A1c-Derived Average Glucose (ADAG) study support 
the notion of a close relationship between A1C levels and AG for both 
type 1 and type 2 diabetes. The A1C assay plays a central role in the 
clinical management of diabetes. Treatment goals designed to reduce the 
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development of long-term complications were adopted in the wake of the 
DCCT (4), and A1C assay methods have been standardized to the DCCT 
values in most of the world (10). A newly developed method of assay 
calibration, which is more stable and specific, should further improve the 
comparability of assays worldwide (11,12). Since this method measures a 
well-defined analyte of only one molecular species of glycated 
hemoglobin, the reference values are lower, compared with the previous 
DCCT-aligned assays. To avoid confusion and potential deterioration of 
glycemic control as a result of having to report lower A1C values (24), the 
current study set out to determine the relationship between A1C and AG. 
The ultimate aim was to determine whether the A1C index of chronic 
glycemia could be reported in the same units as used for day-to-day 
monitoring (12,25). 
Previous studies of the relationship between A1C and average glycemia 
have generally been hampered by limited measurements of glucose values, 
casting doubt on the reliability of the estimates of AG. CGM provides the 
opportunity to measure all glucose levels. A recent study that included 
CGM for 3 months arrived at a relationship between A1C and AG very 
similar to that presented here, providing external validation, but included 
only 25 subjects, most of whom had type 1 diabetes (21). The current 
study provides a relatively complete assessment of day-to-day glycemia 
and establishes a strong enough relationship between A1C and AG levels 
to justify a direct translation from measured A1C to an easier-to-
understand value that is in the same units as fingerstick monitoring. Of 
note, the regression equation in this study provides lower eAG values, 
compared with the widely used equation derived from the DCCT, and the 
scatter around the regression line is less wide (18). The most obvious 
explanation for the difference between AG calculated from the DCCT and 
that calculated in the current study is the difference in the frequency of 
glucose measurements used to calculate AG (a single seven-point profile 
with no overnight measurements during 3 months in the DCCT compared 
with numerous CGM and seven-point profile measurements that captured 
a median of 52 days in ADAG), providing a more complete and 
representative measure of average glucose in ADAG. 
Our results strongly support a simple linear relationship between mean 
glucose and A1C levels in a clinically relevant range of glycemia. Our 
data fulfilled the a priori quality criterion; i.e., 90% of the estimates fell 
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within the ±15% range of the regression line. This criterion was 
considered realistic, allowing for the imprecision of the A1C assay, CGM, 
and self-monitored blood glucose tests. 
The large population allowed us to demonstrate that the relationship 
between A1C and AG was consistent across prespecified subgroups. The 
tight relationship and the consistency of the relationship across different 
subgroups suggest that for many, if not most, patients with diabetes, there 
are no important factors that affect the relationship between mean glucose 
levels and A1C. There was a suggestion (P = 0.07) that the regression line 
was different for African Americans such that for a given value of A1C, 
African Americans might have a slightly lower mean glucose level. This 
borderline result requires further study to be confident that there is no 
relationship between ethnicity and the relationship between mean glucose 
and A1C. There was also a suggestion that age may affect the relationship 
between AG and A1C; however, the effect was not monotonic. The 
regression lines for each age-group crossed at A1C of 7%, with the first 
and last tertile being similar and the middle tertile being different. We 
suspect that this is a spurious finding. There are other well-recognized 
clinical factors, such as anemia and altered erythrocyte turnover, which 
can affect A1C results measured with all assay methods, and 
hemoglobinopathies, which interfere with the measurement of A1C with 
specific methods (22). Potential subjects with these conditions were 
excluded from the study. 
The ADAG study has a few limitations. In contrast to our intention and 
expectation, some ethnic/racial groups were underrepresented, primarily 
because of the withdrawal of one of the centers with a large Asian 
population and a limited number of subjects of African descent. In 
addition, the average glucose estimation was based predominantly on two 
methods: CGM and intermittent self-monitoring of capillary glucose. (The 
Hemocue measurements, recognized as providing values that are 
equivalent to laboratory measurements, were used primarily to calibrate 
the CGM [26].) To combine these measurements into a single calculated 
AG, the CGM and fingerstick capillary measurements had to be weighted 
to take into account the different number of measurements in a day; 
however, in separate analyses comparing the relationships between A1C 
and AG measured with CGM or fingerstick capillary measurements, there 
was no significant difference in the relationships. Finally, since only 
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diabetic patients in stable control and without any suggestion of 
erythrocyte disorders were entered into the study, the current results are 
only directly applicable to this population. Children and pregnant women 
were also excluded; additional data in these groups are needed to confirm 
the established relationship. Of note, a recently published study compared 
the calculated mean glucose of 47 children with type 1 diabetes between 
the ages of 4 and 18 years who had at least one 24-h period of CGM in 6 
of 13 weeks with the A1C at the end of the 13-week period (27). Although 
the authors also concluded that “A1C directly reflects mean glucose over 
time,” they found substantially greater inter-individual variation in the 
relationship between AG and A1C than present in the current study. The 
potential sources of this variability can be identified by comparing the 
DirectNet study in children (27) with ADAG and with the recent study in 
adults (21) who were selected for stable glycemic control and performed 
CGM for 97% of the 12-week study period. The DirectNet study used a 
noncentralized A1C method with relatively poor correlation with a high-
performance liquid chromatography method. Moreover, the children had 
highly variable glycemia and only performed CGM for 67% of the study 
period; this may have failed to accurately capture mean glycemia. 
The current results support the reporting of the measured A1C as eAG. 
The interpretation of the A1C, analogous to reporting serum creatinine as a 
calculated glomerular filtration rate, should provide health care providers 
with a more useful index of chronic glycemia. A recently published 
consensus guideline has endorsed reporting A1C values along with the 
calculated eAG level, assuming that the results of the ADAG were 
acceptable (25). 
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Fedele, and G. Sartore, Padova, Italy; X. Pi-Sunyer (PI), C. Maggio, L. 
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ABSTRACT  
 
OBJECTIVE 
The A1c-Derived Average Glucose study demonstrated a linear 
relationship between HbA1c and mean plasma glucose (MPG). As glucose 
variability (GV) may contribute to glycation, we examined the association 
of several glucose variability indices and the MPG/HbA1c relationship. 
RESEARCH DESIGN AND METHODS 
Analyses included 268 patients with diabetes mellitus type 1 (T1DM) and 
159 with diabetes mellitus type 2 (T2DM). MPG during 3 months was 
calculated from 7-point self-monitored plasma glucose and continuous 
glucose monitoring. We calculated 3 different measures of GV and used a 
multiple step regression model to determine the contribution of the 
respective GV measures to the MPG/HbA1c relationship. 
RESULTS 
GV, as reflected by SD and CONGA4, had a significant effect on the 
MPG/HbA1c relationship in T1DM patients so that high GV led to a higher 
HbA1c level for the same MPG. In T1DM, the impact of confounding and 
effect modification of a low versus high SD at a MPG level of 160 mg/dl 
on the HbA1c level is 7.02 versus 7.43 and 6.96 versus 7.41. All GV 
measures showed the same tendency. 
CONCLUSIONS 
Only in T1DM patients, GV shows a significant interaction with MPG in 
the association with HbA1c.This effect is more pronounced at higher HbA1c 
levels. However, the impact of GV on the HbA1c level in T1DM is modest, 
particularly when HbA1c is close to the treatment target of 7%. 
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Since the Diabetes Control and Complications Trail (DCCT) and United 
Kingdom Diabetes Prospective Diabetes Study (UKPDS)1,2 established the 
relationship between HbA1c, and the development of long-term diabetic 
complications, HbA1c has become the key monitoring tool in diabetes 
management.  
During the lifetime of the erythrocyte, hemoglobin (Hb) is gradually 
glycated. The proportion of the glycated sites, HbA1c, within the 
erythrocyte increases throughout its lifespan and reflect the exposure to 
mean blood glucose (MBG) levels during the preceding 2-3 months.3 This 
non-enzymatic post-translational modification is relatively slow. In vivo 
and in vitro studies have shown, that HbA1c levels are directly proportional 
to the time-averaged concentration of glucose during the erythrocyte’s 
lifespan.3-6 Given the kinetics of glycation, brief periods of 
hyperglycaemia should not have a major impact on HbA1c levels.7-9  
However, increased glycated protein levels are documented in some non-
diabetic pathological states. So hyperglycemia is not the complete answer 
to the etiology of increased early glycated products in non-diabetic 
conditions. A common denominator is oxidative stress. Hypothesized is it 
has been hypothesized that oxidative stress either via increasing reactive 
oxygen species or by depleting the antioxidants may modulate the genesis 
of early glycated proteins in vivo.10,11 Hyperglycemia stimulates oxidative 
stress12 and GV, in particular postprandial glucose excursions have been 
regarded as potentially deleterious, due to among others, their association 
with the increase of oxidative stress.13 Therefore GV could influence the 
glycation of HbA1c. 
Previous studies have examined whether the relationship between MPG 
levels and HbA1c is influenced by glucose variability (GV) and found no 
or minimal influence.10,14,15 However these studies used limited self-
monitoring of blood glucose (SMBG) data to assess mean glucose levels 
and variability in relatively small numbers of measurements. These 
methods could underestimate glycemic excursions. Continuous glucose 
monitoring (CGM) provides a more complete view of glycemic 
excursions, including the duration and frequency of the excursions, and 
allows calculation of features of GV. 
Our aim was to examine the influence of GV on the MPG/HbA1c 
relationship in the A1c-Derived Average Glucose  (ADAG) study.   
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RESEARCH DESIGN AND METHODS  
Study participants 
The ADAG study was conducted at 10 centers in the United States, 
Europe and Africa from 2006-2008 to define the relationship between 
HbA1c and average glucose levels. As a full description of this 
observational study has been published16 we describe it here briefly. A 
total of 268 individuals with T1DM and 159 individuals with T2DM (age 
18-70 years) completed the study. Participants were selected based on 
stable glycemic control as evidenced by two HbA1c values within one 
percentage point of each other in the six months prior to recruitment. 
Individuals with a wide range of HbA1c levels were included. 
Participants with conditions leading to major changes in glycemia 
(infectious disease, steroid therapy, pregnancy) or conditions that might 
interfere with the measurement of HbA1c or the relationship between 
HbA1c and MPG (hemoglobinopathies17, anemia, increased erythrocyte 
turnover, blood loss and/or transfusions, chronic renal or liver disease) 
were excluded.16 The study was approved by the human studies 
committees at the participating institutions and informed consent was 
obtained from all participants.  
 
Measurements of glycemia 
During the study period, continuous interstitial glucose monitoring (CGM) 
(Medtronic Minimed, Northridge, CA) was performed at home 4 times 
with 4 weeks interval during the 16-week study period. Monitoring period 
lasted at least 48 hours, during which time glucose levels were assessed 
every 5 minutes. CGM data were accepted for analysis if there were no 
gaps longer than 120 minutes and if the mean absolute difference with the 
Hemocue calibration results was less than 18%, as recommended by the 
manufacturer. For calibration purposes, participants performed self-
monitoring blood glucose (SMBG) with the Hemocue meter (Hemocue 
Glucose 201 plus, Hemocue, Ängelholm, Sweden) during the days of 
CGM.  
For adequate calculation of MPG, subjects additionally performed a 7-
point SMBG (OneTouch Ultra, Lifescan, Inc. Milipitas, CA) for at least 3 
days per week during the weeks when CGM was not performed. All blood 
glucose values stated are plasma equivalents. 
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HbA1c samples were analyzed with four highly inter-correlated DCCT-
aligned assays; a high-performance liquid chromatography assay, two 
immunoassays, and an affinity assay (all approved by the National 
Glycohemoglobin Study Program).  The mean HbA1c value at the end of 
the 12 week study period was used.16  
 
Calculating glucose variability 
Three indices of intraday glucose variability were calculated based on 
CGM; the standard deviation (SD) of mean glucose concentrations, the 
Mean Amplitude of Glycemic Excursions (MAGE) and the Continuous 
Overlapping Net Glycemic Action (CONGA). High SD, MAGE and 
CONGA values indicate high intra-day glucose variability. MAGE is the 
mean of the differences between consecutive peaks and nadirs, only 
including changes of more tan 1 SD of glycemic values and thus capturing 
only major fluctuations.18 For the calculation of CONGAn, the difference 
of the current value as compared to the value n hours previously is 
calculated for each observation after the first n hours. The CONGAn is the 
SD of these differences.19 In the analyses we used CONGA at 4 hours 
(CONGA4). Calculations based on CGM data were calculated after 
exclusion of the initial 2 hours of monitoring, which is considered to be an 
unstable calibration period. 
 
Statistical analysis  
First we explored the correlations between MPG and HbA1c and measures 
of glycemic variability as SD, MAGE and/or CONGA4 for the total 
diabetes population and the two diabetes types. Multiple linear regression 
was used to investigate confounding and effect modifying influence of 
clinical parameters (glycemic variability) on the relation between the 
determinant (MPG) and outcome (HbA1c) of interest. We then assessed 
which of the variability measures (SD, MAGE and CONGA4) had the 
strongest impact on the MPG/HbA1c relationship, both by confounding or 
effect modification. 
Effect modification was concluded, when the slope of the interaction term 
of glycemic variability and determinant was significant. If no effect 
modification might be concluded, a parameter ΔB was computed as the 
relative difference of the slope of the determinant in the model without and 
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with the clinical parameter. Confounding was concluded, when the 
absolute value of ΔB exceeded the generally accepted threshold of 10%. 
Multivariate confounding was investigated with a variant of stepwise 
regression, in which the stepping criterion was not a p-value, but the ΔB as 
long as it exceeded the threshold. For significancy a threshold of α=0.05 
was used.  
Analyses were done for the total population and stratified for the type of 
diabetes. Finally, we illustrated the magnitude of the effect caused by the 
variability indices, by confounding or effect modification, on the 
MPG/HbA1c relationship. 
 
RESULTS  
Of the 507 patients enrolled, 427 completed the study and had adequate 
glucose monitoring and HbA1c samples, to be included in the analyses. 
Two hundred and sixty eight participants had T1DM and 159 had T2DM. 
The CGM and the SMBG data during the 3-month period included 
approximately 2400 and 300 measurements per subject, respectively. The 
relationship between the HbA1c level at the end of the 3-month study 
period and MPG calculated over the preceding 3 months was expressed as 
the simple linear regressions. The total diabetes population: HbA1c (%) = 
0.028 x MPG (mg/dl) + 2.66. (R2 = 0.80). For T1DM: HbA1c (%) = 0.028 
x MPG (mg/dl) + 2.77 (R2 = 0.77) and for T2DM: HbA1c (%) = 0.028 x 
MPG (mg/dl) + 2.62 (R2 = 0.82) 
The clinical and glycemic characteristics are shown in table 1. Mean 
HbA1c (SD) for T1DM was 7.3% (1.1) and for the T2DM patients 6.8% 
(1.1). 
All GV measures had significant influence on the MPG/HbA1c relationship 
for the total population. The variability index SD showed the strongest 
influence on the MPG/HbA1c relationship. Non of the GV measures 
showed confounding for all DM patients pooled nor for the T1DM and 
T2DM patients separately (Table 2).  
In the T1DM patients the effect modification of SD and CONGA4 was 
significant (p<0.01 and p=0.02) and for the MAGE it was just not 
significant (p=0.06) (Table 2). The MPG/HbA1c linear regression formula 
with confounding for the T1DM: HbA1c (%) = 2.64 + 2.63 x MPG/100 + 
0.58 x SD/100. The MPG/HbA1c linear regression formula with effect 
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modification for the T1DM: HbA1c (%) = 3.91 + 1.79 x MPG/100 – 1.37 x 
SD/100 + 1.25 x MPG/100 x SD/100.  
 
Table 1. Baseline clinical and glycemic characteristics: Means (SD) or % 
 All Type 1 Type 2 
  (n = 427) (n = 268) (n = 159) 
Age 47.6 (13.6) 44.1 (12.9) 56.6 (9.4) 
Gender (% female) 54% 52% 51% 
Ethnicity (% Non-hispanic 
white) 
83% 93% 73% 
Current smokers 11% 12% 9% 
Insulin treatment 76 % 100 % 38 % 
    
Glycaemic measures    
HbA1c (%) 6.8 (1.3) 7.3 (1.1) 6.8 (1.1) 
MPG (mg/dl) 149.4 (39.6) 162 (36) 149.4 (36) 
    
Measures of GV    
CGM SD (mg/dl) 48.6 (25.2) 64.8 (16.2) 39.6 (16.2) 
MAGE (mg/dl) 86.4 (43.2) 115.2 (32.4) 68.4 (27) 
CONGA4 (mg/dl) 66.6 (28.8) 88.2 (23.4) 52.2 (21.6) 
    
Number (%) of patients     
SD (mg/dl) ≤ 30 61 (14.3%) 9 (3.4%) 52 (32.7%) 
SD (mg/dl) < 30 – 60 173 (40.5%) 84 (31.3%) 89 (56%) 
SD (mg/dl) < 60 – 90 173 (40.5%) 155 (57.8%) 18 (11.3%) 
SD (mg/dl) > 90 20 (4.7%) 20 (7.5%) 0 (0%) 
 
The impact of effect modification of low GV (SD=30 mg/dl) versus high 
GV (SD=100 mg/dl) for a MPG level of 160 mg/dl in T1DM on the HbA1c 
level was 6.96 % versus 7.41 % as shown in Table 3. At a MPG level of 
220 mg/dl (HbA1c following the regression formula of 8.89%) a decline in 
the SD parameter from 100 to 30 mg/dl will reduce HbA1c from 9.23 to 
8.26%.  
For all patients pooled there was no effect modification of the respective 
GV measures on the MPG/HbA1c relationship. For T2DM the impact of 
effect modification from the respective GV measures was far from 
significant (Table 2). 
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The number of patients with a predefined SD are shown in Table 1 for all 
patients pooled and for the T1DM and T2DM patients separately. 
 
Table 2: The P values of the influence of the respective GV measures 
themselves, as well as Effect Modification (EF) and the delta of 
Confounding (CF), calculated from the respective slopes (B and B’) from 
the regression equations, on the HbA1c/MPG relationship for all patients 
pooled, as well as T1DM and T2DM patients separately.  
 
    Influence 
of the GV 
measure 
Slope of MPG 
(B) in the 
main 
regression 
formula 
Slope of MPG 
(B’) in the 
regression 
formula with 
the GV 
measure  
*Delta 
CF in 
% 
EM 
  P =    P = 
SD All < 0.01 2.818 2.624 6.9% 0.06 
 T1DM 0.01 2.781 2.631 5.4% < 0.01 
 T2DM 0.06 2.782 2.637 5.2% 0.74 
       
MAGE All < 0.01 2.818 2.700 4.2% 0.37 
 T1DM 0.19 2.781 2.721 2.2% 0.06 
 T2DM 0.19 2.782 2.698 3.0% 0.19 
       
CONGA4 All < 0.01 2.818 2.667 5.4% 0.15 
 T1DM 0.06 2.781 2.687 3.4% 0.02 
  T2DM 0.07 2.782 2.661 4.3% 0.46 
*Delta CF in % =100 x abs ((B’- B)/B) 
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Table 3 shows the quantification or impact of confounding (CF) or effect 
modification (EM) for T1DM patients of a low SD (30 mg/dl) versus a 
high SD (100 mg/d;) for a given MPG in mg/dl or mmol/l on the HbA1c 
level in %, next to the HbA1c values calculated with the regression formula 
for the T1DM. 
 
Mean Plasma Glucose HbA1c (in %) HbA1c (in %) 
   CF EM 
  Regression   
Mg/dl mmol/l formula SD 30 SD 100 SD 30 SD 100 
140 7,8 6.67 6.50 6.90 6,53 6,80 
160 8,9 7.22 7.02 7.43 6,96 7,41 
180 10 7.78 7.55 7.95 7.39 8.02 
200 11,1 8.34 8.08 8.48 7.83 8.62 
220 12,2 8.89 8.60 9.01 8.26 9.23 
240 13,3 9.45 9.13 9.53 8.69 9.84 
 
DISCUSSION  
This study demonstrated a significant effect of GV, as reflected by SD, on 
the MPG/HbA1c relationship. High GV (SD) is associated with higher 
HbA1c levels for a given MPG and this effect was more pronounced at 
higher HbA1c and MPG values. However, the magnitude of this effect of 
GV was small, and only demonstrable in T1DM patients. Possibly, the 
T2DM patient group was too small (n = 159) and the variability in this 
group too low to find this interaction.   
The ADAG study showed a tight correlation between HbA1c and MPG, 
allowing the translation of HbA1c into estimated Average Glucose.16,20 It 
has been suggested earlier that GV could affect the MPG/HbA1c 
relationship, but this has not previously been demonstrated.21-23 To our 
knowledge, the present study is the largest study reporting an influence of 
GV, as expressed by SD, MAGE and CONGA4 calculated from CGM, on 
the MPG/HbA1c relationship. The discrepancies in the MPG/HbA1c 
relationship are less likely caused by technical errors since this study 
included accurate and centralized measurements of HbA1c values and 
intensively measured plasma glucose concentrations (~ 2700 values) in a 
large and diverse population. Also, individuals with conditions or 
treatment that might result in major changes in glycemia or interference 
with the HbA1c assay, or the MPG/HbA1c relationship were excluded. 
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These precautions allow us to search for factors other than MPG that may 
contribute to HbA1c. 
In general, GV is higher in patients with poor glycemic control and in 
T1DM patients as compared to T2DM patients, which can be attributed to 
insulin therapy and higher insulin sensitivity. High GV may affect 
glycation due to periodic exposure of the red blood cell to high glucose 
levels and therefore to faster irreversible glycation. 
Other factors like hyperglycemia-induced oxidative stress may affect the 
glycation process. In recent literature it has been speculated that oxygen 
free radicals per se or with an associated decrease in antioxidants may 
modulate the formation of early glycated protein.10,11  
Brownlee demonstrated that hyperglycemia stimulates oxidative stress.12 
High GV and especially postprandial glucose excursions were also 
previously associated with oxidative stress in T2DM.13 The activation of 
oxidative stress, estimated from urinary excretion rates of isoprostanes, 
was highly correlated with MAGE calculated from CGM.13 However, 
Wentholt et al could not replicate these results in T1DM.24 Recently, 
Ceriello et al demonstrated that high intraday GV was more damaging to 
endothelial function than stable hyperglycemia and that oxidative stress 
plays a key role.15 If oxidative stress influences glycation needs to be 
determined. 
On the other hand it has been demonstrated that erythrocyte survival is 
shorter at chronic high glucose concentrations levels, which might falsely 
lower HbA1c levels. Peterson et al showed that the life span of 51Cr-
labeled erythrocytes increased in all seven subjects when their poorly 
controlled DM was adequately treated.25 Virtue et al.26 concluded that 
there is a hyperglycemia-related decrease in erythrocyte survival as 
measured by carbon monoxide in the expired air, which results in an 
exponential underestimation of the severity of hyperglycemia at higher 
HbA1c levels.11 Similarly, hyperglycemia related osmotic stress may 
influence red blood cell permeability and could cause damage to the 
erythrocyte and shortening its lifespan.  These findings could lead to 
underestimation of HbA1c at higher MPG levels, concealing a glycaemic 
control worse than indicated by HbA1c measurements.  However, we found 
that T1DM patients with high GV display higher HbA1c levels than 
suspected by the MPG. This effect was more pronounced at higher HbA1c 
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levels, indicating that focus on reducing GV, especially in patients with 
poor glycemic control, could help reduce HbA1c levels. 
Limitations of our study are that CGM has a limited range of reliable 
measurements between 2.2 mmol/L and 22.2 mmol/L. Therefore 
theoretically, CGM performance could be less precise in patients with high 
glycemic variability and furthermore CGM has a lag time in glucose 
values compared with the venous measured values (the physiological gap), 
this can underestimate the influence of GV on the glycation of HbA1c and 
no measures of erythrocyte survival, oxidative stress, or clinical follow-up 
are available in this population 
In conclusion, at higher levels of GV the relationship between HbA1c and 
MPG in patients with T1DM is altered leading to a higher HbA1c level for 
a given MPG. However, the impact (near the HbA1c treatment target of 
7%) is only modest.  
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ABSTRACT  
 
BACKGROUND 
Mean plasma glucose (MPG) and HbA1c are tightly related, but inter-
individual variability, quantified by the Hemoglobin Glycation Index 
(HGI), exists and may be attributable to non-glycemic factors affecting 
glycation. We explored whether non-glycemic factors were associated 
with HGI. 
METHODS 
We analyzed data from 268 T1DM, 159 T2DM patients and 80 healthy 
volunteers (HV). HGI was calculated from the MPG/HbA1c regression-
equation. Uni- and multivariate analyses determined whether non-
glycemic factors were associated with HGI. 
RESULTS 
HGI was higher in patients with T1DM than in T2DM and HV. 
Fructosamine (FA) levels were correlated with HGI. Smoking, total 
cholesterol, LDL, Apo-B and age were significantly correlated with HGI 
for the total population. For the high and low outliers combined, glucose 
variability (GV) measures, AUC24 and FA explained the largest fraction 
of the variance of the outlier status (p<0.0001). DM type (p<0.0001), 
insulin treatment (p<0.009), current smoking status (p<0.003) and Apo-
B/A1 (p<0.005) were the next most influential variables explaining outlier 
status. All variables combined explained only 10 to 17% of the variance in 
the MPG/HbA1c relationship for the High and Low outliers. 
CONCLUSION 
GV and FA are the major factors correlated with HGI and high outlier 
status (higher HbA1c than predicted from MPG). High HGI was found 
more often in patients with T1DM, possibly explained by the higher GV. 
The identified non-glycemic variables associated with HGI explained only 
a minor fraction of the variance in the MPG/HbA1c relationship.  
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The rate of non-enzymatic glycation of hemoglobin is determined by 
exposure to glucose throughout the erythrocyte lifespan. Under stable 
erythrocyte conditions, HbA1c, a measure of glycated hemoglobin, reflects 
average glycemia over the preceding 8-12 weeks.1,2 The importance of 
HbA1c as a predictor of outcome in diabetes has been established in large 
intervention studies.3,4,5  
The A1c-Derived Average Glucose (ADAG) study demonstrated a close, 
linear relationship of HbA1c to mean plasma glucose (MPG).6 However, 
variability still exists, both from a measurement perspective (for both 
glucose and HbA1c analyses) and possibly due to biologic variability. 
Other studies have suggested that persons with similar MPG levels, 
usually estimated from limited SMBG data, may have different HbA1c 
levels even in the absence of factors known to interfere with the accurate 
measurement of HbA1c.7-13  
The hemoglobin glycation index (HGI) is a method to quantify the 
difference between a patient’s actual, measured HbA1c and the predicted 
HbA1c level derived from MPG based on glucose monitoring data and the 
MPG/HbA1c regression equation.9,13 Individuals with a high HGI, so-called 
high glycators, have been suggested to have a higher risk of developing 
vascular complications.13-15 16,17  
Whether the concept of high and low glycators is a real phenomenon and 
whether non-glycemic factors play an important additional role is unclear. 
Recently we demonstrated that glucose variability (GV), which has been 
suggested to enhance oxidative stress, affects HbA1c to a modest degree.18 
This may suggest that other factors, known to be linked to oxidative stress, 
may impact the rate of glycation.19,20 
The ADAG data provide a unique opportunity to examine this issue owing 
to the large number of subjects, the density of glucose data used to 
calculate MPG and the carefully performed HbA1c assays used to establish 
the relationship MPG/HbA1c relationship.6 In this study we explored 
whether non-glycemic factors can explain the variability in glycation of 
HbA1c. We hypothesized that demographic, clinical and/or biochemical 
characteristics might explain part of the variability in the relationship 
between MPG and HbA1c. 
 
 
RESEARCH DESIGN AND METHODS  
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Study participants 
The ADAG study was conducted at 10 centers in the United States, 
Europe, and Africa from 2006-2008 to define the relationship between 
HbA1c and average glucose levels. A complete description of this 
observational study has been published6. Briefly, a total of 268 individuals 
with T1DM, 159 individuals with T2DM (age 18-70 years) and 80 healthy 
volunteers completed the study. Participants were selected based on stable 
glycemic control as evidenced by two HbA1c values within one percentage 
point of each other in the six months prior to recruitment.  
Participants with conditions leading to major changes in glycemia (e.g. 
infectious disease, steroid therapy, pregnancy) or conditions that might 
interfere with measurement of HbA1c or the MPG/HbA1c relationship 
(hemoglobinopathies21, anemia, increased erythrocyte turnover, blood 
transfusions, chronic renal or liver disease) were excluded.6  
The study was approved by the human studies ethics review boards at the 
participating institutions.  Informed consent was obtained from all 
participants.6 
 
Measurements of glycemia 
During the 16 week study period, blinded continuous interstitial glucose 
monitoring (CGM) (Medtronic Minimed, Northridge, CA) was performed 
at baseline and approximately at 4 week intervals. The four monitoring 
periods lasted at least 48 hours, during which glucose levels were assessed 
every 5 minutes. CGM data were accepted for analysis if there were no 
gaps longer than 120 minutes and if the mean absolute difference with the 
Hemocue calibration results was less than 18%, as recommended by the 
manufacturer. For calibration purposes, participants performed SMBG 
with the Hemocue meter (Hemocue Glucose 201 Plus, Hemocue, 
Ängelholm, Sweden) during the days of CGM. 
Subjects additionally performed a 7-point SMBG (One Touch Ultra, 
Lifescan, Milipitas, CA) for at least 3 days per week during the weeks 
when CGM was not performed. All blood glucose (BG) values stated are 
plasma equivalents. 
Measurements of MPG, GV and hyperglycaemic episodes were calculated 
based on CGM data after exclusion of the initial 2 hours of monitoring 
(the unstable calibration period). MPG was calculated from the CGM data 
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and the 7-point SMBG (lifescan) data, weighted by the days of 
monitoring.6 
HbA1c samples were analyzed with four highly inter-correlated DCCT-
aligned assays; a high-performance liquid chromatography assay, two 
immunoassays, and an affinity assay, all approved by the National 
Glycohemoglobin Study.22,6 The mean HbA1c value at the end of the 12 
week study period was used. 6 
Fructosamine (FA), a measure of intermediate-term (~2 weeks) average 
glycemia was measured in the VU University Medical Center for all 
participants at baseline. A subset of patients with T1DM and T2DM (n = 
73) had FA levels measured at the end of 3 months. Serum albumin levels 
in the normal range were an inclusion criteria.  
Total and HDL-cholesterol and triglycerides were measured by standard 
enzymatic methods (Roche, Mannheim, Germany). Plasma LDL 
cholesterol was calculated according to Friedewald's formula.23 
Apolipoprotein B and Apolipoprotein A1 concentrations were determined 
nephelometrically using an “Immage 800” immunochemistry system 
(Beckman Coulter Inc., Fullerton, CA).  
  
Calculating glucose variability 
Three indices of intraday GV were calculated based on CGM; the standard 
deviation (SD), the Mean Amplitude of Glycemic Excursions (MAGE), 
and the Continuous Overlapping Net Glycemic Action (CONGA).24 High 
SD, MAGE and CONGA values indicate high intra-day glucose 
variability. MAGE is the mean of the differences between consecutive 
peaks and nadirs, only including changes of more than 1 SD of glycemic 
values and thus capture only major fluctuations.25 For the calculation of 
CONGAn, the difference of the current value as compared to the value n 
hours previously is calculated for each observation after the first n hours.  
The CONGAn is the SD of these differences.24 In these analyses, we used 
CONGA at 4 hours (CONGA4).  
The area under the curve for blood glucose concentrations above 200 
mg/dl (11.1 mmol/L) (AUC>200) was determined as a measure of general 
hyperglycemia calculated on the CGM period. 
 
CHAPTER 4  
   
 90 
Statistical analysis  
Two approaches to calculate HbA1c glycation were used: the Hemoglobin 
Glycation Index (HGI) and HbA1c outlier status. HGI was calculated for 
each patient as the non-standardized residual of HbA1c to the MPG/HbA1c 
regression line, being the difference of the observed HbA1c minus the 
predicted HbA1c (based on the individual MPG inserted in the MPG/HbA1c 
regression equation). 
The HGI as a continuous variable was then correlated to demographic and 
clinical factors including age, gender, diabetes type, smoking status, 
race/ethnicity (white, African or African-American, Hispanic or Asian), 
medication, BMI, waist circumference, blood pressure, measures of GV 
(SD, MAGE, CONGA4), hyperglycemia (AUC>200mg/dL; 11.1 mmol/L), 
lipid profile and FA at baseline and at the end of 3 months. The students t-
test was performed to compare HGI for sex, smokers, age groups (< or > 
50 years), AUC>200mg/dl, medication (lipid lowering and 
antihypertensive). The ANOVA and post hoc test was performed to 
compare patients groups (T1DM, T2DM and participants without 
diabetes) and ethnicity for HGI.  
For assessment of HbA1c Outliers, study subjects were considered outliers 
when their HbA1c fell outside the (arbitrarily chosen) 80% prediction 
interval of the MPG-HbA1c regression line. High outliers were defined by 
HbA1c falling above this 80% prediction range, while low outliers fell 
below this range. 
 
We performed univariate analyses of the relationship between outlier 
status and the above mentioned clinical and demographic factors. 
Multivariate analyses were also performed using logistic regression. P-
values from multivariate analyses were obtained from Fisher’s exact test. 
For the multivariate regression analyses, the same factors used in the 
univariate analyses were used in a forward variable selection to find the 
predictors for low HGI, high HGI and high plus low HGI, respectively. A 
two-sided P-value of 0.05 was used as the selection threshold for each 
variable. We calculated the Nagelkerke R Square explaining the 
percentage of variance. Analyses were performed using SPSS statistical 
package.  
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RESULTS 
Five hundred seven subjects (268 T1DM, 159 T2DM and 80 non-DM) 
completed the study and provided adequate continuous and self-measured 
glucose monitoring and HbA1c samples, to be included in the analyses.6 
The relationship between the HbA1c level as the dependent variable at the 
end of the 3-month study period and the calculated MPG during the 
preceding 3 months, was expressed as the simple linear regression: HbA1c 
(%) = 0.0295 x MPG mg/dL + 2.4, (R2 = 0.84, SE = 0.087 %).  
Seventy-four 74 (14.6%) of the 507 subjects had HbA1c levels outside the 
80% prediction band of the relationship between HbA1c and MPG, 44 
subjects were high outliers with higher than predicted HbA1c levels, and 30 
subjects were low outliers with lower than predicted HbA1c values. 
Baseline characteristics are shown in Table 1.  
HbA1c values were generally stable, with 96% of the subjects maintaining 
HbA1c within +/- 1 percentage point of their baseline value over the course 
of the study. Mean of baseline HbA1c levels were higher in T1DM (7.3% 
+/- 1.1) compared to T2DM patients (6.8% +/- 1.1) and participants 
without diabetes (5.2% +/- 0.3). Furthermore, the degree of GV, whether 
expressed as SD, MAGE or CONGA4, was higher among individuals with 
T1DM compared to those with T2DM or patients without diabetes. (Table 
1) The HGI was normally distributed for the whole population and for the 
T1DM, T2DM patients and the healthy volunteers separately. The HGI 
values were higher and the distribution wider in T1DM (0.535; -1.70 to 
2.77) than in persons with T2DM (0.125; - 1.77 to 1.92) and healthy 
volunteers (-0.730; -1.85 to 0.39). Outlier status was relatively consistent 
during the 3-month study period.  
The univariate correlations between glycemic and non-glycemic variables 
with HGI are shown in Table 2. Measures of GV (SD, MAGE and 
CONGA4) and fructosamine (FA) were significantly correlated with HGI. 
Also total cholesterol, LDL, Apo B and age were significantly correlated 
with HGI for all patients pooled. Ethnicity, gender, age (< or > 50 years), 
smoking status, and blood pressure treatment modality were not associated 
with HGI. 
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Table 1. Baseline clinical and glycemic characteristics: Means (SD) or % 
 
 All  T1DM T2DM Non-diabetic 
  (n = 507) (n = 268) (n = 159) (n = 80) 
 
Age 
 
47.6 (13.6) 
 
44.1 (12.9) 
 
56.6 (9.4) 
 
41 (13.8) 
Gender (% female) 54% 52% 51% 69% 
Ethnicity     
Non-hispanic white 82% 91% 74% 71% 
African/African-American 8% 2% 13% 15% 
Hispanic 8% 6% 8% 15% 
Other 2% 0 5% 0 
Current smokers 11% 12% 9% 9% 
     
Glycemic measures     
HbA1c (%) 6.8 (1.3) 7.3 (1.1) 6.8 (1.1) 5.2 (0.3) 
MPG (mg/dl) 149.4 (39.6) 162 (36) 149.4 (36) 100.8 (7.2) 
MPG (mmol/l) 8.3 (2.2) 9 (2) 8.3 (2) 5.6 (0.4) 
 
Insulin treatment 65 % 100 % 38 % 0 % 
Antihypertensive 
treatment 
42 % 38 % 62 % 13 % 
Lipid lowering treatment 36 % 31 % 60 % 5 % 
Total Cholesterol 
(mmol/l) 
4.5 (0.9) 4.5 (0.9) 4.4 (1) 4.6 (0.9) 
HDL (mmol/l) 1.5 (0.5) 1.7 (0.5) 1.2 (0.4) 1.5 (0.6) 
LDL-size (nm)  
 
21 (0.5) 21.1 (0.4) 20.8 (0.6) 21 (0.5) 
Triglycerides (mmol/l) 1.4 (0.9) 1.1 (0.6) 1.9 (1) 1.3 (0.8) 
     
Glucose Variability 
measures 
    
CGM SD (mg/dl) 48.6 (25.2) 64.8 (16.2) 39.6 (16.2) 14.4 (3.6) 
MAGE (mg/dl) 86.4 (43.2) 115.2 (32.4) 68.4 (27) 25.2 (9) 
CONGA4 (mg/dl) 66.6 (34.2) 88.2 (23.4) 52.2 (21.6) 18 (5.4) 
     
HGI     
Low 30 (5.9%) 17 (6.3%) 11 (6.9%) 2 (2.5%) 
Controls (within 80% 
prediction band) 433 (85.4%) 215 (80.2%) 140 (88.1%) 78 (97.5%) 
High 44 (8.7%) 36 (13.4%) 8 (5%) 0 (0%) 
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Table 2: Pearson Correlations correlation coefficients for the total 
population between the HGI and other measures. 
 
Pearson Correlation HGI Sig. (2-tailed) N =  
HbA1c  0.384 < 0.001 507 
    
SD 0.181 < 0.001 507 
MAGE 0.159 < 0.001 507 
CONGA4 0.174 < 0.001 507 
    
Fructosamine  
       Baseline 
 
0.201 
 
< 0.001 
 
453 
       end of 3 months 0.335 < 0.001 73 
Age 0.122 0.006 507 
Total  cholesterol 0.132 0.005 453 
HDL-cholesterol 0.072 0.126 453 
LDL-cholesterol 0.098 0.037 452 
Triglyceride -0.046 0.331 453 
Apo B 0.103 0.029 445 
 
 
Table 3 shows the results of the univariate analyses of factors associated 
with outlier status. Using the forward variable selection procedure, two-
sided analysis of outliers above the upper limit of the 80% prediction band 
(High HGI) resulted in the following predictors: SD, MAGE, CONGA4 
and AUC24 (p<0.0001), FA (p<0.0001), DM type (p=0.03), smoking status 
(p=0.001), Apo B (p<0.05) Insulin treatment (p<0.0007) and Lipid 
treatment (p<0.01).   
Two-sided analysis of outliers below the lower limit of the 80% prediction 
band (Low HGI) led to the following predictors; FA (p<0.05), AUC24 
(p=0.003), waist (p=0.003), HDL (p=0.009) and Apo A1 (p=0.009).  
An analysis of the combined outliers outside the 80% prediction band 
(high and low HGI) vs. non-outliers identified the following predictors SD 
(p<0.0001), MAGE (p<0.0002), CONGA4 (p<0.0001) and AUC24 
(p<0.0001), FA (p<0.0001), DM type (p=0.002), smoking (p=0.001), 
waist (p=0.01), HDL (p<0.05), Apo A1 (p<0.05), Apo B (p<0.05) Insulin 
treatment (p<0.006).  
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Table 3: Univariate analyses of factors associated with outlier status.╪ 
 
 High outliers = High HGI Low outliers = Low HGI High plus Low outliers  
 OR (95% CI) P value OR (95% CI) Pvalue OR (95% CI) P value 
SD 1.41 (1.22-1.63) <0.0001  NS 1.27 (1.14-1.42) <0.0001 
MAGE 1.16 (1.08-1.25) <0.0001  NS 1.12 (1.05-1.18) 0.0002 
CONGA4 1.27 (1.14-1.40) <0.0001  NS 1.18 (1.09-1.27) <0.0001 
AUC24 1.38 (1.17-1.61) <0.0001 1.29 (1.09-1.52) 0.003 1.37 (1.20-1.57) <0.0001 
FA baseline 1.011 (1.007-1.015) <0.0001 1.005 (1.001-1.009) 0.02 1.008 (1.005-1.011) <0.0001 
FA end 3 M  1.016 (1.005-1.027) 0.004  NS 1.013 (1.004-1.022) 0.006 
Smoking 3.46 (1.62-7.40) 0.001  NS 2.87 (1.50-5.47) 0.001 
DM type  0.03  NS  0.002 
DM1 vs 2  NS  NS 9.61 (2.29 – 40.39) 0.002 
DM2 vs nDM  NS  NS 5.29 (1.20 -23.32) <0.05 
Center  <0.05  NS  <0.01 
Insulin 0.19 (0.07-0.50) 0.0007  NS 0.45 (0.25- 0.80) 0.006 
Lipid treat 0.44 (0.23-0.82) 0.01  NS  NS 
HDL  NS 0.30 (0.13 -0.74) 0.009 0.59 (0.35 -0.99) <0.05 
Apo A1  NS 0.12 (0.02 -0.59) 0.009 0.36 (0.14 -0.93) <0.05 
Apo B 5.42 (1.43-20.6) 0.01  NS 3.64 (1.21-10.99) 0.02 
Waist  NS 1.03 (1.01-1.05) 0.003 1.02 (1.00-1.03) 0.01 
* OR (95% CI) and p values reported 
╪ Age, waist, BMI-body mass index (kg/m2), FA-fructosamine, ACE inhibitors, 
Systolic and diastolic blood pressure, Blood pressure treatment, center, race, 
gender, Tot Chol, LDL, Triglyceride and LDL size were not significantly 
associated with outlier status. 
SD, MAGE and CONGA4  10 mg/dL 
AUC per 106 
 
The results from the multivariate analyses (Table 4 on line appendix) of 
factors associated with outlier status show that the GV measures SD, 
MAGE, and CONGA4, and AUC24 and FA explained the largest fraction of 
the variance of the outlier status for the High outliers (p<0.000). DM type 
(p<0.000) and insulin treatment (p<0.000) and current smoking status 
(p<0.001) were the next variables explaining outlier status. Apo-B 
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(p<0.006), and insulin (p<0.000) and lipid treatment (p<0.007) were 
significant, but only in the High outliers.  
All variables combined explained only 13 to 25 % of the variance in the 
MPG/HbA1c relationship for the High outliers. The “non-glucose 
variables” –diabetes type and insulin treatment (not being independent of 
GV)- didn’t remain significant after accounting for the GV variables. 
(Table 4 On line appendix)  
For the High and low outliers combined, the GV measures SD, MAGE, 
and CONGA4, and AUC24 and FA explained also the largest fraction of the 
variance of the outlier status (p<0.000). DM type (p<0.000), insulin 
treatment (p<0.009) and current smoking status (p<0.003) and Apo-B/A1 
(p<0.005) were the next variable explaining outlier status. All variables 
combined explained only 10 to 17 % of the variance in the MPG/HbA1c 
relationship for the High and Low outliers. 
 
DISCUSSION 
Both glycemic and non-glycemic factors significantly contributed to the 
variation in the relationship between MPG and HbA1c, albeit none 
strongly. Of the measured variables, measures of glucose variability (GV) 
were the main determinants of a high HGI.  
The GV estimate SD explained the largest fraction of the outlier status for 
the High outlier, but not Low outlier, group. The small number of patients 
in the latter group may explain this finding. Smoking status was the next 
variable explaining outlier status. Finally, diabetes type, Apo-B levels and 
insulin and lipid treatment were associated with High outliers. However 
these factors combined explained only 25% of the variance in the 
MPG/HbA1c relationship for the High outliers. The “non-glucose 
variables” diabetes type and insulin were not independently associated 
with HGI. Smoking status, LDL, Apo-B and Apo-B/A1, independent of 
GV, were related with high HGI. Smoking history may change RBC 
turnover. 
FA concentrations measured at baseline (n = 507) were significantly 
correlated with HGI and outlier status. This interesting finding suggests 
that patients with a high HGI and thus a higher than predicted HbA1c also 
have higher FA levels. This finding supports prior suggestions that the 
period of glycemic exposure in the few weeks before an HbA1c 
measurement- as reflected by FA- may play a disproportionate role in the 
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HbA1c value. Alternatively, GV may affect the rate of glycation in general, 
measured as HbA1c or FA. 
As expected, the T1DM group had higher average BG, HbA1c and GV 
values than T2DM and non-DM groups. This explains the greater variance 
in the relationships with High HGI. Kilpatrick et al. found that HbA1c 
values vary markedly between subjects without diabetes, while values 
within the same individual are very consistent.7 A potential, unproved 
explanation for this biological variability is the concept of fast and slow 
glycation, as described by Hempe9 and by earlier smaller studies in people 
without7,10,11 and with diabetes.8,12 Most of these studies suffered from 
inadequate number of glucose measurements, therefore, discrepancies 
between HbA1c and MPG could be secondary to an inaccurate appreciation 
of MPG. The ADAG study included frequent measurements of blood 
glucose over time, with frequent measurements 52 of 84 days prior to 
HbA1c measurement. The HbA1c level was established with four highly 
precise assays performed in one central laboratory. Therefore, 
discrepancies in the MPG/HbA1c relationship among individuals are less 
likely due to errors in the measurements of either MPG or HbA1c.  
Although the ADAG study population was selected to limit factors known 
to interfere with the measurement of MPG or HbA1c, or with the 
relationship between them, inter-individual differences, such as race, 
gender, age, were of course not excluded.  
Limitations of this study include the limited range of reliable 
measurements outside the 40 mg/dL and 400 mg/dL (2.2 and 22.2 
mmol/L) when using CGM and the variation in MPG measurement with 
the Lifescan meter. Although it is one of the largest studies examining the 
relationship between HbA1c and MPG, the relatively small sample size of 
the subpopulations (Table 1) may have affected our findings. Finally, the 
measurement of HGI is not independent of the HbA1c level, so the 
associations documented with HGI may be confounded by the HbA1c level 
itself.26  
In conclusion, higher GV was associated with higher HGI. Measures of 
GV (SD, MAGE and CONGA4) and FA are strongly correlated with HGI 
and high outlier status. The GV measure SD and smoking status explained 
the largest fraction of outlier status for the High outliers. These variables 
together explained only around 13 % of the variance in the MPG/HbA1c 
relationship. 
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Table 4 (on-line appendix) P values of variables that remain significant 
in the next steps of the multivaraite analyses and the nagelkerke R2 
R2 = Nagelkerke R square, Lip Tr = Lipid treatment.  
 
 HGI High HGI Low HGI High + Low 
Step 0 1 2 3 4 5 0 1 2 3 0 1 2 3 
SD 0.000 0.020 0.026        0.000    
MAGE 0.000    0.047      0.000    
CONGA4 0.000 0.011 0.010  
  
   
 0.000 
  
 
AUC24200 0.000    
  
0.001   
 0.000 
  
 
FA 0.000      0.009  0.043  0.000    
DM type 0.000    
  
   
 0.000 
  
 
Smoker 0.001 0.004 0.011 0.024 0.049       0.012 0.028  
Waist  0.021   
  
0.005 0.011  
 0.003 
0.000  
 
HDL     
  
0.029 0.020  
 0.015 
0.004  
 
LDL    0.021           
Apo-A1     
  
0.037 0.033  
  
0.006  
 
Apo-B 0.006 0.036 0.033 0.012        0.049   
Apo-B/A1 0.025 0.029 0.043 0.017 
  
0.048   
 0.013 
0.006  
 
Insulin 0.000    
  
   
 0.005 
  
 
Lip Tr 0.007 0.001         0.009 0.030   
DM type:  
I vs II     
  
   
  
  
 
I vs N 0.005    
      0.001 
0.048  
 
R2  0.132 0.177 0.207 0.236   0.055 0.093   0.103 0.154  
    0.254                 0.117                                   0.170 
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ABSTRACT 
 
AIMS 
Plasma 1,5 AnhydroGlucitol (1,5AG) is cleared renally by competitive 
inhibition at glucose levels above the renal threshold for glucose. As 
previous studies have shown reduced 1,5AG levels in hyperglycaemic 
patients, 1,5AG has been proposed as a marker of glycaemic excursions. 
The primary objective was to assess the performance of 1,5AG to detect 
hyperglycaemic episodes according to predefined HbA1c levels.  
METHODS 
We examined the correlation of 1,5AG, stratified for HbA1c, with 
measures of glucose variability (GV) and hyperglycaemic episodes in 231 
subjects with Type 1 and 137 with Type 2 diabetes mellitus in the A1c 
Derived Average Glucose study. Measures of GV were obtained from 48-
h Continuous Glucose Monitoring. Pearson correlations and Receiver 
Operating Characteristic (ROC) analyses were performed to assess the 
performance of 1,5AG to detect hyperglycaemic episodes.  
RESULTS 
The test performance of 1,5AG to detect hyperglycaemic episodes in 
patients with HbA1c ≤ 64 mmol/mol (8%) was fair (AUC of ROC curve 
0.73, p < 0.001). GV measures showed, even when adjusted for HbA1c, 
consistent inverse correlations with 1,5AG in patients with HbA1c ≤ 64 
mmol/mol (8%), but not with HbA1c > 64 mmol/mol (8%).  
CONCLUSION  
The test performance of 1,5AG to detect hyperglycaemic episodes in 
moderately controlled patients (HbA1c ≤ 64 mmol/mol (8%)) is fair. 
Measures of GV and hyperglycaemic episodes correlated significantly and 
inversely with 1,5AG at HbA1c levels ≤ 64 mmol/mol (8%) and between 
43 and 64 mmol/mol (6 - 8%). Measuring 1,5AG in addition to HbA1c may 
identify  GV, especially in moderately controlled patients with diabetes. 
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Introduction 
The currently available markers for long-term glycaemic control, including 
HbA1c and Fructosamine, reflect average glucose concentrations, and do 
not provide information on glucose variability (GV). However, previous 
studies have suggested that GV and/or elevated postprandial glucose levels 
may be associated with an increased risk of cardiovascular disease. [1-3] 
Patients in acceptable glycaemic control according to HbA1c levels may 
still have significant postprandial hyperglycaemia. [4] Therefore, an 
additional, easily measured, marker reflecting postprandial glucose-
excursions could be valuable in the management of patients with diabetes. 
The 1-deoxy form of glucose, or plasma 1,5 AnhydroGlucitol (1,5AG), 
has been proposed as such a marker of glycaemic excursions [5] as 
previous studies have shown reduced 1,5AG levels in hyperglycaemic 
patients.  
1,5AG is a naturally occurring dietary polyol. In normoglycaemic persons, 
plasma 1,5AG concentrations are maintained at a constant steady-state 
level, mainly because 1,5AG is not metabolized and is distributed in a 
large body pool. [6,7] 1,5AG is renally filtered and completely reabsorbed 
at the proximal renal tubule. [8] However, when blood glucose 
concentrations reach values above the renal threshold, 1,5AG levels 
decline due to competitive inhibition of the renal tubular re-absorption by 
glucose. Previous studies have shown 1,5AG levels to be determined by 
hyperglycaemia, the duration and the magnitude of glucosuria [11,12] and 
by the renal threshold for glucose. [13,14,15] Also 1,5AG levels gradually 
normalize in response to blood glucose lowering therapies. [9,10]  
An automated assay for 1,5AG (Glycomark) has recently been approved in 
the United States by the Food and Drug Administration as a short-term 
marker for glycaemic control.[16] A similar assay has been in use in Japan 
for over a decade. [17] 
The main aim of this study was to examine whether 1,5AG levels can 
detect patients with increased glucose variability (GV), as well as 
increased (postprandial) hyperglycaemic episodes in the extensive glucose 
monitoring data of the A1c Derived Average Glucose (ADAG) study. [18]  
In addition, we analyzed whether the relationships between 1,5AG and 
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measures of glycaemia, and Glucose variability were influenced  by 
predefined ranges of HbA1c. 
Patients and Methods   
Study participants  
The ADAG study was conducted at 10 centers: 6 in the United States, 3 in 
Europe, and 1 in Cameroon from 2006-08 to define the relationship 
between HbA1c and average glucose levels. A full description of this 
observational study population and design has previously been published. 
[18] A total of 268 individuals with Type 1 Diabetes (T1DM) and 159 
individuals with Type 2 Diabetes (T2DM) (age 18-70 years) and 80 
participants without diabetes completed the study. The participants 
without diabetes had a plasma glucose level <5.4 mmol/l (97 mg/dl) after 
an overnight fast, HbA1c < 48 mmol/mol (6.5%) and no history of 
diabetes. Participants were selected based on stable glycaemic control as 
evidenced by two HbA1c values within one percentage point of each other 
in the six months prior to recruitment. Individuals with a wide range of 
HbA1c levels were included.  
Participants with conditions leading to major change in glycaemia (e.g. 
infectious disease, steroid therapy, pregnancy), or conditions that might 
interfere with the measurement of HbA1c or the relationship between 
HbA1c and mean plasma glucose (MPG) (haemoglobinopathies, anemia, 
severe renal or liver disease) were excluded. The human study committee 
at the participating institutions approved the study and informed consent 
was obtained from all participants. 
These analyses are based on 368 patients with diabetes (231 T1DM and 
137 T2DM) and 60 participants without diabetes who had acceptable 
measurements of HbA1c, 1,5AG and adequate continuous glucose 
monitoring (CGM) to calculate all GV variables. Because of missing 
laboratory data and for technical reasons (gaps in CGM readings) we 
could not calculate all the measures of glucose variability in all original  
participants of the ADAG study. 
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Measurements of HbA1c, 1,5AG and blood glucose levels  
HbA1c samples from baseline visit were frozen and shipped to a central 
laboratory and analyzed with four highly inter-correlated DCCT-aligned 
assays, all aligned with the National Glycohemoglobin Study Program. 
[18,19] Likewise, plasma 1,5AG was measured at baseline from frozen 
samples by an automated enzymatic colorimetric assay for 1,5AG 
(Glycomark; Tomen America, New York, NY) in a central laboratory. The 
intra- and inter-assay precision was 1.3-3.8% and 0.8-3.8%, respectively. 
The reference means (SD) for 1,5AG µg/ml for men and women without 
DM are 22.5 (5.8) and 17.7 (6.2), respectively. The (non parametric) 
reference intervals of 1,5AG for men and women without DM are 10.7 - 
32.0 and 6.8 – 29.3 µg/ml, respectively. [20]   
During the study period, continuous interstitial glucose monitoring (Gold, 
Medtronic Minimed, Northridge, CA) was performed at home 4 times with 
4-week intervals during the 16-week study period. Monitoring periods 
lasted at least 48 hours, during which time glucose levels were assessed 
every 5 minutes. CGM data were accepted for analysis if there were no 
gaps longer than 120 minutes and if the mean absolute difference with the 
Hemocue calibration results was less than 18%, as recommended by the 
manufacturer. For calibration purposes, participants performed self-
monitoring of blood glucose (SMBG) with the Hemocue meter (Hemocue 
Glucose 201 Plus, Hemocue, Ängelholm, Sweden) during the days of 
CGM. For adequate calculation of MPG, subjects additionally performed a 
7-point SMBG (One Touch Ultra, Lifescan, Milipitas, CA) for at least 3 
days per week during the weeks when CGM was not performed. 
 
Calculation of glycaemic indices  
Three indices of glucose variability were calculated based on CGM data 
(one 48-hour period) at baseline visit; the standard deviation (SD), the 
Mean Amplitude of Glycaemic Excursions (MAGE), and the Continuous 
Overlapping Net Glycaemic Action (CONGA). The SD, MAGE and 
CONGA are measures of glucose fluctuations during the day. In other 
words high SD, MAGE and CONGA values indicate high intra-day 
glucose variability. MAGE is the mean of the differences between 
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consecutive peaks and nadirs, only including changes of more than 1 SD 
of glycaemic values and thus capturing only major fluctuations. [21] For 
the calculation of CONGAn, the difference of the current value as 
compared to the value n hours previously is calculated for each 
observation after the first n hours. The CONGAn is the SD of these 
differences and can only be calculated on complete traces. [22] In the 
analyses we used CONGA at 4 hours (CONGA4). CONGA analyses for 1, 
2, and 6 h correlated to CONGA4 with correlation coefficients of 0.94, 
0.98, and 0.99, respectively (data not shown). Calculations based on CGM 
data were calculated after exclusion of the initial 2 hours of monitoring, 
which is considered to be an unstable calibration period. 
The area under the glucose curve was determined above the level of 180 
mg/dl (10 mmol/L) (AUC180) from the CGM data. This was used as an 
index of over-all hyperglycaemic episodes or the duration of time in 
seconds*106 having glucose levels above 180 mg/dl (10 mmol/L) which is 
above the renal threshold of glucose. Also from CGM, a postprandial 
AUC (AUCpp) was calculated. We used the premeal SMBG measurement 
as a first reading before a meal to determine the 2 or 4 hours postprandial 
area under the curve at the CGM reading. The mean of AUCpp is 
computed for each person at baseline visit in order to get one AUCpp 
measure. This was only possible in a limited number (129 = 61.4%) of 
patients with T1DM and (81 = 38.6%) patients with T2DM because of 
missing data.  
 
Statistical analyses  
The primary objective was to assess the performance of 1,5AG to detect 
hyperglycaemic episodes according to predefined HbA1c levels. The 
secondary objective of the analysis was to examine whether the 
relationships between 1,5AG and measures of glycaemia (MPG and 
HbA1c), GV (defined as SD, MAGE and CONGA4) and hyperglycaemic 
episodes (AUC180 and AUCpp) were influenced by HbA1c level, all 
measured at baseline. Subjects were only included in the analysis when all 
these data were available. Measures of participants without diabetes were 
used to validate the reference range for persons without diabetes.  
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We performed Receiver Operating Characteristic (ROC) analyses to 
examine the test performance of 1,5AG in detecting hyperglycaemic 
episodes, testing the sensitivity (true positive) and the 1-specificity (false 
positive) of the test marker 1,5AG. Because 1,5AG is cleared renally by 
competitive inhibition above a renal threshold of approximately 180 mg/dl 
(10 mmol/L), we defined the test performance of 1,5AG to detect 
hyperglycaemic episodes as defined by AUC180 > 0. Participants with 
AUC180 > 0 are defined as positive cases and participants with no periods 
of AUC180 > 0 are defined negative cases. We stratified our analyses at 
pre-specified levels of HbA1c: full HbA1c range, ≤ 42 mmol/mol (6%), 43 
– 64 mmol/mol (6-8%), > 64 mmol/mol (8%) and ≤ 64 mmol/mol (8%). 
The 95% CI and p value are asymptotic. 
We explored the bivariate associations (Pearson correlations) between 
1,5AG (log transformed) and glycaemic indices obtained from CGM data, 
stratified by pre-specified baseline HbA1c level, and adjusted for diabetes 
type, sex, and age. To examine whether assessing 1,5AG adds clinical 
value to HbA1c alone in the prediction of hyperglycaemic episodes or GV, 
we performed partial correlations adjusted for diabetes type, sex and age 
and HbA1c. 
 
Results  
In a total of 368 patients with diabetes (231 T1DM, 137 T2DM) all 
relevant glycaemic measures from CGM, laboratory values of HbA1c, and 
1,5AG were available.  Mean HbA1c of the patients with T1DM and 
T2DM was 58 mmol/mol (7.5%) (range 31 – 130 mmol/mol (5% – 14%)) 
and 53 mmol/mol (7.0%) (range 33 – 109 mmol/mol (5.2% – 12.1%)) 
respectively. We also present 1,5AG values for 60 participants without 
diabetes (39 women, 21 men, mean HbA1c 33 mmol/mol (5.2%) (range 27 
– 39 mmol/mol (4.6% – 5.7%)) 1,5AG levels for the male participants 
without diabetes significantly exceeded those of the females. 1,5AG levels 
for all participants, stratified for HbA1c, are depicted in Table 1. The 
1,5AG levels were lower in patients with higher HbA1c levels.  
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Table 1: Plasma 1,5AG values in µg/ml for participants without diabetes 
(no DM), men and women separately and shown for patients with diabetes 
in the different HbA1c group (HbA1c ≤ 42 mmol/mol (6 %), 43 – 64 
mmol/mol (6–8%), > 64 mmol/mol (8 %) and ≤ 64 mmol/mol (8 %)) 
 
 N = Min Max Mean Std 
Devia 
tion 
Me
dian 
 Ref Interval 
Lower   Upper 
 
Male no DM 21 12.1 44.1 25.1  8.3 26.1 11.6 - 48.5 
Female no DM 39 3.5 29.3 18.2 6.3 16.8 7.4 - 39.4 
DM HbA1c ≤  42 
(6 %) 48 2.3 29.1 14.4 6.3 15.4 4.1 – 39.7 
DM HbA1c 43–64 
(6 – 8%)  224  1.3 27.1 7.3 4.6 6.1 1.8 – 20.3 
DM HbA1c > 64 
(8%) 96 0.9 12.9 3.5 2.1 2.9 1.1 – 8.4 
DM HbA1c ≤  64 
(8%) 272 1.3 29.1 8.6 5.6 7.1  1.9 – 25.6 
 
We performed a ROC analysis on the data of all participants (60 without 
diabetes and 368 participants with diabetes), testing the sensitivity (true 
positive) and the 1-specificity (false positive) of the test marker 1,5AG to 
detect hyperglycaemic episodes as defined as AUC180 mg/dl (AUC10 
mmol/L) greater then 0. Participants with AUC180 > 0 are defined as 
positive cases and participants with no periods of AUC180 > 0 are defined 
negative cases. In this dataset (328 positive and 100 negative cases) the 
AUC of the ROC curve was 0.86 (SE 0.023, 95% CI = 0.82 – 0.91, p < 
0.001).  (Figure 1) 
The ROC analysis performed on the patients with diabetes in the full 
HbA1c range (322 positive and 46 negative cases) revealed an AUC of 0.78 
(SE 0.040, 95% CI = 0.71 – 0.86, p < 0.001) (Figure 2). This value ranged 
from 0.67 (SE 0.080 95% CI = 0.51 – 0.83 p < 0.047) in the HbA1c group 
≤ 42 mmol/mol (6%) (21 positive and 27 negative cases) to 0.73 (SE 
0.047, 95% CI = 0.63 – 0.82, p < 0.001) in the HbA1c group ≤ 64 
mmol/mol (8%) (227 positive and 45 negative cases). In the HbA1c group 
> 64 mmol/mol (8%) (n = 96), this analysis could not be performed 
because of the lack of negative cases. 
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Figure 1: ROC Curve for 1,5AG to detect hyperglycaemic episodes for 
patients with T1DM and T2DM in the full HbA1c range (322 positive and 
46 negative cases) The AUC of the ROC curve is 0.78 (SE 0.040, 95% CI 
= 0.71 – 0.86, p < 0.001). This value ranged from 0.67 (SE 0.080 95% CI 
= 0.51 – 0.83 p < 0.047) in the HbA1c group ≤ 42 mmol/mol (6%) (21 
positive and 27 negative cases) to 0.73 (SE 0.047, 95% CI = 0.63 – 0.82, p 
< 0.001) in the HbA1c group ≤ 64 mmol/mol (8%) (227 positive and 45 
negative cases). In the HbA1c group > 64 mmol/mol (8%) (n = 96), this 
analysis could not be performed because of the lack of negative cases i.e. 
were always hyperglycaemic.  
 
The relationship between 1,5AG and AUC180 was hyperbolic (Figure 2 A 
for the population with diabetes and over the full HbA1c range). The 
relationship in sub-groups based on pre-specified HbA1c categories (≤ 42 
mmol/mol (6%), 43 – 64 mmol/mol (6–8%) and > 64 mmol/mol (8%)) is 
shown in figure 2 B, C and D. At HbA1c levels ≤ 42 mmol/mol (6%) most 
patients had no hyperglycaemic episodes above 180 mg/dl (10 mmol/L) 
and the range of 1,5AG values was quite broad (Table 1). At HbA1c levels 
> 64 mmol/mol (8%) almost all patients experienced episodes above 180 
mg/dl (10 mmol/L) and 1,5AG values were generally low (mean 3.5 
µg/mL). In the HbA1c range between 43 – 64 mmol/mol (6 - 8%), the 
relationship between 1,5AG and AUC180 was quite heterogeneous. (Figure 
2 C)  
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Figure 2: The relationship between 1,5AG µg/mL and AUC > 180 mg/dl 
(10 mmol/L) for all patients with T1DM and T2DM (A) and divided into 
groups by HbA1c: HbA1c ≤ 42 mmol/mol (6 %) (B), 43 – 64 mmol/mol (6 
– 8%) (C) and > 64 mmol/mol (8%) (D), respectively. 
 
AUC180 sec*mg/dl = scale in sec*mg/dl x 106   = the duration of time in seconds 
having glucose levels above 180 mg/dL  in sec*mg/dl x 106, 1,5AG in µg/ml 
Bivariate associations (partial correlations) between 1,5AG and measures 
of glycaemic control and the post-prandial measures (AUCpp) in patients 
with T1DM and T2DM, stratified for HbA1c and adjusted for sex, diabetes 
type and age, are shown in Table 2. At HbA1c level between 43 – 64 
mmol/mol (6 - 8%), ≤ 64 mmol/mol (8%) and in the full HbA1c group 
there was a significant correlation between 1,5AG and measures of GV, 
MPG, AUCpp and AUC180. At HbA1c level ≤ 42 mmol/mol (6%) none of 
these correlations were statistically significant. At HbA1c levels > 64 
mmol/mol (8%), 1,5AG correlated with MPG and AUC180, but the 
correlation with measures of GV and with AUCpp was lost. In the full 
HbA1c group there was still a significant correlation between 1,5AG and 
measures of GV when we adjusted for HbA1c (Table 2).  
A B 
C D 
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Table 2: Correlation Coefficients of bivariate associations (partial 
correlations) of 1,5AG (log transformed), stratified for HbA1c, and 
measures of glycaemic control and GV, postprandial and hyperglycaemic 
episodes in patients with T1DM and T2DM pooled, adjusted for diabetes 
type, sex and age. The AUCpp values were not available in all patients but 
only in a smaller sample size. Correlation is significant; p-value < 0.05 * 
or < 0.01 ** 
 
Cor-
relation 
Co-
efficients  
1,5AG  
Full HbA1c 
range 
1,5AG  
Full HbA1c 
range 
Adjusted for 
HbA1c 
1,5AG  
HbA1c ≤42 
(6%) 
1,5AG 
HbA1c  
43-64  
(6-8%) 
1,5AG 
HbA1c ≤64 
(8%) 
1,5AG 
HbA1c >64 
(8%) 
N = 368 368 48 224 272 96 
MPG -0.546** -0.107* 0.013 -0.309** -0.411** -0.350** 
SD -0.479** -0.243** -0.247 -0.376** -0.441** -0.110 
MAGE -0.357** -0.212** -0.248 -0.268** -0.348** -0.130 
CONGA4 -0.440** -0.231** -0.213 -0.334** -0.404** -0.143 
AUC180 -0.443** -0.055 -0.102 -0.290** -0.341** -0.298** 
 1,5AG  
Full HbA1c 
range 
1,5AG  
Full HbA1c 
range 
Adjusted for 
HbA1c 
1,5AG  
HbA1c ≤42 
(6%) 
1,5AG 
HbA1c  
42-64 
(6-8%) 
1,5AG 
HbA1c ≤64 
(8%)  
1,5AG 
HbA1c >64 
(8%) 
N = 200 200 25 123 148 52 
AUCpp 2 
hours -0.410** -0.096 0.028 -0.191* -0.277** -0.151 
AUCpp 4 
hours -0.405** -0.068 -0.037 -0.214* -0.282** -0.169 
MPG = mean plasma glucose, SD = Standard deviation of glucose values, MAGE 
= mean amplitude of the glycaemic excursions, CONGA4 continuous overlapping 
net glycaemic action at n = 4 hours, AUC180 = Area under the curve of glucose 
value above 180 mg/dl, AUCpp = Area under the curve postprandial, respectively 
2 and 4 hours postprandial, 1,5AG = 1,5 Anhydroglucitol.
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Discussion 
The ROC analyses show that the test performance of 1,5AG to detect 
hyperglycaemic episodes (AUC180) in the moderately controlled patients 
(HbA1c ≤ 64 mmol/mol (8%)) was fair. Our study also showed that a 
significant number of patients with good to moderate glycaemic control 
(HbA1c ≤ 64 mmol/mol (8%)) experienced hyperglycaemic episodes 
(AUC180), and even at HbA1c values ≤ 42 mmol/mol (6%), 21 of the 49 
patients (43%) had glucose periods above 180mg/dl (10 mmol/L).  
This study also showed inverse correlations between 1,5AG values and 
several measures of glucose variability in patients with HbA1c levels ≤ 64 
mmol/mol (8%). Of the glucose variability measures tested, the largest 
(absolute) correlation was found between 1,5AG and SD of the mean 
glucose values. At HbA1c levels ≤ 64 mmol/mol (8%), we also found 
inverse correlations between 1,5AG and AUC180 and postprandial 
measures, confirming earlier studies that 1,5AG is associated with post-
prandial hyperglycemia in moderately controlled patients. [11,13,23] At 
HbA1c ≤ 42 mmol/mol (6%), non of the correlations was significant but 
this group was small, and glycaemic indices overall low. At HbA1c levels 
> 64 mmol/mol (8%) the relationship of 1,5AG with measures of GV and 
postprandial hyperglycemia was lost. This is, probably due to glucosuria-
induced lowering of 1,5AG levels as a result of overall hyperglycemia and 
consistent with the known kinetics of 1,5AG. At HbA1c levels > 64 
mmol/mol (8%) the 1,5AG levels were overall low (mean 1,5AG 3.1 
µg/mL). A HbA1c level of 64 mmol/mol (8%) reflects an MPG of 183 
mg/dl (10.2 mmol/L) (95% CI is 147 - 217 mg/dl) following the regression 
equation from the ADAG study. [18] Therefore, blood glucose will often 
be >180mg/dl (10 mmol/L), and levels of 1,5AG will be persistently low. 
Measuring 1,5AG in patients with an HbA1c > 64 mmol/mol (8%) 
therefore provides no additional information, as it has also been suggested 
in prior studies. [13,23,24] 
The partial correlations adjusted for diabetes type, sex and age and HbA1c 
for the full HbA1c range still shows significant correlations (numbers are 
small) between 1,5AG and measures of glucose variability (SD, MAGE 
and CONGA4). Measuring 1,5AG gives slight additional information to 
HbA1c alone to predict glucose variability. This is to our knowledge the 
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first study assessing the relationships of 1,5AG with glucose variability 
measures and episodic hyperglycemia, measured here as AUC180, 
calculated from CGM data, at different HbA1c levels.  
At the full range of HbA1c levels the correlation between 1,5AG and MPG 
and hyperglycaemic episodes (AUC180) was statistically significant. 
Furthermore 1,5AG correlated better with MPG than with AUC180 and 
indices of glucose variability. This is in line with earlier results. [24] 
The range of 1,5AG values, as established in participants without diabetes, 
is quite broad, indicating a large biological variation in the population. 
This is in line with previous results of Nowatzke et al. [20] The 1,5AG 
values of patients with DM in good glycaemic control (as measured with 
HbA1c ≤ 42 mmol/mol (6%)) show a similar broad range of 1,5AG values. 
These results are in line with presented data for patients with T2DM and 
patients with impaired glucose tolerance. [8,13,20,23] The 1,5AG values 
in the well to moderately controlled patients with diabetes (HbA1c levels ≤ 
64 mmol/mol (8%)) also show the same wide range. This broad range for a 
laboratory test result makes it difficult to interpret the 1,5AG values in 
clinical practice. 1,5AG values are influenced by multiple factors, 
encompassing dietary factors, renal threshold for glucose and glomerular 
filtration rate. Low values have been observed during pregnancy and in 
patients with terminal end stage renal failure, advanced cirrhosis and 
following prolonged fasting periods. [16,20]  Unfortunately, we were not 
able to adjust for kidney function, but participants with severe renal 
impairment were excluded. 
The relation between 1,5AG and AUC180 is a hyperbolic figure. It can be 
seen as a form of change of form of the relation. In the HbA1c range 
between 43 and 64 mmol/mol (6 and 8%), the relationship between 1,5AG 
and AUC180 is quite heterogeneous. The stratified scatter plots with the 
partial correlation coefficients seem to confirm the secondary hypothesis 
that the relationships between 1,5AG and measures of GV (SD, MAGE 
and CONGA4) and hyperglycaemic episodes (AUC180 and AUCpp) were 
influenced by HbA1c level. If the HbA1c value is known, 1,5AG gives only 
slight additional information regarding GV as shown in Table 2 for the 
whole patient group adjusted for HbA1c. 
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Other factors then dietary factors that could influence this relationship are 
the total duration of hyperglycaemic periods as well as kidney function, as 
these factors influence the time-period of filtration and the filtration 
threshold of 1,5AG. HbA1c < 64 mmol/mol (8%) is a relevant range to 
measure 1,5AG as changes in postprandial glycaemia will impact overall 
glycaemic control disproportionally more than at higher HbA1c values. 
[7,16,12]  
The main limitation of this study is that all variables were only measured 
at one single time point (one 48-hour period), which does not precisely 
cover the time period reflected by the different measured parameters 
(HbA1c and 1,5AG). Since, only participants in relatively stable glycaemic 
control were included in the study, we assumed that the GV measures and 
MPG, assessed at this time point, were representative for the period prior 
to the measurement. Also, we couldn’t correct 1,5AG values for kidney 
function. 
In conclusion, at HbA1c ≤ 64 mmol/mol (8%), a low 1,5AG value is 
predictive of hyperglycaemic episodes. The test performance of 1,5AG to 
detect hyperglycaemic episodes in the moderately controlled patients 
(HbA1c ≤ 64 mmol/mol (8%)) was fair. Measures of GV and 
hyperglycaemic episodes correlated highly significantly and inversely with 
1,5AG at HbA1c levels ≤ 64 mmol/mol (8%) and between 43 and 64 
mmol/mol (6 and 8%). Measuring 1,5AG in addition to HbA1c may 
identify GV especially in the good to moderately controlled diabetes 
patients. This may be clinically relevant in patients where stringent control 
of glycaemia is indicated. 
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ABSTRACT 
 
OBJECTIVE  
Various methods are used to quantify postprandial glycemia or glucose 
variability, but few have been compared and none are standardized. Our 
objective was to examine the relationship among common indexes of 
postprandial glycemia, overall hyperglycemia, glucose variability, and 
A1C using detailed glucose measures obtained during everyday life and to 
study which blood glucose values of the day provide the strongest 
prediction of A1C. 
METHODS  
In the ADAG study, glucose levels were monitored in 507 participants 
(268 T1DM, 159 T2DM, and 80 nondiabetic subjects) with continuous 
glucose monitoring (CGM) and frequent self-monitoring of blood glucose 
(SMBG) during 16 weeks. We calculated several indexes of glycemia and 
analyzed their intercorrelations. The association between glucose 
measurements at different times of the day (pre- and postprandial) and 
A1C was examined using multiple linear regression. 
RESULTS  
Indexes of glucose variability showed strong intercorrelation. Among 
postprandial indexes, the area under the glucose curve calculated from 
CGM 2 h after a meal correlated well with the 90-min SMBG postprandial 
measurements. Fasting blood glucose (FBG) levels were only moderately 
correlated with indexes of hyperglycemia and average or postprandial 
glucose levels. Indexes derived with SMBG strongly correlated with those 
from CGM. Some SMBG time points had a stronger association with A1C 
than others. Overall, preprandial glucose values had a stronger association 
with A1C than postprandial values for both diabetes types, particularly for 
type 2 diabetes. 
CONCLUSIONS  
Indexes of glucose variability and average and postprandial glycemia 
intercorrelate strongly within each category. Variability indexes are 
weakly correlated with the other categories, indicating that these measures 
convey different information. FBG is not a clear indicator of general 
glycemia. Preprandial glucose values have a larger impact on A1C levels 
than postprandial values. 
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New treatment regimens and guidelines have increasingly focused on 
postprandial hyperglycemia as an additional target beyond average glucose 
control (1). However, direct evidence for an effect of specifically 
controlling postprandial glucose (PPG) and glucose excursions (over and 
above the effect of reducing average glucose levels on long-term diabetes 
complications) is limited. The current debate about whether postprandial 
hyperglycemia and excessive glucose variability are associated with an 
increased risk of diabetes complications is largely based on 
epidemiological studies (2–6). Many of these findings (2,4–6) are based on 
an extrapolation of glucose levels 2 h after an oral glucose tolerance test 
(OGTT) as a model for the postprandial state rather than on “real-life” 
PPG measurements. Only a few studies (4,7,8) have also measured the 
effect of A1C for comparison, and these show conflicting results. 
Studies examining PPG control use various methods to quantify PPG, 
overall hyperglycemia, and glucose variability (9), without any 
standardization of methods. One approach to assess the role of PPG has 
been to examine the extent to which it contributes to overall glucose 
exposure, measured as A1C (10–13). Limited evidence suggests that 
postprandial glycemia is the dominant contributor to overall 
hyperglycemia in patients with good to moderate glycemic control (A1C 
<8.5%), while fasting glucose levels represent the major contributor at 
higher A1C levels (14). These findings have been used to support the need 
to measure and treat PPG in order to reach clinical guideline levels of A1C 
(15,16). Measures of nocturnal glycemia are rarely used in the prediction 
of A1C. Available literature exploring the nocturnal glucose exposure is 
sparse and mostly focused on nocturnal hypoglycemia or assessment of 
glucose variability during glucose-lowering therapies. 
Our aim was to examine the relationship among the most commonly used 
indexes of PPG, overall hyperglycemia, glucose variability, nocturnal 
glycemia, and A1C using glucose measures obtained during everyday 
activities from the A1C-Derived Average Glucose (ADAG) study. 
Additionally, we studied which blood glucose value(s) of the day provide 
the strongest prediction of mean blood glucose, as measured by A1C, 
especially focusing on pre- and postprandial glucose contributions to mean 
blood glucose levels. 
.     
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RESEARCH DESIGN AND METHODS 
The ADAG study was conducted at 10 centers in the U.S., Europe, and 
Africa from 2006 to 2008 to define the relationship between A1C and 
average glucose levels. A full description of the study has been published 
(17). A total of 268 individuals with type 1 diabetes, 159 individuals with 
type 2 diabetes, as well as 80 nondiabetic control subjects (aged 18–70 
years) completed the study. Participants were selected based on stable 
glycemic control as evidenced by two A1C values within one percentage 
point of each other in the 5 months prior to recruitment. Individuals with a 
wide range of A1C levels were included. The nondiabetic control subjects 
had a plasma glucose level ≤5.4 mmol/l (97 mg/dl) after overnight fasting, 
A1C levels <6.5%, and no history of diabetes or use of antidiabetes 
medication. The study was approved by the human studies ethical 
committees at the participating institutions, and informed consent was 
obtained from all participants. 
 
Measurements of glycemia. 
During the study period, levels of glucose concentrations were assessed 
through three different methods. Continuous interstitial glucose 
monitoring (Medtronic Minimed, Northridge, CA) was performed four 
times with 4-week intervals during the 16-week study period. Monitoring 
periods lasted at least 48 h, during which time glucose levels were 
assessed every 5 min. Continuous glucose monitoring (CGM) data were 
accepted for analysis if there were no gaps longer than 120 min and if the 
mean absolute difference with the Hemocue calibration results was <18%, 
as recommended by the manufacturer. 
For calibration purposes, and for measurement of pre- and postprandial 
glycemia, participants performed an eight-point self-monitoring of blood 
glucose (SMBG) profile (preprandial, 90 min postprandial, bedtime, and 
3:00 a.m.) with the HemoCue meter (Hemocue Glucose 201 Plus; 
Hemocue, Ängelholm, Sweden) during the days of CGM. In addition, 
during the weeks when CGM was not performed, subjects performed a 
seven-point SMBG (the same as the eight-point profile above without the 
3:00 a.m. measurement) (OneTouch Ultra; LifeScan, Milipitas, CA) for at 
least 3 days per week. 
All blood glucose values stated are plasma equivalents. 
Blood samples were analyzed for A1C levels with four different Diabetes 
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Control and Complications Trial–aligned assays: a high-performance 
liquid chromatography assay, two immunoassays, and an affinity assay (all 
approved by the National Glycohemoglobin Study Program). The mean 
value at the end of the 12-week study period was used (17). 
 
Calculated indexes of glycemia. 
Indexes of glucose variability and postprandial glucose levels were 
calculated from the glucose monitoring data. The average blood glucose 
and SD were calculated based on CGM data and the seven-point SMBG 
(LifeScan) data. A combined average blood glucose was calculated from 
CGM and SMBG, weighted by the days of monitoring for each. Indexes 
based on CGM were calculated after exclusion of the initial 2 h of 
monitoring, which is considered to be an unstable calibration period. 
Two indexes of intraday glucose variability were calculated based on 
CGM: the mean amplitude of glycemic excursions (MAGE) and the 
continuous overlapping net glycemic action (CONGA). MAGE is the 
mean of the differences between consecutive peaks and nadirs, only 
including changes of >1 SD of glycemic values and thus capturing only 
major fluctuations (18,19). For the calculation of CONGAn, the difference 
of the current observation and the observation n hours previously is 
calculated for each observation after the first n hours. The CONGAn is the 
SD of these differences (19). We analyzed CONGA for 1, 2, and 4h. Both 
high MAGE and CONGA values indicate high intraday glucose 
variability. As an indicator of overall hyperglycemia, the 24-h cumulative 
exposure to glucose levels above different thresholds was calculated as the 
area under the curve (AUC) of CGM above levels of 7.0, 11.1, and 16.7 
mmol/l (or 126, 200, and 300 mg/dl, respectively). This was done for the 
first 24 h of each CGM period after the initial calibration period. Indexes 
of nocturnal blood glucose were calculated as the mean blood glucose 
from the CGM period 6 h prior to the fasting blood glucose (FBG) 
measurement. Furthermore, for each individual, a mean of all 3:00 a.m. 
SMBGs (HemoCue) was calculated. Also from CGM, a postprandial AUC 
(AUCpp) was calculated for periods of 2 or 4 h after a meal (without blood 
glucose thresholds), and the postprandial increment was calculated from 
the preprandial glucose level to the highest peak for periods of 2 or 4 h 
after a meal. Finally, pre- and postprandial measurements from SMBG 
(HemoCue) were used to calculate mean pre- and postprandial blood 
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glucose, as well as pre- and postbreakfast, lunch, and dinner values. The 
prebreakfast blood glucose was used as the FBG. 
 
Statistical analyses. 
The Pearson correlation coefficient (r) was computed for each pair of 
glycemic indexes. This was done including only the diabetic population, as 
the measurements from nondiabetic participants inflate the correlations. 
Scatterplots of all pairs are presented with an indicator of the Pearson 
correlation coefficient (r). 
A1C was modeled by multiple linear regression using SMBG 
measurements at different times of the day as explanatory variables. The 
association to A1C was examined in three separate analyses, including 
glucose before and after main meals, mean of all pre- and postmeal 
glucose measures, and adding nocturnal (3:00 a.m.) SMBG. These models 
were fitted for all individuals with diabetes and separately for type 1 and 
type 2 diabetes treated with and without insulin. We defined the proportion 
of A1C variation (SD) explained by each model as the difference between 
the A1C SD for each subgroup and the residual SD of the model divided 
by the SD. 
 
RESULTS 
Glucose monitoring in the ADAG study was completed by 507 
participants. Approximately 2,700 glucose values from each participant 
were available for analysis. We excluded 10 nondiabetic participants from 
the analyses of average SMBG and SDs due to missing LifeScan 
measurements and 1 participant with type 1 diabetes due to erroneous, 
extreme HemoCue measurements of pre- and postprandial values. 
Characteristics of the study population are summarized in Table 1. A1C 
levels were higher among those with type 1 diabetes (7.3 vs. 6.8% for type 
2 diabetes, P < 0.01). Also, the degree of variability, expressed as the SD 
of the CGM or SMBG measurements and the calculated MAGE and 
CONGA, was higher among individuals with type 1 diabetes compared 
with those with type 2 diabetes or nondiabetic individuals (P < 0.01). 
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TABLE 1 Clinical and glycemic characteristics 
 
 
         All 
 
Type 1 
diabetes 
Type 2 
diabetes 
No 
diabetes 
N 507 268 159 80 
Age (years) 47.6 ± 13.6 44.1 ± 12.9 56.6 ± 9.4 41 ± 13.8 
Sex (% female) 54 52 51 69 
Ethnicity (% Caucasian) 82 91 74 68 
BMI (kg/m2)     
Female 28.1 ± 7 26.3 ± 4.7 32.7 ± 8.7 25.9 ± 5.5 
Male 27.6 ± 5.1 26.1 ± 3.4 30.8 ± 6.2 25 ± 3.3 
Treatment with insulin 65 100 38 0 
A1C (%) 6.8 ± 1.3 7.3 ± 1.1 6.8 ± 1.1 5.2 ± 0.3 
FBG (mmol/l) 7.8 ± 2.4 8.5 ± 2.5 7.8 ± 2.1 5.3 ± 0.6 
Average blood glucose (mmol/l) 8.3 ± 2.2 9 ± 2 8.3 ± 2 5.6 ± 0.4 
CGM average (mmol/l) 8.5 ± 2.2 9.3 ± 2 8.5 ± 2 5.8 ± 0.6 
SMBG average (mmol/l) 8.2 ± 2.2 8.9 ± 2.1 8.3 ± 2 5.5 ± 0.5 
Nocturnal measures     
Mean 3:00 a.m. SMBG (mmol/l) 8.1 ± 2.7 9.2 ± 2.7 7.6 ± 2.3 5.6 ± 0.7 
Mean nocturnal blood glucose 
CGM (mmol/l) 
8.0 ± 2.3 8.9 ± 2.3 7.8 ± 2.1 5.6 ± 0.6 
Prandial measures     
Preprandial SMBG (mmol/l) 7.7 ± 2.1 8.4 ± 2 7.6 ± 1.9 5.4 ± 0.5 
Postprandial SMBG (mmol/l)* 9 ± 2.4 9.7 ± 2.1 9.4 ± 2.2 6.1 ± 0.7 
AUCpp 2-h CGM (h/mmol/l) 17.6 ± 4.5 19.1 ± 4.1 17.8 ± 4 12 ± 1.4 
PPG increment 2-h CGM 
(mmol/l)† 
2.8 ± 1.4 3.4 ± 1.2 2.7 ± 1.2 1.2 ± 0.5 
Variability measures     
CGM SD (mmol/l) 2.7 ± 1.4 3.6 ± 0.9 2.2 ± 0.9 0.8 ± 0.2 
SMBG SD (mmol/l)§ 3.2 ± 1.5 4.1 ± 1 2.6 ± 1 1.1 ± 0.4 
MAGE (mmol/l) 4.8 ± 2.4 6.4 ± 1.8 3.8 ± 1.5 1.4 ± 0.5 
CONGA4 (mmol/l) 3.7 ± 1.9 4.9 ± 1.3 2.9 ± 1.2 1 ± 0.3 
 
Data are means ± SD or percent. Glucose values are expressed as plasma 
equivalent mmol/l. 
*Defined as mean of 90-min postprandial self-monitored glucose levels. 
†Defined as the increment from the preprandial blood glucose to highest peak 2-h 
postprandially. 
§Defined as the SDs of all self-monitored blood glucose. 
 
As an indicator of overall hyperglycemia, the 24-h cumulative exposure to 
glucose levels above selected glucose thresholds was calculated as the 
AUC of glucose (AUC [in hours × mmol/l]) by subgroups defined by type 
of diabetes and, for type 2 diabetes, insulin therapy. In each subgroup, a 
different proportion of participants reached each respective threshold at 
least at some point during the CGM period. While >80% of those with 
type 1 diabetes and 63% of those with type 2 diabetes on insulin treatment 
reached a level of 16.7 mmol/l (300 mg/dl), only 31% of those with type 2 
diabetes without insulin treatment did so. One individual without diabetes 
reached this level briefly.  
(These results can be seen in the online appendix Table, available at 
http://diabetes.diabetesjournals.org/cgi/content/full/db091774/DC1). 
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The relationship between the different indexes of glycemia is illustrated in 
pairwise scatterplots in Fig. 1 (and in an extended online appendix Fig. 2). 
Although the different indexes were strongly correlated within each 
category, some indexes do capture somewhat different information. All 
glucose variability indexes calculated from CGM were closely correlated. 
CONGA analyses for 1, 2, and 6 h correlated to CONGA4h with 
correlation coefficients of 0.94, 0.98, and 0.99, respectively (data not 
shown). CONGA4 and CGM SD (not shown) were both strongly 
correlated with MAGE (r = 0.95). The SMBG variability index (SD) 
correlated with the CGM indexes MAGE, the CGM SD, and the 
CONGA4, with coefficients of 0.83, 0.86, and 0.83, respectively. The 
variability measures did not correlate well with the postprandial 
measurements or indexes of fasting or average glycemia (illustrated in 
Supplemental Fig. 2 in the online appendix). The postprandial indexes 
calculated from CGM 2 or 4 h after meal, AUCpp2 and AUCpp4, were 
strongly correlated (r = 0.97) and correlated well with the SMBG 
postprandial measurements (r = 0.92 and 0.89, respectively) (only AUCpp2 
is shown). The postprandial increment, from preprandial blood glucose 
level to highest blood glucose peak within a 2- or 4-h postprandial 
window, did not correlate well with any other measure. The correlation 
coefficients with SMBG postprandial measurements were as low as 0.51. 
The nocturnal blood glucose mean from CGM and the self-monitored 3:00 
a.m. “random” night blood glucose correlated by a correlation coefficient 
of 0.83. 
 
Table 2 shows the effects of specific SMBG of the day on A1C levels. 
Among participants with type 1 diabetes, prebreakfast, prelunch, and 
postlunch blood glucose measurements had the largest effect on A1C. 
Among participants with type 2 diabetes, pre-breakfast, postlunch, and 
predinner values had the largest effects on A1C, regardless of insulin 
treatment. In general, the mean of all preprandial values predicted A1C 
better than the mean of all postprandial values among those with either 
type of diabetes both before and after adding nocturnal blood glucose to 
the model (statistical significant difference [P < 0.05] for the total diabetic 
group but not for diabetic subgroups or the nondiabetic group). The 
proportion of A1C variation (SD) explained by the glucose features of 
each model can be seen in Table 2 and can be compared with variation 
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explained by average blood glucose. Adding a nocturnal glucose index 
(3:00 a.m. SMBG) only minimally increased the proportion of variation 
explained. 
 
 
 
 
 
FIG. 1. 
Pairwise scatter diagrams illustrating selected correlations of glycemic 
variables with Pearson correlation coefficients (r) for each pair of indexes 
(not including data for no diabetes), highlighting the different participant  
subgroups with different shades (type 1 diabetes, dark gray; type 2 
diabetes, light gray; and no diabetes, black). 
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TABLE 2 Effects of specific glucose measurements and 
A1C in three multiple linear regression models 
 
All diabetes 
 (n = 427) 
Type 1 diabetes 
 (n = 268) 
Type 2 diabetes  
(n = 99) 
 
Type 2 diabetes 
 (n = 60) 
 
Non–insulin-
treated 
Insulin 
-treated 
A     
Prebreakfast 0.122  
(0.086–0.157)* 
0.107  
(0.065–0.149)* 
0.116  
(0.031–0.201)* 
0.179  
(0.088–0.270)* 
Postbreakfast 0.020  
(−0.011 to 0.050) 
0.000  
(−0.37 to 0.038) 
0.029 
 (−0.035 to 0.093) 
0.078  
(0.008–0.148)* 
Prelunch 0.097  
(0.059–0.134)* 
0.130  
(0.086–0.175)* 
0.055  
(−0.053 to 0.164) 
0.002  
(−0.088 to 0.091) 
Postlunch 0.108  
(0.071–0.145)* 
0.120  
(0.077–0.164)* 
0.092  
(−0.009 to 0.192) 
0.103  
(0.015–0.191)* 
Predinner 0.093  
(0.058–0.128)* 
0.053  
(0.012–0.095)* 
0.085  
(−0.034 to 0.204) 
0.140  
(0.052–0.229)* 
Postdinner 0.052  
(0.018–0.085)* 
0.077  
(0.037–0.117)* 
0.066  
(−0.021 to 0.153) 
−0.012  
(−0.109 to 0.085) 
A1C variation expl.† 41% 39% 49% 43% 
B     
All preprandial 0.315 
 (0.267–0.362)* 
0.288  
(0.227–0.349)* 
0.259  
(0.164–0.354)* 
0.340  
(0.207–0.473)* 
All postprandial 0.167  
(0.123–0.211)* 
0.186  
(0.129–0.242)* 
0.177  
(0.094–0.259)* 
0.134  
(0.024–0.245)* 
Difference pre-
/postprandial‡ 
P < 0.01 P = 0.07 P = 0.34 P = 0.08 
A1C variation expl.† 40% 37% 48% 38% 
C     
All preprandial 0.257 
 (0.204–0.310)* 
0.244  
(0.178–0.310)* 
0.136  
(0.004–0.268)* 
0.312  
(0.176–0.447)* 
All postprandial 0.163  
(0.120–0.206)* 
0.183  
(0.128–0.239)* 
0.182  
(0.102–0.262)* 
0.106 
 (−0.008 to 0.220) 
Nocturnal SMBG 0.071  
(0.040–0.102)* 
0.060  
(0.022–0.098)* 
0.117  
(0.027–0.207)* 
0.069  
(−0.019 to 0.156) 
Difference pre-
/postprandial1 
P = 0.04 P = 0.28 P = 0.64 P = 0.07 
A1C variation expl.† 41% 38% 50% 39% 
A1C variation expl. 
by average glucose§ 
53% 51% 56% 53% 
 
Data are β coefficients (in % A1C per mmol/l) from multiple 
linear regression models (95% CI), unless otherwise indicated. A: 
model including mealtime measurements. B: model including 
mean of all pre- and postprandial values. C: model with both 
prandial and nocturnal blood glucose. 
*P value for estimates <0.05. 
†The proportion of A1C variation (SD) explaned by the glucose 
features of each model. 
‡P values from test of difference between pre- and postprandial 
estimates. 
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DISCUSSION 
Based on frequent glucose monitoring during usual daily activities, we 
found, in a large set of individuals with type 1 diabetes, type 2 diabetes, or 
those without diabetes, that many of the commonly used indexes of 
glycemic variability, average glycemia, and postprandial glycemia were 
strongly correlated within each category. Indexes of glucose variability 
(CONGA, SD of CGM or SMBG, and MAGE) were especially highly 
correlated. These findings indicate that the different methods of 
characterizing glucose variability tend to convey similar information. 
The putative roles of glucose variability and PPG as risk factors for 
diabetes complications are based on 1) studies reporting an association 
between excessive PPG levels and factors that may lead to development of 
diabetes complications (20–23), 2) epidemiological studies associating 2-h 
post-OGTT values with increased mortality and cardiovascular disease (2–
5), and 3) a few clinical trials in very specific subgroups (e.g., pregnant 
women [24] and individuals with impaired glucose tolerance [25] or type 2 
diabetes post-AMI [26]), which have addressed the issue with different 
methods and have had conflicting results. The roles of PPG and glucose 
variability as risk markers need further exploration, and an understanding 
of the differences and similarities among the different measures of PPG, 
overall hyperglycemia, and glucose variability is critical. 
MAGE (18) has previously been described as the gold standard with 
which to measure variability (19, 27). Our findings show that CONGA or 
the “simple” SD captures variability to a very similar degree as MAGE. 
Regarding the methods to assess PPG, we found that the postprandial 
AUC from CGM 2 h after a meal correlates well with SMBG postprandial 
measurements, with a correlation coefficient of 0.92. This suggests that a 
routine 90-min postprandial SMBG measurement contains much of the 
information about the glucose curve in the hours after a meal. The ADAG 
study also showed that seven-point profile SMBG levels, measured on 
average 3 days per week, and CGM, measured on 2 days per month, both 
over a 3-month period, predict average glucose and A1C similarly (17). 
The postprandial increment in glucose levels (the difference from 
preprandial to highest postprandial value in a 2-h window) showed 
generally weak correlations with postprandial blood glucose levels (r = 
0.45–0.51) and with indexes of average glycemia (r = 0.26–0.27). 
Postprandial increments have been used to assess glucose variability and 
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PPG in other studies (14,28). The difference between the calculated 
increments (from CGM) and the difference between the pre- and 
postprandial measurements from SMBG (Table 1) might be because the 
latter is measured by the participant ~90 min after eating (not necessarily 
capturing the highest postprandial value). One might expect large 
postprandial increments to reflect high glucose variability; however, the 
correlation with the variability measures was also only moderate (r = from 
0.41 [SMBG SD] to 0.54 [CONGA4]). 
As expected, A1C correlated well with average blood glucose from CGM, 
SMBG, and the two combined. When exploring the contribution of 
glucose levels from SMBG at different times of the day to average 
glycemia (Table 3), the preprandial glucose levels had a larger effect on 
A1C than postprandial glucose levels, presumably because they resemble 
the 24-h glucose levels (and thus the long-term exposure to glucose) more 
closely. This result was the same before and after including the nocturnal 
blood glucose index to the regression model, which, surprisingly, only 
lead to a small increase in the proportion of A1C variation explained. 
The frequently cited article by Monnier et al. (14) concludes that 
postprandial glucose levels are the dominant contributor to A1C levels in 
patients with A1C <8.5%, while fasting glucose levels were the major 
contributor for patients with A1C >8.5%. The calculations underpinning 
this conclusion were based on AUCs derived from meal-period 
measurements only, thus disregarding the contribution of glucose exposure 
outside meal periods to A1C. 
Monnier et al. (14) define postprandial glycemia as the AUC above each 
individual's fasting value, while preprandial glycemia is defined as the 
AUC between 6.1 mmol/l (110 mg/dl) and measured FBG for each 
individual. This approach introduces a bias when comparing the 
association between these two indexes and A1C. Individuals with A1C 
levels >8.5% will strongly tend to also have high FBG. Their postprandial 
AUC values will therefore be small by artifact, as only excursions above 
these high individual FBG values are considered postprandial glucose 
exposure. Simultaneously, Monnier et al.'s definition yields larger 
preprandial AUCs in this same group, thus introducing the reported effect. 
This methodological problem might explain why Monnier et al.'s results 
differ from our findings and those of others (12,29). 
Our study shows that no single blood glucose measurement during the day 
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accurately predicts A1C. This is in accordance with previous studies (29–
31) showing that single or limited numbers of blood glucose 
measurements daily do not accurately reflect A1C levels. However, any 
insights into the specific timed glucose measurement or combination of 
measurements that have the largest effect on A1C can help patients and 
clinicians to plan optimal glucose-monitoring regimens. 
Levels of FBG alone were not clear indicators of overall hyperglycemia. 
The correlation coefficients to indexes of hyperglycemia and average or 
postprandial blood glucose levels are between 0.60 and 0.70 in the present 
study. This adds to previous findings (30,31) showing that A1C and 
postchallenge blood glucose are difficult to predict from FBG values 
alone. Bouma et al. (30) found a correlation coefficient of 0.77 between 
A1C and FBG in 1,020 individuals with type 2 diabetes. 
This study is based on frequent glucose monitoring during real-life 
activities in a large, heterogeneous population of people with diabetes and 
those without diabetes and provides the opportunity to assess reliably the 
different features of glycemia. The limitations of the study are that the 
ADAG study population was selected to exclude patients with severe 
renal/liver disease, pregnancy, and anemia. Therefore, the results may not 
be extrapolated to all patients with diabetes. However, patients were 
chosen to span a large range of A1C levels. Moreover, the ADAG study 
recruited a broad multicenter population, so we feel it is justifiable to draw 
general conclusions from our results. 
The fact that participants had stable A1C (<1% A1C change 6 months 
prior to study) could have lead to underestimation of glucose variability. 
However, high levels of glucose variability were seen among our subjects 
despite stable A1C levels. Even though type 1 diabetes and type 2 diabetes 
have different glucose patterns due to different disease mechanisms, the 
mechanism of hemoglobin glycation is likely to be the same. The 
correlation of the glycemic indexes were therefore calculated for the 
combined group. Limitations of the MiniMed CGM system include the 
inability to measure glucose values <2.2 mmol/l (40 mg/dl) or >22.2 
mmol/l (400 mg/dl) (measurements outside this range were treated as 2.2 
or 22.2 mmol/l, respectively, for the analyses). The mean FBG is derived 
from prebreakfast measurements and thus can contain blood glucose not 
preceded by 8 h of fasting. 
In summary, the role of glucose excursions and postprandial glycemia in 
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day-to-day diabetes control and risk management is still debated. We 
found relatively weak correlations between variability indexes and indexes 
of fasting, postprandial, and mean glycemia, indicating that the variability 
indexes convey different information. Fasting glucose values had only a 
moderate correlation with other indexes, confirming that it is not a clear 
indicator of general glycemia. The mean of all preprandial glucose levels 
had a larger impact on A1C levels than postprandial glucose levels in type 
1 and type 2 diabetic patients. 
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APPENDIX 
 
ADAG Study Group 
Study centers: J.K. (principle investigator [PI]), G.S.M.A Kerner, and A. 
van Iperen, Amsterdam, the Netherlands; E. Horton (PI), A. Cohen, S. 
Herzlinger-Botein, and J. Paradis, Boston, MA; C. Saudek (PI), K. Moore, 
A. Greene, and M. Islas, Baltimore, MD; J. Nerup (PI), R.B., and C. 
Glümer, Copenhagen, Denmark; A. Mosca (co-PI), A. Lapolla (co-PI), D. 
Fedele, and G. Sartore, Padova, Italy; X. Pi-Sunyer (PI), C. Maggio, L. 
Haselman, and C. Bellino, New York, NY; S. Smith (PI), A. Reynolds, T. 
Robertson, H. Binner, and K. Hurtis, Rochester, MN; S. Schwartz (PI), A. 
Ramos, A. Gonzales, A. Childress, and Y. Martinez, San Antonio, TX; I. 
Hirsch (PI), D. Khakpour, and C. Farricker, Seattle, WA; and J.C. Mbanya 
(PI), E. Sobngwi, and E. Balti, Yaoundé, Cameroon. Central laboratory: R. 
Slingerland (PI), E. Lenters, and H.P van Berkel, Zwolle, the Netherlands. 
Biostatistics center: D.S. (PI), H.Z., K. Pelak, and R. Wilson, Boston, MA. 
Coordinating center: D.M.N. (PI), N. Kingori, and H. Turgeon, Boston, 
MA. Study chairs: R.H. and D.M.N. 
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ABSTRACT  
 
AIMS  
Real-life glycaemic profiles of healthy individuals are poorly studied. Our 
aim was to analyse to what extent individuals without diabetes exceed the 
OGTT thresholds for impaired glucose tolerance (IGT) and diabetes. 
METHODS  
In the A1c Derived Average Glucose (ADAG) study, 80 participants 
without diabetes, completed an intensive glucose monitoring period of 12 
weeks. From these data, we calculated the average 24 hour glucose 
exposure as the time spent above different plasma glucose thresholds. 
Furthermore, indices of postprandial glucose levels, glucose variability 
and HbA1c were derived. 
RESULTS  
Ninety-three percent of participants reached glucose concentrations above 
the IGT threshold of 7.8 mmol/l and spent a median of 26 min/day above 
this level during continuous glucose monitoring. Eight individuals (10%) 
spent more than 2 hours in the IGT range. They had higher HbA1c, fasting 
plasma glucose (FPG), age, and BMI than those who did not. Seven 
participants (9%) reached glucose concentrations above 11.1mmol/l during 
monitoring. 
CONCLUSIONS  
Even though the monitored non-diabetic individuals in the ADAG study 
were selected by a very low level of baseline FPG, 10 % of individuals 
spent a considerable amount of time at glucose levels considered to be 
‘prediabetic’ or levels of impaired glucose tolerance. This highlights that 
some of the exposure to moderately elevated glucose levels remains out of 
sight when we classify individuals based on isolated glucose 
measurements.  
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Current understanding of normoglycaemia is largely based on studies of 
populations without diabetes, with a limited number of glucose 
measurements per individual. This results in a limited insight into patterns 
of real-life glycaemia experienced by normoglycaemic individuals. As 
new options of diabetic treatment increasingly focus on specific glucose 
profiles, such as post-prandial glycaemia, it is important to have a clearer 
understanding of what constitutes a normal glucose profile. Knowledge 
about the amount of time that normoglycaemic individuals spend at 
different levels of glycaemia under real-life conditions is needed to serve 
as a benchmark for the more detailed study of impaired glycaemic states 
and the capacity of novel treatments to normalize glucose profiles. 
We therefore studied the glucose profiles of nondiabetic individuals who 
participated in the A1C Derived Average Glucose (ADAG) study. This 
observational study included continuous glucose monitoring (CGM) under 
real life conditions. Our aim was to analyse to what extent individuals 
without diabetes exceed the oral glucose tolerance test (OGTT) thresholds 
for impaired glucose tolerance (IGT) and diabetes (1).  
 
MATERIAL AND METHODS 
 
Study participants 
The ADAG study was conducted at 10 centres in the United States, 
Europe, and Africa from 2006 to 2008 to define the relationship between 
glycated haemoglobin (HbA1c) and average glucose levels. A full 
description of the study has been published (2). The population for the 
present analysis consists of the 80 non-diabetic control participants who 
completed the intensive glucose monitoring period of 12 weeks. The non-
diabetic participants were selected on the basis of having no history of 
diabetes, a plasma glucose (PG) level <5.4 mmol/l (97 mg/dl) after an 
overnight fast, and a HbA1c level <6.5%. The PG cut-off was chosen due 
to its high specificity for excluding diabetes without performing an OGTT 
(3). 
Assessing glycaemia 
Glucose levels were assessed with two different methods during the study 
period. Continuous interstitial glucose monitoring (CGM) (Medtronic 
Minimed, Northridge, CA) was performed for at least 48 hours at baseline 
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and 3 times at 4-week intervals during the 12 week study period. 
Participants also measured an 8-point self-monitored blood glucose 
(SMBG) profile (preprandial, 90 minutes postprandial, prebedtime, and 
3:00 A.M.) with the HemoCue meter (Hemocue Glucose 201 Plus, 
Hemocue, Ängelholm, Sweden) during the days of CGM. This protocol 
yielded approximately 2,300 glucose values for each participant. The 
median time of CGM was 230 hours per subject. All presented blood 
glucose concentrations are plasma glucose equivalents. 
As an indicator of over-all hyperglycaemia, the time spent above selected 
glucose thresholds was calculated for the first 24 hours of each CGM 
monitoring period after the initial 2-hour calibration period. The mean of 
these time periods was used. This was done for glucose concentrations 
corresponding to the different cut-points in the diagnostic criteria; 6.1, 7.0, 
7.8, 11.1, as well as 16.7 mmol/l (110, 126, 140, 200 and 300 mg/dl, 
respectively).  
Pre- and postprandial measurements from SMBG (HemoCue), were used 
for calculation of mean pre- and postprandial PG. The prebreakfast PG 
was used as fasting plasma glucose (FPG). HbA1c samples were analyzed 
with four highly inter-correlated DCCT-aligned assays, all National 
Glycohemoglobin Standardization Program approved. The mean value at 
the end of the 12 week study period was used (2). 
 
 
RESULTS 
The study population had a mean age of 41 years (SD 13.8), 69 % was 
female, 68 % Caucasian, mean HbA1c was 5.2 % (SD 0.3), and mean BMI 
was 25.9 kg/m2 (5.5) for men and 25.0 kg/m2 (3.3) for women. During the 
monitoring period, mean FPG was 5.3 mmol/l (SD 0.6), mean preprandial 
PG 5.4 mmol/l (SD 0.5) and mean postprandial PG 6.1 mmol/l (SD 0.7). 
Glucose variability from CGM measured as mean SD was 0.8 mmol/l (SD 
0.2). 
Table 1 shows the time spent above selected glucose thresholds along with 
the proportion of participants who reached each respective threshold at any 
time during the CGM measurement. Figure 1 shows the distribution of 
individuals at selected glucose concentrations. Looking at the graph for the 
7.8 mmol/l threshold, participants spent a median of 26 minutes per day 
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(range 0-412 minutes) above this IGT level. A quarter of the individuals 
experienced glucose levels above this threshold for at least 1 hour and 15 
minutes per day, and three individuals (3.8%) remained in this range for 5 
hours or more per day. These three individuals had HbA1c levels in the 
normal range (5.4-5.7 %) and mean FPG between 4.9-6.5 mmol/l, whereas 
the 8 individuals who spent more than 2 hours above IGT level had higher 
mean HbA1c (5.7%), FPG (6.1 mmol/l), age (55 yrs), and BMI 
(female/male: 29/30 kg/m2) than those who did not. Two individuals 
spend more that one hour above 11.1 mmol/l. 
 
Table 1. Time spent above selected plasma glucose concentrations. 
(Calculated from periods of 24 hours of CGM per visit, mean of all visits) 
PG level 
Mmol/l 
(mg/dl) 
 
Proportion that 
reaches PG level 
during CGM 
 
Mean minutes 
Spend above 
level 
 
Standard 
Deviation 
 
 
Median 
minutes 
spend 
above level 
>6.1 (110) 100 % 480 278 395 
>7.0 (126) 99 % 144 137 107 
>7.8 (140) 93 % 54 79 26 
>11.1 (200) 9 % 2.8 16.2 0 
>16.7 (300) 1 % 0.4 3.6 0 
 
 
 
Figure 1. Curves illustrating the cumulative proportion of individuals 
spending time at glucose concentrations above selected glucose thresholds 
per mean 24-h monitoring period (one curve per threshold). 
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DISCUSSION 
We found that nearly all individuals without diabetes exceed the IGT 
threshold of 7.8 mmol/l (140mg/dl) at some point during the day and 
spend a median of 26 minutes (range 0 min – 6 h 52 min) per day above 
this level. We further found that one in ten reach diabetic levels (11.1 
mmol/l, 200 mg/dl). These findings suggest that ambient glucose levels in 
persons without diabetes are frequently in the IGT range and that a 
substantial proportion reach diabetic levels.  Previous smaller studies have 
suggested similar patterns, albeit in more homogeneous populations. A 
study of 32 individuals with confirmed normal glucose tolerance found 
that 7 participants (22%) reached glucose concentrations above 11.1 
mmol/l (200 mg/dl) during an average of 28 days of CGM and that 
participants spent on average 42 minutes per day at glucose concentrations 
above 7.8 mmol/l (140mg/dl)(4). In a smaller study, 15 hospital staff 
without known diabetes monitored with CGM for 24 hours, were found to 
spend an average of 72 minutes per day with glucose levels higher than 7.0 
mmol/l (125 mg/dl) (5). 
During a standardised OGTT, it is well established that glucose 
concentrations can exceed 7.8 mmol/l in individuals with NGT in the time 
preceding the 2 hour value (6). However, since the 75g OGTT is an 
extreme glucose load compared to an average mixed meal in regard to the 
glucose concentration and the simple carbohydrate structure (fast uptake), 
we find that our results based on real life monitoring add an important 
dimension.  
The limitations of the current study include the absence of OGTTs to rule 
out diabetes with certainty or to classify subjects as having IGT. However, 
our fasting PG exclusion criterion has been shown to be highly specific for 
ruling out diabetes (3). In addition, our HbA1c exclusion criterion of > 
6.5% has recently been proposed as the new diagnostic level for diabetes 
(7). Mean HbA1c was considerably lower, at 5.2 % (SD 0.3).  Factors that 
cause glucose fluctuations, such as food intake, exercise, and stress, or 
beta-cell function and insulin sensitivity, were not examined in this study 
under free-living conditions.  
Our results confirm that considerable variability of glucose levels exists 
even among individuals classified as not having diabetes. The effect of this 
normoglycaemic glucose variability on progression to diabetes and 
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development of early stages of diabetic complications is unknown and 
makes an interesting basis for further investigation.  
 
CONCLUSION 
When glucose levels are measured under real-life conditions in non-
diabetic individuals defined by a very low level of FPG and HbA1c levels 
less than 6.5%, a considerable amount of time is spent with glucose levels 
classified as ‘prediabetic’ or even diabetic. Since chronic glucose exposure 
is considered to be one of the main mediators of long-term outcomes, 
including microvascular and cardiovascular disease, our findings highlight 
that some of the exposure to moderately elevated glucose levels remains 
out of sight when we classify individuals based on isolated glucose 
measurements. The current diagnostic classification does not identify all 
individuals subjected to hyperglycemia during every-day experience with 
glucose levels consistent with IGT and diabetes.  
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ABSTRACT 
 
AIMS  
Increased glucose excursions and postprandial hyperglycaemia have been 
suggested as unique risk factors of cardiovascular disease (CVD) and 
mortality in patients with diabetes mellitus. Much of the evidence is based 
on a single 2-hour glucose value after oral glucose tolerance testing in 
epidemiological studies. We examined the association between various 
indices of glycaemia measured during every-day activities and metabolic 
CVD risk factors in the A1c Derived Average Glucose (ADAG) study. 
METHODS  
Participants (268 with type 1 diabetes, 159 with type 2 diabetes) 
completed 16 weeks of intensive continuous glucose monitoring (CGM) 
and self-monitoring of blood glucose (SMBG). From these data, common 
indices of postprandial glycaemia, over-all hyperglycaemia, glucose 
variability and HbA1c were derived. The associations between glycaemic 
indices and known CVD risk factors (lipids, hs-C-reactive protein, blood 
pressure) were explored in linear regression models. 
RESULTS  
An increase of one HbA1c percent was associated with increases of 2.4 
mmHg in systolic blood pressure, 0.1 mmol/l in total cholesterol, 0.47 
mg/ml in hs-CRP, and a decrease in HDL of 0.06 mmol/l. HbA1c and mean 
blood glucose (BG) were consistently associated with CVD risk factors. 
Associations between self-monitored postprandial and fasting glucose and 
CVD risk factors were weaker, but significant. Measurements of BG 
variability showed non-significant associations. Overall, calculations 
based on CGM were not more informative than those based on frequent 
SMBG. 
CONCLUSIONS 
Mean glycaemia and HbA1c show consistent and stronger associations with 
CVD risk factors than fasting glucose or postprandial glucose levels or 
measures of glucose variability in patients with diabetes. 
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The role of postprandial hyperglycaemia and glucose variability in relation 
to risk of cardiovascular disease (CVD) is heavily debated. 
Epidemiological studies (1-6) indicate that non-fasting glucose (2 hour 
post oral glucose tolerance test (OGTT) or postprandial glucose 
concentrations (PPG)) may be more closely associated with mortality from 
CVD and overall prognosis in the general population than other measures 
of glycaemia. Many of these results (1;3-6) are based on an interpretation 
of OGTT glucose levels as a model of the postprandial state rather than on 
‘real life’ PPG measurements and the vast majority of studies have relied 
on a single test value. In some studies, the predictive value of postprandial 
hyperglycaemia diminished or disappeared after adjustment for other 
cardiovascular risk factors. Only a few studies have measured HbA1c for 
comparison (3;7;8), and these show conflicting results. These 
epidemiological findings are supported by pathophysiological studies 
showing that excessive PPG levels induce oxidative stress, activate blood 
coagulation and cause endothelial dysfunction, pathways that may lead to 
the development of atherosclerosis (9-12). 
Based on these considerations, treatment regimens and guidelines have 
increasingly focused on PPG control as an additional target beyond 
average glucose control (13). However, direct evidence for an additional 
effect of controlling PPG excursions - over and above an effect on reduced 
average glucose levels - on relevant diabetic endpoints is limited. A recent 
randomised clinical trial in patients with type 2 diabetes mellitus and CVD 
did not support an added benefit of targeting control of PPG on subsequent 
CVD events (14). 
The objective of this study was to examine the association between 
different indices of glycaemia measured during daily life activities and 
CVD risk factors. The intensive glucose monitoring data from the A1c 
Derived Average Glucose (ADAG) study provided the opportunity to 
perform these analyses. 
 
MATERIAL AND METHODS 
Study participants 
The ADAG study was initiated to define the mathematical relationship 
between HbA1c and average glucose levels and to determine whether 
HbA1c could be expressed and reported as an estimated average glucose in 
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the same units as used in self-monitoring (15). Between January 2006 and 
March 2008, 268 individuals with type 1 diabetes mellitus and 159 
individuals with type 2 diabetes mellitus completed the study protocol at 
one of 10 centers in the United States, Europe, and Africa. Participants 
(between 18 and 70 years of age) were selected based on stable glycaemic 
control as evidenced by two HbA1c values within one percentage point of 
each other in the six months prior to recruitment. Individuals with a wide 
range of HbA1c levels were included. We excluded individuals with 
conditions that might result in a major change in glycaemia (e.g. disease, 
treatment, or pregnancy), interfere with the HbA1c assays (e.g. 
haemoglobinopathies), or with the relationship between HbA1c and plasma 
glucose concentrations (e.g. anemia, severe renal or liver disease, 
medication). 
The ADAG study was observational and changes in therapy were not 
recommended during the study. Diabetes management was left to the 
patients and their usual health care providers. Clinical data collected at the 
study baseline included anthropometric measurements and self-reported 
data on treatment (age, type of diabetes, ethnicity, gender, smoking, 
height, weight, waist circumference, blood pressure, treatment with 
insulin, lipid lowering, or antihypertensive medication). A full description 
of the study population has previously been published (15). 
The study was approved by the human studies committees at the 
participating institutions and informed consent was obtained from all 
participants. 
 
Measurements of glycaemia 
Glucose levels were assessed with three different methods. Continuous 
interstitial glucose monitoring (CGM) (Medtronic Minimed, Northridge, 
CA) was performed at baseline and 3 times at 4-week intervals during the 
12-week study period. Monitoring periods lasted at least 48 hours, during 
which glucose levels were assessed every 5 minutes. CGM data were 
accepted for analysis if there were no gaps longer than 120 minutes and if 
the mean absolute difference with the Hemocue calibration results was less 
than 18%, as recommended by the manufacturer. 
For calibration purposes and for the measurement of pre- and postprandial 
glycaemia, participants performed an 8-point profile of self-monitored 
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blood glucose (SMBG) (preprandial, 90 minutes postprandial, bedtime, 
and 3:00 A.M.) with the HemoCue meter (Hemocue Glucose 201 Plus, 
Hemocue, Angelholm, Sweden) during the days of CGM.  
In addition, during the weeks when CGM was not performed, participants 
performed a 7-point SMBG (same as the 8-point profile above without the 
3:00 A.M. measurement) (OneTouch Ultra, Lifescan, Milipitas, CA) for at 
least 3 days per week. 
All BG values stated are plasma equivalents. 
 
Calculated indices of glycaemia 
The average BG and the standard deviation (SD) were calculated based on 
CGM data and the 7-point SMBG (Lifescan) data. A combined average 
BG was calculated from CGM and SMBG, weighted by the days of 
monitoring (15). Indices based on CGM were calculated after exclusion of 
the initial 2 hours of monitoring, which is considered to be the unstable 
calibration period. 
Two indices of intraday glucose variability were calculated based on 
CGM: The Mean Amplitude of Glycaemic Excursions (MAGE) and the 
Continuous Overlapping Net Glycaemic Action (CONGA). MAGE is the 
mean of the differences between consecutive peaks and nadirs, only 
including changes of more than 1 SD of glycaemic values and thus 
capturing only major fluctuations (16;17). For the calculation of CONGAn, 
the difference between the current observation and the observation n hours 
previously is calculated for each observation after the first n hours. The 
CONGAn is the SD of these differences (17). Both higher MAGE and 
CONGA values therefore indicate greater glucose variability.  
As an indicator of overall hyperglycaemia, the 24-hour cumulative 
exposure to glucose levels above different thresholds was calculated as the 
Area Under the CGM Curve (AUC) above levels of 6.1, 7.0, 7.8, 10.0, 
11.1, and 16.7 mmol/l (110, 126, 140 180, 200, and 300 mg/dl, 
respectively). This was done for the first 24 hours of each CGM 
monitoring period after the initial calibration period. 
Also from CGM, a postprandial AUC (AUCpp) was calculated for periods 
of 2 or 4 hours after a meal (without BG thresholds), and the postprandial 
increment was calculated from the preprandial glucose level to the highest 
peak for periods of 2 or 4 hours after a meal. Finally, pre- and postprandial 
CHAPTER 8  
 
  
  
158 
measurements from SMBG (HemoCue) were used to calculate mean pre- 
and postprandial BG, as well as pre- and post-breakfast, lunch, and dinner 
values. The prebreakfast BG was used as fasting blood glucose (FBG). 
 
Laboratory analyses 
HbA1c samples were analysed with four highly inter-correlated DCCT-
aligned assays; a high-performance liquid chromatography assay, two 
immunoassays, and an affinity assay (all approved by the National 
Glycohemoglobin Study Program). The mean value at the end of the 12 
week study period was used (15). Blood samples for analyses of lipids and 
high-sensitivity-C-reactive protein (hs-CRP) were obtained at baseline 
(not necessarily fasting), frozen at –80 degrees C, and shipped to a central 
laboratory. Total and HDL cholesterol levels and triglyceride levels were 
measured by standard enzymatic methods (Roche, Mannheim, Germany). 
Plasma LDL cholesterol was calculated according to Friedewald's formula 
(18). Apolipoprotein B and apolipoprotein A1 concentrations were 
determined nephelometrically using an “Immage 800” immunochemistry 
system (Beckman Coulter Inc., Fullerton, CA). Plasma CRP was measured 
with a high-sensitivity sandwich enzyme-linked immunosorbent assay 
(19). LDL-particle size was determined by high-performance gel-filtration 
chromatography as described previously, using thyroglobulin (17.0 nm) 
and fibrinogen (22.2 nm) as calibrators (20).  
 
Statistical analysis 
The associations of the calculated glycaemic indices on CVD risk factors 
were explored in individual linear regression models. Models were 
adjusted for gender, age, smoking, and diabetes type. To facilitate 
comparison of associations, potentially explanatory glycaemic variables 
were standardised by the study population standard deviation (SD). Each 
regression estimate represents the change in the individual CVD risk factor 
per standard unit (one SD) change in the explanatory variable. Non-
standardised estimates are given as examples in clinically relevant units. 
In order to assess combined cardiovascular risk, a combined Z-score was 
calculated. CVD risk factors were standardised (based on the distribution 
within each subpopulation of the two diabetes types), and Z-scores for 
HDL-cholesterol and ApoB/A ratio were multiplied by (-1) to make a high 
HbA1c and MBG show stronger Associations to CVD Risk Factors than 
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Z-score indicative of high risk overall. Individual Z-scores were combined 
within each of four categories: 1) lipid levels (total cholesterol, HDL, 
triglyceride, LDL-particle size, and Apo B/A ratio), 2) anthropometrics 
(BMI and waist circumference), 3) inflammation (hs-CRP), and 4) blood 
pressure (diastolic and systolic). Each category had equal weight of 1/4 of 
the total Z-score, which was used as a combined outcome in additional 
regression analyses.  
 
RESULTS 
Glucose monitoring in the ADAG study was completed by 427 
participants with diabetes. Approximately 2,700 glucose values from each 
participant were available for analyses. We excluded one participant with 
type 1 diabetes mellitus due to erroneous, extreme HemoCue 
measurements of pre- and postprandial values. The numbers of 
participants with laboratory-based CVD risk factors available for the 
different analyses ranged from 89 to 94% of the study cohort (table 1). 
Characteristics of the study population are summarised in Table 1. 
Participants with type 2 diabetes mellitus had a higher BMI, waist 
circumference, and blood pressure than those with type 1 diabetes mellitus 
(p < 0.01). HbA1c levels were higher among those with type 1 diabetes 
mellitus than with type 2 diabetes mellitus (7.3% vs. 6.8%, p < 0.01).  The 
pattern of a poorer average glycaemic control among those with type 1 
diabetes mellitus was also evident for measurements of both pre- and 
postprandial glycaemia. Also, the degree of variability, expressed as the 
standard deviation (SD) of the CGM and SMBG measurements and the 
calculated MAGE and CONGA4, was higher among participants with type 
1 diabetes mellitus compared to those with type 2 diabetes mellitus (p < 
0.01). 
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Table 1. Clinical characteristics. Means (SD) or proportions (%). 
 
All 
 
(n=427) 
 
Type 1 
diabetes 
(n=268) 
 
Type 2 
diabetes 
(n=159) 
 Age (yrs) 48.7 (13.2) 44.1 (12.9) 56.6 (9.4) 
Gender (% female) 52% 52% 51% 
Ethnicity (% Caucasians) 85% 91% 74% 
BMI (kg/cm2)    
     F 28.6 (7.2) 26.3 (4.7) 32.7 (8.7) 
     M 27.9 (5.2) 26.1 (3.4) 30.8 (6.2) 
Waist circumference (cm)    
     F 91.3 (17.8) 85.0 (12.7) 102.3 (20.0) 
     M 97.6 (14.6) 93.2 (12.0) 105.1 (15.6) 
Blood Pressure (mmHg)    
Systolic 127.6 (16.8) 125.1 (16.8) 131.9 (15.9) 
Diastolic 75.9 (9.6) 74.8 (9.6) 77.9 (9.3) 
HbA1c (%) 7.1 (1.1) 7.3 (1.1) 6.8 (1.1) 
Fasting Plasma Glucose (mmol/l) 8.2 (2.4) 8.5 (2.5) 7.8 (2.1) 
Postprandial SMBG (mmol/l)a 9.6 (2.2) 9.7 (2.1) 9.4 (2.2) 
Glucose variability (SD) (mmol/l)b 3.5 (1.3) 4.1 (1.0) 2.6 (1.0) 
Total Cholesterol (mmol/l) [n= 390] 4.5 (0.9) 4.5 (0.9) 4.4 (1.0) 
HDL Cholesterol (mmol/l) [n= 390] 1.5 (0.5) 1.7 (0.5) 1.2 (0.4) 
LDL-size (nm) [n= 403] 21.0 (0.5) 21.1 (0.4) 20.8 (0.6) 
Triglycerides (mmol/l) [n= 390] 1.4 (0.9) 1.1 (0.6) 1.9 (1.0) 
ApolipoproteinB/A-ratio [n= 382] 0.6 (0.2) 0.5 (0.2) 0.7 (0.2) 
Hs-CRP (mg/l) [n= 397c] 2.7 (3.5) 2.4 (3.4) 3.2 (3.7) 
Current smokers 11 % 12 % 9 % 
Insulin treatment 76 % 100 % 38 % 
Antihypertension treatment 47 % 38 % 62 % 
Lipid Lowering treatment 41 % 31 % 60 % 
aDefined as mean of 90 min postprandial self-monitored glucose levels 
bDefined as the standard deviations of all self-monitored blood glucose 
cOne individual with hs-CRP level >40 mg/l was excluded from the analyses. 
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Table 2 presents the associations between different glycaemic indices and 
known CVD risk factors in regression analyses adjusted for gender, age, 
smoking, and diabetes type. Explanatory variables are standardised and 
can be compared within columns for each CVD factor regardless of 
different glycaemic units. 
 
HbA1c and mean BG consistently showed statistically significant 
associations with the different CVD risk factors with a larger magnitude 
than most of the associations of the self-monitored postprandial glucose 
measurements. PPG based on CGM, fasting blood glucose and overall 
hyperglycaemia, measured as AUC above glucose concentrations of 7.8  
and 11.1 mmol/l, also showed statistically significant associations with 
CVD risk factors, albeit at a lower level. Measurements of glucose 
variability did not show significant associations with CVD risk factors. 
Likewise, the postprandial increment (from preprandial glucose 
concentration to the highest postprandial concentration) showed no 
significant associations.  
The same pattern of associations was present for the different lipid 
measures, blood pressure, and the inflammatory marker hs-CRP. 
Adjustment for antihypertensive treatment or lipid lowering medication, or 
exclusion of all blood pressure and lipid treated participants from the 
analyses, did not substantially alter the results. 
Associations showed the same over all tendency upon stratification by 
diabetes type, although some estimates were not statistically significant in 
these subgroups. E.g. for type 1 diabetes HbA1c, Mean BG, PPG 
(SMBG), and FBG were associated to systolic blood pressure by 
standardised estimates of 1,21, 1,36, 1,12, and 1,15, respectively and to 
triglycerides by 0,19, 0,14, 0.08, and 0.08, respectively. For type 2 
diabetes HbA1c, Mean BG, PPG (SMBG), and FBG were associated to 
systolic blood pressure by standardised estimates of 4.39, 3.58, 2.79, and 
2.48, respectively and to triglycerides by 0,21, 0,26, 0.18, and 0.18, 
respectively. 
Unfortunately the ethnic subgroups in this study were too small to perform 
meaningful stratified analyses. We examined the linear associations in a 
model adjusted for Caucasian/non-Caucasian ethnicity. These analyses did 
not alter the conclusions, except for the fact that the glucose variability 
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indices showed stronger and more statistically significant associations to 
the hs-CRP measurements (data not shown). 
The calculated indices based on CGM were not more informative than 
those based on frequent SMBG. In fact, the postprandial and variability 
indices based on SMBG showed stronger or equal associations to the CVD 
risk factors than those based on CGM (table 2). 
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Table 3 shows non-standardised results in clinically relevant units. For 
every 1% increase in HbA1c, systolic blood pressure will be higher by 2.2 
mmHg, total cholesterol by 0.1 mmol/l, and HDL lower by 0.04 mmol/l.  
The association of the different glycaemic indices on the combined CVD 
Z-score is illustrated in Figure 1. The strongest associations were seen 
with the measures of average glycaemia (MBG and HbA1c) and with the 
mean of all self monitored postprandial BG. Again, the association of the 
variability indices with CVD risk factors was not statistically significant. 
 
Table 3: The actual (non-standadised) association between the various 
glycaemic indices and the CVD risk factors. Non-standadised estimates in 
original units (95%CI) adjusted for gender, age, smoking, and diabetes 
type. Statistical significant estimates in bold (P>0.05). (Examle: HDL 
decreases 0.04 mmol/l per mmol/l mean BG increase). HbA1c estimates 
can not be compared to BG measures (vertically) due to different units.  
 
  
HDL chol 
(mmol/l) 
Total chol 
(mmol/l) 
LDL-size 
(nm) 
Systolic BP 
(mmHg) 
hs-CRP 
(mg/l) 
HbA1c 
(%) 
-0.04 (-0.08,-0.00)  0.13 (0.05,0.21) -0.04 (-0.09,0.00) 2.20 (0.88,3.52) 0.39 (0.09,0.69) 
 
Mean 
BG  
(mmol/l) 
-0.02 (-0.04,-0.00)  0.05 
(0,01,0.10) 
 
 
 
 
 
-0.03 (-0.06,-0.01) 1.17 (0.43,1.92) 0.26 (0.09,0.44) 
 
PPG 
(SMBG) 
(mmol/l) 
-0.03 (-0.05,-0.01) -0.00 (-0.04,0.04) -0.02 (-0.05,-0.00) 0.81 (0.14,1.50) 0.17 (0.01,0.32) 
 
FBG 
(SMBG) 
(mmol/l) 
-0.02 (-0.04,-0.00)  0.01 (-0.03,0.05) -0.02 (-0.04,0.01) 0.68 (0.05,1.31) 0.19 (0.04,0.33) 
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Figure 1. Standardised associations between different glycaemic indices 
and the Z-score derived from the CVD risk factors. (Associations per 1 
population SD with 95% CI). 
 
 
 
DISCUSSION 
Among a wide set of indicators of glycaemic level and variability, we 
found that average glucose and HbA1c showed the strongest and most 
consistent associations with known CVD risk factors. FBG had a less 
pronounced association with CVD risk factors compared to either mean or 
postprandial glucose levels and several indices of glycaemic variability 
showed no significant correlations with CVD risk factors. 
The association between hyperglycaemia and CVD and all-cause mortality 
is well established (21). In addition, elevated postprandial glucose levels 
and/or glucose variability have been suggested to increase the risk of 
CVD. However, only a few studies have tested this hypothesis directly and 
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even fewer have compared the effect to that of overall glucose exposure 
(e.g. HbA1c) and shown postprandial glucose levels and/or glucose 
variability to be independent mechanisms. A single-blind randomized trial 
comparing the effect of two insulin secretagogues with different effects on 
postprandial profiles found that specific control of postprandial 
hyperglycaemia led to a reduction in carotid intima medial thickness in 
patients with type 2 diabetes compared with the control group even though 
both groups achieved similar HbA1c reduction (22). After one year, the two 
treatment strategies were not associated with different lipid or blood 
pressure levels, but the therapy with lower PPG levels was associated with 
significant reductions in the inflammatory markers IL-6 and hs-CRP 
levels. On the other hand, the recent multicenter clinical trial HEART2D, 
which compared the effects of postprandial versus fasting glycaemic 
control on cardiovascular event rates in patients with type 2 diabetes after 
acute myocardial infarction, revealed no differences in cardiovascular 
outcomes between the two intervention groups (14). There was no benefit 
of specifically controlling postprandial values over and above the similar 
effect of either treatment on HbA1c reduction. 
In our study, glucose variability and postprandial hyperglycaemia were not 
stronger associated with known metabolic CVD risk factors than measures 
of average glucose. This suggests that the impact of PPG on 
cardiovascular risk is likely to be captured by the assessment of average 
blood glucose or HbA1c. Our results also suggest that the findings of the 
HEART2D study may apply to more heterogeneous diabetic populations 
at a lower level of cardiovascular risk. 
Multivariate models, including both average and postprandial glycaemia, 
were considered. We decided against this model as average blood glucose 
and HbA1c are closely related to the meal-related glucose values, and such 
analyses would render small fluctuations highly influential. 
Several of the previous epidemiological studies demonstrating an 
association between post-OGTT hyperglycaemia and increased CVD and 
mortality, did not take an average glucose measurement (for example by 
HbA1c) into account (1;2;6;23). The failure to make this comparison may 
explain part of the discrepancy between our findings and those of previous 
studies. Moreover, the measurement of glycaemia repeatedly in real life 
circumstances in the current study provides a more reliable index of day-
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to-day exposure than the usual single measurement of glucose levels after 
an OGTT. 
In studies of type 1 diabetes mellitus, glucose variability has not been 
shown to be associated with development of complications. In the DCCT, 
BG variability (from SMBG 7-point profiles) did not appear to be a factor 
in the development of microvascular complications, and pre- and 
postprandial glucose values contributed equally to small-vessel 
complications (24). In our data, glucose indices were analysed for type 1 
and type 2 diabetes mellitus combined. The pathophysiology and insulin 
treatment of type 1 diabetes mellitus lead to the highest variability; 
however, the largest differences in glucose variation was between 
individuals not between types of diabetes. For example, the range of 
glucose variability (the Standard Deviation of SMBG) in our data was 1.0-
6.6 mmol/l for type 1 diabetes mellitus, and 0.6-5.4 mmol/l for type 2 
diabetes mellitus. 
Another important finding of this study is that the glucose indices derived 
from CGM did not have stronger associations to CVD risk factors than 
those derived from SMBG and HbA1c. CGM has the advantages of 
comprehensive BG data collection and a great pedagogical potential, but it 
also requires extra resources. These extra recourses might, arguably, be 
cost-effective when the goal is to improve overall glucose control (25), but 
the use of CGM does not seem to be necessary for assessing the degree of 
variability and PPG in situations where intensive SMBG is feasible. 
The strength of this study is the analysis of ‘real life’ glycaemia, including 
postprandial glucose concentrations from a large number of individuals 
with diabetes using repeated measures. In addition, the intensive glucose 
monitoring with several methods allowed several approaches to define 
PPG, and provided sufficient measurements to assess reliably the different 
features of glycaemia such as glucose variability. 
The main limitation of the study is its cross sectional character. While it 
has a very high resolution, the glucose monitoring is short term and our 
outcomes are CVD risk factors rather than actual CVD events. Therefore, 
although this study can not make direct conclusions regarding the impact 
of postprandial glucose levels or glucose variability on CVD endpoints, 
our results show that if such an effect exists, it is likely to be mediated 
through other mechanisms than those examined in our study. The CVD 
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risk factors we chose are well-validated risk factors of CVD (lipids and 
blood pressure) and one indicator of low-grade-inflammation (hs-CRP). 
Treatment to lower these CVD risk factors might have confounded our 
findings, but the results were largely the same when medically treated 
individuals were excluded. 
The underrepresentation of non-Caucasian ethnic groups in the ADAG 
study precluded analyses stratified by ethnicity. Analyses adjusted for 
Caucasian/non-Caucasian ethnicity did not alter the pattern of results, 
indicating that in our sample ethnicity does not explain the consistently 
strong association between measures of over all glycaemia and CVD risk 
factors.  
Factors that cause glucose fluctuations, such as food intake, exercise, 
stress, beta-cell function or insulin sensitivity, were not examined in this 
study under free-living conditions. Although this limits our ability for a 
detailed exploration of sources of glycaemic variation, it does not affect 
our ability to compare the associations between different measures of 
glycaemia and CVD risk factors.  
The ADAG study included a subgroup of 80 healthy controls. As 
expected, this non-diabetic subgroup presented little variation both in 
regard to the explanatory glyceamic variables and to the range of CVD 
risk factors and thus did not contribute substantially to the linear 
regression analyses. For this reason we limited the analyses to the diabetic 
population only. 
The study excluded participants unable to perform intensive self-
monitoring and patients with anemia or severe renal or liver disease, 
resulting in a population comparable to the average uncomplicated diabetic 
patients. Therefore, our findings have direct relevance for the primary 
prevention of diabetic complications, for which this population is the 
target.  
The participants had stable HbA1c at baseline (defined as a <1% HbA1c 
change during the 6 months prior to the study), and were relatively stable 
during the study. We may therefore have limited the range of glucose 
variability as seen in a diabetic population. However, high levels of 
glucose variability were seen even among our individuals despite stable 
HbA1c levels. 
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Our results do not support a unique role of postprandial hyperglycaemia in 
CVD. Monitoring PPG and glucose variability may be important in 
adjusting treatment to achieve target mean glycaemia and to avoid daily 
excursions including hypoglycaemia, but our results suggest that 
interventions to reduce CVD risk are best aimed at controlling mean 
glucose and HbA1c. 
 
CONCLUSION 
Mean glycaemia and HbA1c show stronger and consistent associations with 
CVD risk factors than fasting glucose and most measures of postprandial 
glucose and glucose variability. The previously observed associations 
between glucose variability and postprandial hyperglycaemia (often based 
on one OGTT) and CVD events, if true and independent of mean 
glycaemia, can not be explained by an association with CVD risk factors. 
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The ADAG study (Chapter 2) 
 
The A1c Derived Average Glucose (ADAG) study [1] was an international 
multicenter study (2006-2008) which examined the relationship between 
the average blood glucose concentrations (over 3 months) and HbA1c in a 
diverse population and to determine whether HbA1c could be expressed 
and reported as average glucose in the same units as used in self-
monitoring. Further we examined the influence of factors such as age, 
gender, race (Caucasian, African or African American, or Hispanic), and 
smoking history on the relationship between HbA1c and mean blood 
glucose (MBG). A total of 507 participants from 10 international centers 
completed 3 months of frequent glucose monitoring. 
 
Major findings 
The ADAG study showed a tight linear relationship between HbA1c and 
MBG in both T1DM and T2DM patients (R2 = 0.84). This relationship 
was earlier described in the Diabetes Control and Complications Trial 
(DCCT) study (R = 0.82) [2], and by Nathan (R = 0.90) but only in T1DM 
patients [3]. Furthermore the DCCT included 1441 patients with T1DM 
and followed them several years to monitor complications, however these 
patients performed 7-point blood glucose profiles only once during 3-
months. Nathan included only 22 patients with T1DM and 3 patients 
without Diabetes Mellitus (DM), who performed continuous glucose 
monitoring (CGM) during a 3-month period.  
 
The ADAG study was designed to establish the relationship between 
HbA1c and MBG and had the important advantages of frequent blood 
glucose monitoring allowing for an accurate determination of MBG in a 
more diverse population as we included different ethnic groups. A total of 
507 participants (268 T1DM, 159 T2DM, and 80 non-DM) were included 
and approximately 2700 glucose values per patient that captured a median 
of 52 days, were measured in a 3-month study period. Furthermore four 
DCCT aligned HbA1c measurement methods were used and all samples 
were measured in a central laboratory. These are the likely explanations 
for the less wide scatter around the regression line, suggestive of a higher 
precision, and for the lower estimated Average Glucose (eAG) values, 
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compared with the widely used equation derived from the earlier 
mentioned DCCT study.  
 
Age, gender, racial and ethnic differences 
The linear regression equations did not differ significantly across 
subgroups based on age, gender, diabetes type, race/ethnicity, or smoking 
status.  
 
Age and gender: A meta-analysis of data from the Framingham Offspring 
Study and the National Health and Nutrition Examination Survey showed 
that in non-­‐diabetic persons HbA1c values gradually increase by 
approximately 7 mmol/mol HbA1c (0.6%) between the ages of 40 and 70 
years, reflecting the change in average glycemia with age [4]. Other 
studies confirm the positive association between age and HbA1c in adults 
[5, 6]. Faerch et al. and Gulliford et al. both found somewhat higher levels 
of HbA1c in men compared to women [7, 8], but other studies found no 
gender-related differences in HbA1c [9, 10]. 
 
Race/ethnicity: The results of the ADAG trial suggested (P = 0.07) that the 
regression line was different for African Americans such that for a given 
value of HbA1c, African Americans might have a slightly lower mean 
glucose level. The African and Indian ethnic groups were unfortunately 
underrepresented in the ADAG study. The latter was mainly due to one of 
the South-East-Asian centers withdrawing from the study due to technical 
difficulties. The influence of ethnicity on the MBG-HbA1c relationship 
therefore requires further studies. 
 
Recently, racial and ethnic differences in the relationship between HbA1c 
and blood glucose have been reported [11-13]. Ziemer et al. found higher 
HbA1c levels in black persons than in white persons across the full 
spectrum of glycemia after adjustments for plasma glucose and other 
characteristics known to correlate with HbA1c levels [14]. And also, 
subjects of South Asian origin showed to have higher HbA1c levels than 
white subjects independent of fasting and post-load glycemia during an 
oral glucose tolerance test (OGTT) [15]. 
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The results of the Diabetes Prevention Program (3819 individuals ≥ 25 
years old with impaired glucose tolerance (IGT)) indicate that ethnicity is 
an independent factor in determining HbA1c: ‘Adjusting for glucose 
concentration and a range of other factors, mean HbA1c levels were 5.78% 
for whites, 5.93% for Hispanics, 6.00% for Asians, 6.12% for American 
Indians, and 6.18% for African Americans (p < 0.001) [13]. Although the 
potential reasons for racial and ethnic differences remain unknown, factors 
such as differences in red cell survival, extracellular-intracellular glucose 
balance, and non-glycemic genetic determinants of hemoglobin glycation 
are being explored as possible contributors. Also the way MBG was 
assessed, e.g. pre- versus post meal blood glucose measurements will 
affect the MBG estimation and thereby the assessment of the relationship 
with HbA1c. 
 
Until the reasons for these differences are more clearly defined, reliance 
on HbA1c as the sole, or even preferred, criterion for the diagnosis of 
diabetes creates the potential for systematic error and misclassification. 
HbA1c must be used thoughtfully and in combination with traditional 
glucose criteria when screening for and diagnosing diabetes. 
 
There is growing literature describing measures of glycemic control in 
specific racial/ethnic groups, and the differences among groups [13]. One 
study found racial/ethnic differences in HbA1c and 1,5 AnhydroGlucitol 
(1,5AG) that could not be attributed to MBG [16]. These data raise 
questions about concordance of self-monitoring of blood glucose (SMBG), 
HbA1c, and 1,5AG, and highlight the need to better understand factors that 
could influence each of these parameters before comparisons of these 
measures across different racial/ethnic groups can be considered reliable. 
Of course these results cannot be compared to the ADAG study as these 
studies were not primarily designed to assess the MBG-HbA1c relationship 
and were not able to obtain a reliable measure of MBG. 
 
Currently, HbA1c is the primary marker of glycemic control in patients 
with DM, primarily because of the strong predictive relationship with 
long-term complications. However, the ADAG study and other more 
recent findings suggest the potential for using multiple measures of 
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glycemia, e.g. 1,5AG and glucose variability (GV) to improve our 
understanding of overall glycemic control across diverse populations [16]. 
 
Smoking and alcohol consumption: A negative association between 
alcohol consumption and HbA1c has been found in at least three studies 
regarding the association between alcohol consumption and HbA1c [7, 17, 
18]. In contrast, Meyer et al. could not confirm these findings in their 
study to the relations of alcohol patterns with HbA1c in non-diabetic men 
[19]. Several studies have documented that smoking is associated with 
higher HbA1c levels [7, 10, 20, 21], but Koga et al. found no association 
between smoking and HbA1c levels [22]. Glycotoxins found in cigarette 
smoke may induce the higher rate of glycation of HbA [23] or the relative 
higher tissue hypoxia [24] can explain increased HbA1c levels in smokers 
[25]. 
 
Limitations 
The ADAG study has a few limitations. In contrast to our intention and 
expectation, some ethnic/racial groups were underrepresented, primarily 
because of the withdrawal of one of the centers with a large Asian 
population and a limited number of subjects of African descent.  
 
In addition, the average glucose estimation was based predominantly on 
two methods: continuous glucose monitoring (CGM) and intermittent 
SMBG. (The Hemocue measurements, recognized as providing values that 
are equivalent to laboratory measurements, were used primarily to 
calibrate the CGM.) To combine these measurements into a single 
calculated eAG, the CGM and finger-stick capillary measurements had to 
be weighted to take into account the different number of measurements in 
a day; however, in separate analyses comparing the relationships between 
HbA1c and eAG measured with CGM or finger stick capillary 
measurements, there was no significant difference in the relationships.  
 
Finally, since only diabetic patients in stable glycemic control and without 
any suggestion of erythrocyte disorders were entered into the study, the 
current results are only directly applicable to this population. 
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Persons with clinical conditions that potentially could affect HbA1c results 
by affecting erythrocyte lifespan, were excluded from the ADAG study. 
These included pregnant women, persons with hematological conditions 
(e.g. anemia, hemoglobinopathies, blood loss) and those with severe renal 
or liver disease. It has been argued that additional data in these groups are 
needed to confirm the established MBG-HbA1c relationship. However, for 
this to be carried out a more complex design and logistics of the 
measurements would be required. Accordingly, glucose monitoring 
periods would have to be planned at specific stages of pregnancy, and at 
specific levels of anemia, renal disease etc. Such an approach is 
challenging and may not be feasible. Instead emphasis should be placed on 
the fact that the glycation process depends on erythrocyte lifespan – no 
matter what assay or units are implemented. 
 
Conclusions  
We concluded that HbA1c levels could be expressed as eAG for most 
patients with T1DM and T2DM and patients without DM. The MBG-
HbA1c relationship in non-Caucasian groups and in young patients should 
be examined further. 
 
Implementation of IFCC HbA1c test results 
Amongst the important diabetes organizations and the American 
Association for Clinical Chemistry (AACC) there is consensus that HbA1c 
should be reported in both National Glycohemoglobin Standardization 
Program (NGSP) units in % and International Federation of Clinical 
Chemistry (IFCC) units in mmol/mol along with eAG in either mmol/L or 
mg/dL)[26] 
(www.aacc.org/gov/gov_affairs/positions/pos_stat_09/Documents/AACC
Position eAG.pdf). Table 1 depicts the National Glycohemoglobin 
Standardization Program (NGSP) standardized HbA1c values and the eAG 
in mmol/L and mg/dL for different given IFCC-HbA1c values. 
 
However, the final decision on what to report and to whom is being made 
country by country. Some countries decided not to report 3 different test 
results per patients. Other associations were not convinced about the 
clinical benefit of reporting eAG in clinical practice, mainly because of the 
wide eAG range for a given HbA1c level. Indeed, the regression line from 
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the ADAG study demonstrated a wide range of average glucose levels for 
individuals with the same HbA1c level (Fig. 1). An HbA1c value of 6.0% 
corresponds to an eAG of 5.5 – 8.5 mmol/l (100–152 mg/dl), and an 
HbA1c value of 7.0% corresponds to an eAG of 6.8 – 10.3 mmol/l (123–
185 mg/dl) (95% confidence intervals) [1]. 
 
 
Table 1: NGSP standardized HbA1c values and the eAG in mmol/L and 
mg/dL for different IFCC-HbA1c values  
IFCC-HbA1c  NGSP-HbA1c  eAG  eAG  
(mmol/mol)   (%)   (mg/dL) (mmol/l) 
31    5    97  5.4 
42    6    126  7.0  
53    7    154  8.6  
64    8   183  10.2 
75   9    212  11.8 
86    10   240  13.4 
97   11   269  14.9 
108   12   298  16.5 
 
 
Figure 1: Linear relationship between estimated Average glucose (eAG 
over 3 months) and HbA1c at the end of the 3 months [1]. 
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In the US, reporting NGSP % HbA1c along with eAG has been 
recommended by the American Diabetes Association (ADA) and the 
AACC. Most countries report IFCC and NGSP and some switched to 
IFCC only. Notwithstanding the different numbers, reported results will 
always be traceable to the anchor IFCC assay. (Table 2) The ADA, 
International Diabetes Federation (IDF), European Association for the 
Study of Diabetes (EASD), and International Society Pediatric and 
Adolescent Diabetes (ISPAD) as well as other member associations in 
different countries currently provide patient care guidelines that relate 
directly to the DCCT aligned NGSP numbers. These will need to be 
updated to include both NGSP and IFCC reference values.  
 
As stated earlier, the aim was to report the HbA1c as eAG, in the same 
units as used for day-to-day monitoring to facilitate the interpretation in 
routine clinical care, but this failed. Unfortunately, the worldwide 
standardization and the implementation on how to report HbA1c test results 
has not been successful. The reporting and interpretation of HbA1c of 
clinical data and research results in the diabetes field worldwide has 
become more complicated, but the comparability of assay’s worldwide has 
improved as they are all traceable to the anchor IFCC assay.  
 
IFCC Network as an NGSP anchor  
The IFCC network is now a secondary anchor for the NGSP. The stability 
of the relationship over time between the IFCC and NGSP will continue to 
be monitored. The NGSP certification process will not change and an 
IFCC Laboratory Network has been established. The lists of current 
approved and candidate IFCC Network Laboratories can be found at: 
http://www.ifcchba1c.net/. Table 2 shows the conversion factors for IFCC 
compared to each of the designated comparison methods (DCMs) 
including the NGSP.  
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Table 2: Conversion factors for IFCC compared to each of the designated 
comparison methods (DCMs) including the NGSP. 
DCM   
From IFCC to DCM    From DCM to IFCC  
NGSP (USA)  
NGSP = (0.09148*IFCC) + 2.152   IFCC = (10.93*NGSP) - 23.50 
   
JDS/JSCC (Japan) 
JDS = (0.09274*IFCC) +1 .724  IFCC = (10.78*JDS) - 18.59 
 
Mono-S (Sweden) 
Mono-S = (0.09890*IFCC) + 0.884 IFCC = (10.11*Mono-S) - 8.94  
 
 
Glucose Variability and HbA1c (Chapter 3) 
 
Glucose Variability 
The potential contribution of GV or postprandial hyperglycemia to the 
Hemoglobin glycation process is still unclear. Fasting and postprandial 
glucose (PPG) excursions both contribute to the MBG or total glucose 
exposure, and therefore to HbA1c [27]. The specific question is whether 
PPG and GV, apart from the contribution to MBG, also affect the 
glycation process and therefore may affect the relationship between MBG 
and HbA1c. 
 
Assessing Glucose Variability 
There are different methods to quantify GV. In the ADAG study we 
calculated several variability metrics, as for example “Amplitudes of 
glycemic excursions”, the Standard Deviation (SD) of all blood glucose 
values, and the Magnitude of the Amplitude of Glycemic Excursions 
(MAGE) as described by Service et all [28]. Furthermore we applied the 
Continuous Overlapping Net Glycemic Action (CONGA) to calculate the 
GV from CGMS. The CONGA is defined as the standard deviation of the 
differences, and measures the overall intra-day variation of glucose 
recordings [29]. 
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Influence of glucose variability on the MBG-HbA1c relationship 
In Chapter 3 we examined the influence of GV on the MBG-HbA1c 
relationship. We found that all GV measures significantly, although 
modestly, influenced the MBG-HbA1c relationship. The variability 
measure SD showed the strongest influence. High GV (SD) was associated 
with higher HbA1c levels for a given MBG, and this effect was more 
pronounced at higher HbA1c levels. However the magnitude of this effect 
of GV was small and only demonstrable in patients with T1DM. Possibly, 
the T2DM patient group was too small and the variability in this group too 
low to find this interaction. 
 
Our results are in line with the results of the DirectNet study in children 
[30]. Although the authors also concluded that HbA1c directly reflects 
mean glucose over time, they found substantially greater inter-individual 
variation in the relationship between MGB and HbA1c than in our and 
Nathan’s study in adult patients with T1DM [3]. The DirecNet study used 
a non-centralized HbA1c method with relative poor correlation with a high-
performance liquid chromatography (HPLC) method, and only performed 
CGM for 67% of the study period, compared to 97% of the 12-week study 
performed by Nathan [3]. In addition, these children had highly variable 
glycemia, which will have affected the accuracy of capturing mean 
glycemia. With high GV it may be difficult to capture the real MBG that 
determines the measured HbA1c value, as the timing of the assessment in 
relation to the HbA1c measurement will be critical.  
 
Given the slow kinetics of glycation, brief periods of hyperglycemia 
should theoretically not have a major impact on HbA1c levels. Previous 
studies have examined whether the relationship between MBG levels and 
HbA1c is influenced by GV and found no or minimal influence [31-33]. 
However, these studies used limited SMBG data in relatively small 
numbers of patients to assess mean glucose levels and variability. These 
limitations affect the precision and accuracy of the estimations of MBG 
and of the glycemic excursions. CGM provides the opportunity to assess 
more precisely glycemic excursions, including the duration and frequency 
of the excursions, and allows the calculation of different measures of GV. 
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In general, GV is higher in patients with poor glycemic control and in 
patients with T1DM than in patients with T2DM, which probably can be 
attributed to insulin therapy and higher insulin sensitivity. High GV may 
affect glycation by exposing the red blood cell to periodic high glucose 
levels, which in turn stimulates oxidative stress and acceleration of 
irreversible glycation [34-38]. Recently it has been speculated that oxygen 
free radicals may promote the formation of early glycated proteins [34, 
35]. As proposed by Brownlee, hyperglycemia can be the underlying 
mechanism for an enhanced oxidative stress [36, 37]. 
 
High GV and especially postprandial glucose excursions were also 
previously associated with oxidative stress in T2DM [38]. The activation 
of oxidative stress, estimated from urinary excretion rates of Isoprostanes, 
was highly correlated with MAGE calculated from CGM [38]. However, 
Wentholt et al could not replicate these results in T1DM [39]. 
 
Recent evidence suggests that also hypoglycemia may play an important 
role in the vascular complications of diabetes [40]. Hypoglycemia also 
causes oxidative stress [41], inflammation [42], and endothelial 
dysfunction [43]. Oxidative stress is considered the key player in the 
pathogenesis of diabetes complications [44, 45]. During hyperglycemia, 
oxidative stress is produced at the mitochondrial level [44], similarly as in 
hypoglycemia [41]. Therefore, oxidative stress might be considered the 
common factor linking hyperglycemia, hypoglycemia, and the vascular 
complications of diabetes. Consistent with this hypothesis is the evidence 
that hyperglycemia [46] and hypoglycemia both produce endothelial 
dysfunction and inflammation through the generation of oxidative stress 
[43]. Endothelial dysfunction and inflammation are well-recognized 
pathogenic factors for vascular disease, particularly in diabetes [47]. 
 
However, Ceriello et al showed that the way in which recovery from 
hypoglycemia takes place might also have an effect on cardiovascular risk. 
When recovery from hypoglycemia results in normoglycemia, the 
deleterious effects of the previous hypoglycemia are mainly 
counterbalanced, whereas when recovery is obtained resulting in 
hyperglycemia, endothelial function, oxidative stress, and inflammation 
are further worsened [48]. 
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The strength of the ADAG study is the great precision with which the 
MBG was measured in a large number of individuals with and without 
diabetes using repeated measures. The intensive glucose monitoring using 
several methods also allowed to explore several approaches to define PPG, 
and provided sufficient measurements to reliably assess different features 
of GV.  
 
Limitations 
Limitations of the MiniMed CGM system include the inability to measure 
glucose values below 2.2 mmol/l or above 22.2 mmol/l. As the participants 
were selected to have stable HbA1c at baseline (defined as a < 1% HbA1c 
change during the 6 months prior to the study), and remained relatively 
stable during the study, we may have limited the range of GV compared to 
the general diabetic population. Despite a stable HbA1c the GV was still 
considerable among the participants of the ADAG study.  
 
Conclusions 
At higher levels of GV the relationship between HbA1c and MBG in 
patients with T1DM is altered, leading to a higher HbA1c level for a given 
MBG. However, the impact (near the HbA1c treatment target of 7 %) is 
only modest. The	  potential influence of GV on the glycation process, and 
on HbA1c in particular, is modest. The mechanism needs to be further 
elucidated. 
 
 
Are blood glucose concentrations the sole determinant 
of HbA1c value? (Chapter 4)  
 
Mean blood glucose and HbA1c are tightly related, but inter-individual 
variability, quantified by the Hemoglobin Glycation Index (HGI), exists 
and may be attributable to non-glycemic factors affecting glycation. We 
explored whether non-glycemic factors were associated with HGI. 
 
Seventy-four 74 (14.6%) of the 507 subjects had HbA1c levels outside the 
80% prediction band of the relationship between HbA1c and MBG, 44 
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subjects were high outliers with higher than predicted HbA1c levels, and 30 
subjects were low outliers with lower than predicted HbA1c values. 
 
Measures of GV were the main determinants of a high HGI. The GV 
measures SD, MAGE, and CONGA4, and AUC24 and fructosamine 
explained the largest fraction of the variance of the outlier status for the 
High outliers, but not Low outlier group. The small number of patients in 
the latter group may explain this finding.  
 
Smoking status was the next variable explaining outlier status. As 
described earlier smoking is associated with higher HbA1c levels [7, 10, 
20, 21], but other found no association between smoking and HbA1c levels 
[22]. Smoking history may change RBC turnover. 
 
Finally, diabetes type, Apo-B levels and insulin and lipid treatment were 
associated with High outliers. However these factors combined explained 
only 25% of the variance in the MBG-HbA1c relationship for the High 
outliers. The “non-glucose variables” diabetes type and insulin were not 
independently associated with HGI. Smoking status, LDL, Apo-B and 
Apo-B/A1, independent of GV, were related with high HGI.  
 
Fructosamine concentrations measured at baseline (n = 507) were 
significantly correlated with HGI and outlier status. This suggests that 
patients with a high HGI and thus a higher than predicted HbA1c also have 
higher fructosamine levels. This finding supports prior suggestions that the 
period of glycemic exposure in the few weeks before an HbA1c 
measurement- as reflected by fructosamine- may play a disproportionate 
role in the HbA1c value. Alternatively, GV may affect the rate of glycation 
in general, measured as HbA1c or fructosamine. 
 
As expected, the T1DM group had higher MBG, HbA1c and GV values 
than T2DM and non-DM groups. This explains the greater variance in the 
relationships with High HGI. Kilpatrick et al. found that HbA1c values 
vary markedly between subjects without diabetes, while values within the 
same individual are very consistent [49]. A potential, unproved 
explanation for this biological variability is the concept of fast and slow 
glycation, as described by Hempe [50] and by earlier smaller studies in 
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people without [49, 51, 52] and with diabetes [53, 54]. Most of these 
studies suffered from insufficient number of glucose measurements, 
therefore, discrepancies between HbA1c and MBG could be secondary to 
an inaccurate appreciation of MBG. The ADAG study included frequent 
measurements of blood glucose over time, with frequent measurements 52 
of 84 days prior to HbA1c measurement. The HbA1c level was established 
with four highly precise assays performed in one central laboratory. 
Therefore, discrepancies in the MBG-HbA1c relationship among 
individuals are less likely due to errors in the measurements of either 
MBG or HbA1c.  
 
Limitations 
Although the ADAG study population was selected to limit factors known 
to interfere with the measurement of MBG or HbA1c, or with the 
relationship between them, inter-individual differences, such as ethnicity, 
age and gender were of course not excluded.  
 
Other limitations of this study include the limited range of reliable 
measurements outside the 40 mg/dL and 400 mg/dL (2.2 and 22.2 
mmol/L) when using CGM and the variation in MBG measurement with 
the Lifescan meter. Although it is one of the largest studies examining the 
relationship between HbA1c and MBG, the relatively small sample size of 
the subpopulations may have affected our findings. Finally, the 
measurement of HGI is not independent of the HbA1c level, so the 
associations documented with HGI may be confounded by the HbA1c level 
itself [55]. 
 
Conclusions 
We concluded that higher GV was associated with higher HGI. Measures 
of GV (SD, MAGE and CONGA4) and AUC24 and fructosamine are 
strongly correlated with HGI and high outlier status. The GV measure SD 
and smoking status explained the largest fraction of outlier status for the 
High outliers. These variables together explained only around 13 % of the 
variance in the MBG-HbA1c relationship. Finally, diabetes type, Apo-B 
levels and insulin and lipid treatment were associated with High outliers. 
However, all these factors combined explained only 25% of the variance 
in the MBG-HbA1c relationship for the High outliers. 
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1,5 AnhydroGlucitol (Chapter 5) 
 
Markers for longer-term glycemic control, including fructosamine and 
HbA1c, reflect average glucose concentrations over 2 and 8 till 10 weeks 
respectively, but do not provide information on GV. Patients in acceptable 
glycemic control according to HbA1c levels may still have significant 
postprandial hyperglycemia [56]. 
 
Plasma 1,5AG is cleared renally by competitive inhibition of reabsorption 
at glucose levels above the renal threshold for glucose. Previous studies 
have shown reduced 1,5AG levels in hyperglycemic patients. Therefore, 
1,5AG has been proposed as a marker of glycemic excursions. We 
examined whether 1,5AG might be used as an indicator of GV including 
overall (postprandial) hyperglycemic episodes at predefined HbA1c ranges. 
 
Conclusions 
We concluded that the test performance of 1,5AG to detect hyperglycemic 
episodes in moderately controlled patients (HbA1c ≤ 64 mmol/mol (8%)) 
was fair (AUC of ROC curve 0.73, p < 0.001). Measures of GV and 
hyperglycemic episodes correlated significantly and inversely with 1,5AG 
at HbA1c levels ≤ 64 mmol/mol (8%) and between 42 and 64 mmol/mol (6 
- 8%). Measuring 1,5AG in addition to HbA1c may identify GV and 
postprandial hyperglycemia, especially in moderately controlled patients 
with diabetes. 
 
Limitations 
The main limitation of this study was that all variables were measured at 
one single time point (one 48-hour period), which does not fully cover the 
time period reflected by the different measured parameters (HbA1c and 
1,5AG). Since, only participants in relatively stable glycemic control were 
included in the study, we assumed that the GV measures and MBG, 
assessed at this time point, were representative for the period prior to the 
measurement. Also, we couldn’t correct 1,5AG values for kidney function, 
but participants with severe renal impairment were excluded. 
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1,5AG in routine daily practice? 
1,5AG may be used as an additional tool to monitor glycemic control 
during the 2 to 3 weeks prior to the HbA1c measurement. This may 
motivate patients to monitor glycemic excursions and to achieve better 
glycemic control. The down side is the need of an additional blood sample 
as, since at present, no home-test for 1,5AG is available. 
 
The reference range of the 1,5AG test is established in persons without 
diabetes and is quite broad, indicating a large biological variation in the 
population. This, and also the fact that the 1,5AG concentration is 
influenced by the level of MBG and HbA1c, makes the test less reliable and 
less easy to interpret. Patients can easily check their glycemic control by 
performing SMBG at relevant time points, and by assessing an HbA1c test 
every 3 months.  
 
Unfortunately it is not useful in pregnant women, a patient group where 
tight glycemic control is of special importance, as the glomerular filtration 
rate can change during pregnancy. Abnormal values have also been noted 
in individuals with abnormal glomerular filtration rates [57]. Low 1,5AG 
values have also been observed in terminal stage renal failure, dialysis 
patients, advanced cirrhosis, and prolonged fasting. More studies are 
required to establish the clinical utility of measuring 1,5AG, and in 
particular in specific patient populations, as for example in pregnancy. 
 
 
Associations between different glucose indices and 
HbA1c (Chapter 6) 
 
Assessing glucose exposure  
Various established methods exist to quantify postprandial glycemia or 
GV, but only few have been compared with each other and with HbA1c. 
We examined the relationship among common indices of GV, average 
glycemia, postprandial glycemia and HbA1c using detailed glucose 
measures obtained during real-life in the ADAG study cohort. As we 
expected, our analyses revealed that many of these glycemic indices were 
strongly correlated within each category. Additionally, we studied which 
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blood glucose value(s) of the day provide the strongest prediction of 
MBG, as measured by HbA1c, especially focusing on pre- and postprandial 
glucose contributions to MBG levels.  
 
Indices of postprandial glycemia and glucose variability 
Especially indices of GV (CONGA, SD of CGM or SMBG, and MAGE) 
were highly intercorrelated indicating that these calculated measures of 
variability express almost identical information. MAGE has previously 
been described as the ‘gold standard’ of assessing GV [28]. 
Our findings show that MAGE and CONGA or the ‘simple’ standard 
deviation (SD) capture information regarding variability to a very similar 
degree, indicating that the choice can be made on the basis of ease of 
calculation or practical considerations. The variability measures did not 
correlate well with the postprandial measurements or indexes of fasting or 
average glycemia. 
 
The CGM captured postprandial AUC 2-hours following a meal correlates 
well with the SMBG postprandial measurements. This means that the 
glucose excursion in the hours after a meal is reliably captured by a 
routine 90 minutes postprandial SMBG measurement. Both the SMBG and 
the CGM postprandial measurements correlate moderately with overall 
hyperglycemia as measured with CGM (AUC >11.1 mmol/l), average BG 
and HbA1c. 
 
A ‘postprandial increment’ has been used to assess GV and PPG in 
previous studies [27, 58], but the definition and calculation methods have 
varied. When we defined the postprandial increment as the difference in 
glucose level from the pre-prandial glucose concentration to highest 
postprandial value in a 2-hour window the index showed low correlations 
with postprandial BG levels (ρ= 0.45-0.51) and with indices of average 
glycemia or hyperglycemia (ρ= 0.26-0.27). Large postprandial increments 
may be expected to reflect high GV; however, the correlation to the 
variability measures are not strong (ρ= from 0.41 (SMBG SD) to 0.54 
(CONGA4)). Hence, postprandial glucose increments do not seem to be a 
satisfactory way to assess GV. 
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As expected, HbA1c correlated well with average blood glucose from 
CGM, SMBG, and the two combined. When exploring the contribution of 
glucose levels from SMBG at different times of the day to average 
glycemia, the pre-prandial glucose levels had a larger effect on HbA1c than 
postprandial glucose levels, presumably because they resemble the 24-h 
glucose levels (and thus the long-term exposure to glucose) more closely. 
This result was the same before and after including the nocturnal blood 
glucose index to the regression model, which, surprisingly, only lead to a 
small increase in the proportion of HbA1c variation explained. 
 
The frequently cited article by Monnier et al [27] concludes that 
postprandial glucose levels are the dominant contributor to HbA1c levels in 
patients with HbA1c < 8.5%, while fasting glucose levels were the major 
contributor for patients with HbA1c > 8.5%. The calculations underpinning 
this conclusion were based on AUCs derived from meal-period 
measurements only, thus disregarding the contribution of glucose exposure 
outside meal periods to HbA1c.  
 
Monnier et al [27] define postprandial glycemia as the AUC above each 
individual’s fasting value, while pre-prandial glycemia is defined as the 
AUC between 6.1 mmol/l (110 mg/dl) and measured FBG for each 
individual. This approach introduces a bias when comparing the 
association between these two indexes and HbA1c. Individuals with HbA1c 
levels 8.5% will strongly tend to also have high FBG. Their postprandial 
AUC values will therefore be small by artifact, as only excursions above 
these high individual FBG values are considered postprandial glucose 
exposure. Simultaneously, Monnier et al.’s definition yields larger pre-
prandial AUCs in this same group, thus introducing the reported effect. 
This methodological problem might explain why Monnier et al.’s results 
differ from our findings and those of others [59, 60]. 
 
The putative roles of GV and PPG as risk factors for diabetes 
complications are based on 1) studies reporting an association between 
excessive PPG levels and factors that may lead to development of diabetes 
complications [38, 61-63], 2) epidemiological studies associating 2-h post-
OGTT values with increased mortality and cardiovascular disease [64-67], 
and 3) a few clinical trials in very specific subgroups (e.g. pregnant 
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women [68] and individuals with impaired glucose tolerance [69] or 
T2DM post-AMI [70]), which have addressed the issue with different 
methods and have had conflicting results. The roles of PPG and GV as risk 
markers need further exploration, and an understanding of the differences 
and similarities among the different measures of PPG, overall 
hyperglycemia, and GV is critical.  
 
Fasting Blood Glucose (FBG) levels were only moderately correlated with 
indexes of hyperglycemia and average or postprandial glucose levels. 
 
The ADAG glucose monitoring protocol was intensive and not feasible in 
daily clinical routine. Measurements of FBG, well timed postprandial 
glucose and HbA1c are much easier to implement in clinical care. 
 
CGM versus SMBG  
Conventional SMBG is well known and regularly used by most patients. 
CGM has the advantage of a comprehensive BG data collection and has a 
marked educational potential, but also requires considerable additional 
resources, especially staff and education facilities. This makes CGM more 
costly to implement in daily clinical practice as well as in research 
settings. These extra resources might, arguably, be cost-effective when the 
goal is to improve overall glucose control [71] but the use of CGM does 
not seem to be necessary for assessing the degree of variability and PPG in 
situations where frequent SMBG is feasible.  
 
Limitations 
The fact that participants had stable HbA1c (< 1% HbA1c change 6 month 
prior to study) could have led to underestimation of GV. However, high 
levels of GV were seen among our subjects despite stable HbA1c values. 
Even though patients with T1DM and T2DM have different glucose 
patterns because of different pathophysiologies, the mechanism of 
hemoglobin glycation is likely to be the same. The relationships of the 
glycemic indices were therefore calculated for the combined group. 
 
Conclusion 
The relevance of glucose excursions and postprandial glycemia in the day-
to-day diabetes control and risk management is still debated. Different 
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indices based on different monitoring and calculation methods 
intercorrelate well within each category (variability, postprandial, average 
indices). Variability indices are weakly correlated with the other categories 
indicating that these measures convey different information. However, 
indices of postprandial, average, and overall hyperglycemia correlate 
moderately between categories. 
 
Our findings confirm that FBG is not a clear indicator of general glycemia. 
The mean of all pre-prandial, as compared to postprandial glucose values 
have a stronger relationship with HbA1c, both in patients with T1DM and 
T2DM. 
 
Glucose variability in clinical practice 
Clinicians must understand GV both qualitatively and quantitatively and 
endeavor to reduce that variability before trying to reduce the mean level 
of blood glucose. This sounds intuitively obvious [72, 73] and can also be 
demonstrated mathematically. If the mean glucose level was 5.6 mmol/L 
(100 mg/dL) but the SD was 2.2 mmol/L (40 mg/dL), one could predict 
that there would be an unacceptable incidence of severe hypoglycemia 
even though the mean glucose is in the euglycemic range. 	  
 
This applies to blood glucose as measured by SMBG, laboratory 
measurements of venous samples and interstitial glucose as measured by 
CGM. When titrating a medication such as basal insulin, it is essential to 
know the between-day (within-subject) variability in fasting plasma 
glucose to be able to set the target glucose level appropriately so that risk 
of hypoglycemia is at an acceptable level. Unfortunately, these estimates 
of GV are rarely obtained.  
 
GV also serves as one facet of the quality of glycemic control, another 
reason to quantify GV. Epidemiologic and preclinical studies suggest that 
GV contributes to the risk of complications in diabetes [72, 74-81]. This 
hypothesis remains controversial and will remain an active area of 
research [82-92]. 
 
The above three considerations, the requirement to achieve good control, 
the desire to assess quality of glycemic control, and the plausible link to 
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complications, provide a major impetus for development, testing and 
application of methods to quantify GV. To assist the clinician with the 
interpretation of measures of GV, we need to have ‘‘normative’’ or 
‘‘reference’’ data. Data obtained in non-diabetic individuals, as reported 
by Mazze et al. [93] and Zhou et al. [94], are helpful in setting a baseline. 
However, these values are so far removed from what is observed in 
patients with diabetes that they have only minimal relevance.  
We need to be able to assess the observed variability in a large population 
(or populations) of people with diabetes (T1DM and T2DM). Because 
most measures of GV are closely related to mean glucose and HbA1c 
levels, criteria should be developed for multiple ranges of HbA1c values. 
 
Several groups have developed computer programs to calculate GV. These 
include methods for calculation of MAGE [95, 96], software called a 
‘‘Gly-Culator’’ [97] and spreadsheets to calculate various types of SDs 
[98, 99] among others. The aim was to introduce a degree of 
standardization and thereby reduce the risk of errors in the computations.  
 
Now there is a plethora of measures of GV, and the number continues to 
grow [72, 74-79, 100-103]. We need to make sure that these parameters 
become clinically useful, by providing reference ranges for defined types 
of patients (defined by type of diabetes, type of therapy, degree of 
glycemic control by the ‘‘gold standard’’ HbA1c) [104]. Data reduction 
needs to be fully automated, whether the glucose data are generated from 
SMBG, CGM, or hospital-based systems.  
 
 
Real life glycemic profiles in non-diabetic individuals 
(Chapter 7) 
 
Glucose profiles obtained in healthy persons under real-life conditions 
may serve as a benchmark for studies in patients with hyperglycemia. 
Current understanding of normoglycemia is largely based on studies of 
populations without diabetes, with a limited number of glucose 
measurements per individual in experimental conditions. Real-life 
glycemic profiles of healthy individuals are not readily available [93, 94]. 
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In the ADAG study real-life glycemia, including PPG concentrations from 
80 individuals without diabetes was obtained. The objective was to assess 
glycemic variability in individuals without diabetes and to study whether 
OGTT thresholds for impaired glucose tolerance (IGT) and diabetes were 
exceeded in real life. The median time of CGM (over a 3 months period) 
was 230 hours per individual offering detailed information on glucose 
features under real-life conditions and allowed several approaches to 
define PPG, and provided sufficient measurements to reliably assess 
features of GV (SD).  
 
We found that nearly all (93%) individuals without diabetes exceeded the 
IGT threshold of 7.8 mmol/l at some point during the day and spent a 
median of 26 minutes (range 0 min – 6 h 52 min) per day above this level. 
Eight individuals (10%) spent more than 2 hours in the IGT range. One in 
ten reached levels (11.1 mmol/l) diagnostic of diabetes. These findings 
suggest that ambient glucose levels in persons without diabetes are 
frequently in the IGT range and that a substantial proportion reach even 
higher levels.  
 
This highlights that, even though the monitored non-diabetic individuals in 
the ADAG study were selected by a very low level of baseline fasting 
plasma glucose (FPG), some of the exposure to moderately elevated 
glucose levels remains out of sight when we classify individuals based on 
isolated glucose measurements and HbA1c levels. Previous smaller studies 
have suggested similar patterns, albeit in more homogeneous populations 
[93, 105]. 
 
Glucose and HbA1c levels from persons without diabetes and patients with 
IGT/diabetes are part of a continuum; there are no strict cut-off points, but 
a gradual distribution.  
 
During a standardized OGTT, it is well established that glucose 
concentrations can exceed 7.8 mmol/l in individuals with normal glucose 
tolerance in the time preceding the 2-hour value [106]. However, since the 
75g OGTT is an extreme liquid glucose load compared to an average 
mixed meal, we find that our results based on real-life monitoring add an 
important dimension.  
CHAPTER 9  
 198 
Limitations 
A limitation of the ADAG study when examining individuals without 
diabetes is the absence of OGTTs at screening to rule out diabetes with 
certainty or to classify subjects as having IGT. However, our fasting PG 
exclusion criterion of < 5.4 mmol/l has been shown to be highly specific 
for ruling out diabetes [107].  
 
In addition, the exclusion criterion of HbA1c > 6.5% used in the ADAG 
study was recently proposed as the new diagnostic level for diabetes [108]. 
The mean HbA1c for non-DM in the study was considerably lower: 5.2 % 
(SD 0.3). Furthermore, it would have been interesting to analyze measures 
of glucose fluctuations.  
 
 
HbA₁c and mean blood glucose show stronger 
associations with cardiovascular disease risk factors 
than do postprandial glycemia or glucose variability in 
persons with diabetes (Chapter 8) 
 
Assessing glucose exposure  
Increased glucose excursions and postprandial hyperglycemia have been 
suggested as unique risk factors of cardiovascular disease (CVD) and 
mortality in patients with diabetes mellitus. Much of the evidence is based 
on a single 2-hour glucose value after oral glucose tolerance testing in 
epidemiological studies. Treatment regimens and guidelines have 
increasingly focused on PPG control as an additional target beyond 
average glucose control. 
 
However, direct evidence for an additional effect of controlling PPG 
excursions - over and above an effect on reduced average glucose levels - 
on relevant diabetic endpoints is limited. 
Only a few studies have tested this hypothesis directly or compared the 
effect with that of overall glucose exposure (HbA1c) and shown PPG levels 
and/or GV to be independent mechanisms. One single-blind randomised 
trial comparing the effects of two insulin secretagogues with different 
effects on PPG found that control of postprandial hyperglycemia led to a 
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reduction in carotid intima–media thickness in patients with T2DM 
compared with the control group [109]. Therapy with lower PPG levels 
was associated with significant reductions in the concentrations of the 
inflammatory markers IL6 and hs-CRP. A recent randomized clinical trial 
in patients with T2DM and CVD did not support an added benefit of 
targeting control of PPG on subsequent CVD events [70]. However, in this 
study the difference in PPG between the 2 intervention groups might have 
been to small to find this effect. 
 
We examined the association between various indices of glycemia 
measured during every-day activities and metabolic CVD risk factors 
(lipids, hs-C-reactive protein, blood pressure). In order to correlate the risk 
factors of CVD to glucose exposure, we had to define categories of 
commonly used indices of glycemic variability, average and postprandial 
glycemia. As we expected, our analyses revealed that many of these 
glycemic indices were strongly correlated within each category.  
 
In our study, indices of GV showed no significant associations with CVD 
risk factors. GV and postprandial hyperglycemia were not stronger 
associated with known metabolic CVD risk factors than measures of 
average glucose. This suggests that the impact of PPG on cardiovascular 
risk is likely to be captured by the assessment of average blood glucose or 
HbA1c.  
Several epidemiological studies demonstrating an association between 
post-OGTT hyperglycemia and increased CVD and mortality, did not take 
an average glucose measurement (for example by HbA1c) into account [64, 
65, 110, 111].  
Moreover, the thorough measurement of glycemia under real-life 
circumstances in the ADAG study provides a more reliable index of day-
to-day exposure than the usual single measurement of glucose levels after 
an OGTT. 
 
In addition, the intensive glucose monitoring with several methods 
allowed several approaches to define PPG, and provided sufficient 
measurements to assess reliably the different features of glycemia such as 
GV. 
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In T1DM, GV has not been shown to be associated with the development 
of complications. In the DCCT, GV (from seven- point profiles) did not 
appear to be a factor in the development of micro-vascular complications, 
and pre- and postprandial glucose values contributed equally to small- 
vessel complications [84]. 
 
The CVD risk factors we chose are well-validated or “traditional” risk 
factors of CVD (lipids [112-114] and blood pressure [115]) and one 
indicator of low-grade inflammation (hs-CRP) [116]. We have considered 
the possible impact of treatment to lower these risk factors on our findings 
by excluding participants receiving lipid lowering or anti-hypertension 
treatment. This did not substantially alter the results. 
 
The associations between the calculated glycemic indices and CVD risk 
factors were explored in individual linear regression models adjusted for 
age, gender, and diabetes type. We considered the use of multivariate 
models including both average and postprandial glycemia. We decided 
against this model as average blood glucose and HbA1c are closely related 
to the meal-related glucose values, and such analyses would allow small 
fluctuations to be highly influential. 
 
To facilitate comparison of associations, potentially explanatory glycemic 
variables were standardized by the study population standard deviation 
(SD). As our data are cross-sectional and without information on CVD 
outcomes, we considered ways to estimate risk of CVD as a continuous 
outcome. A well-established, reproducible risk score like the UKPDS risk 
score would have been a way to do this. However, since no data regarding 
atrial fibrillation and diabetes duration were available, both of which 
factors are included in the UKPDS risk engine, this risk analysis tool could 
not be used. Therefore, a combined Z-score was calculated from the 
standardized CVD risk factors. This Z-score is based on the distribution in 
the present study population (standardized by SD), and thus results are not 
comparable to other populations. However, using this score gave us an 
index for a combined cardiovascular risk for each individual. 
 
Our results do not support a unique role of postprandial hyperglycemia in 
CVD. Monitoring PPG and GV may be important in adjusting treatment to 
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achieve target mean glycemia and to avoid daily excursions including 
hypoglycemia, but our results suggest that interventions to reduce CVD 
risk are best aimed at controlling mean glucose and HbA1c. 
 
Limitations 
The main limitation of the study in this context is it’s cross sectional 
character. While it has a very high resolution, the glucose monitoring is 
short term and our outcomes are CVD risk factors rather than actual CVD 
events. Therefore, this study cannot reach direct conclusions regarding the 
impact of PPG levels or GV on CVD endpoints. However, our results 
indicate that if such an effect exists, it is unlikely to be mediated through 
the mechanisms (risk factors) examined in our study.  
 
Furthermore, the participants had stable HbA1c at baseline (defined as a < 
1 % unit change in HbA1c during the 6 months prior to the study), and 
were relatively stable during the study. We may therefore have limited the 
range of GV as seen in a diabetic population. However, high levels of GV 
were seen among our individuals despite stable HbA1c levels.  
 
Conclusions  
Mean glycemia and HbA1c show consistent associations with CVD risk 
factors at a stronger level than fasting glucose and most measures of PPG 
and GV. In our study, the previously observed associations between GV 
and PPG and CVD events cannot be explained by an association with 
known metabolic CVD risk factors. 
 
 
Future perspectives 
 
The NGSP certification process will ensure standardization and the IFCC 
Laboratory Network will continue to serve as a second anchor for the 
NGSP. The reporting of HbA1c test results to clinicians, patients and in the 
scientific literature will however vary across countries and regions. 
Scientific reporting will gradually change to the SI units (mmol/mol), 
whereas physicians and patients will continue to use DCCT or estimated 
Average Glucose values.  
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HbA1c will increasingly be used for diagnostic purposes and in primary 
care and in emerging countries. This increased demand has led to a 
greater supply for new and cheaper HbA1c assay systems. The higher cost, 
compared to the glucose assay, is set-off by ease of use (no fasting 
required) and potentially less personnel as glucose tolerance tests will not 
be required. 
 
Glucose variability will continue to capture the interest of diabetes 
researchers. The questions that need to be addressed include: what is the 
best measure of glucose variability in daily life? How to define it for 
different patient groups and for different levels of glycemic control? How 
to implement this in daily clinical practice? New technology for 
continuous glucose monitoring has led to the availability of large numbers 
of blood glucose measurements. Now we need the software to develop 
clinically meaningful, i.e. actionable information from these rich data 
sources. 
 
Another area of interest remains the role of glucose variability in 
oxidative stress, and the putative relationship with the development of 
diabetes related complications. This needs to include a better 
understanding of the role of oxidative stress and advanced glycation end 
products (AGE) in the pathophysiology of complications. The focus will 
move away from postprandial glucose to all aspects of glucose variability.  
 
1.5AG has been propagated as clinically meaningful information for 
patients. New assay systems will be developed for home-use. This will 
hopefully support patients to reach and keep good and more stable 
glycemic control. This needs to be established in well-controlled studies.  
 
 
 
 
 
 
 
 
 
General Discussion  
 
  203 
Conclusions 
 
The overall conclusions of this Ph.D. thesis are:  
 
The ADAG study showed a simple linear relationship between mean 
glucose and HbA1c levels in a clinically relevant range of glycemia for 
patients with T1DM and T2DM. Factors influencing this relationship are; 
race/ethnicity, smoking, high glucose variability, altered erythropoiesis, 
altered erythrocyte lifespan, pregnancy, renal failure, bleeding, blood 
transfusion and hemoglobinopathies. 
 
HbA1c can be translated into an eAG with a standard deviation of 0.87 
mmol/l. The worldwide use of eAG in clinical practice has failed.  
 
The worldwide standardization on how to report HbA1c test results has not 
been successful. The comparability of assay’s worldwide has improved but 
the reporting and interpretation of  
HbA1c in clinical data and research results in the diabetes field worldwide 
has become more complicated. 
 
We found that all GV measures modestly, but significantly, influenced the 
MBG-HbA1c relationship. 
 
Higher GV was associated with higher HGI. Measures of GV (SD, MAGE 
and CONGA4) and fructosamine are strongly correlated with HGI and 
high outlier status.  
 
The GV measure SD and smoking status explained the largest fraction of 
outlier status for the High outliers. These variables together explained only 
around 13 % of the variance in the MPG-HbA1c relationship. 
 
Measuring 1,5AG in addition to HbA1c may identify GV and postprandial 
hyperglycemia, especially in moderately controlled patients with diabetes. 
 
In general, calculations based on CGM were not more informative than 
those based on frequent 7-point SMBG. 
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Indices of variability did not correlate strongly with indices of fasting, 
postprandial or total hyperglycemia. 
 
The mean of all pre-prandial glucose levels had a larger impact on HbA1c 
levels than postprandial glucose levels in patients with T1DM and T2DM. 
 
Non-diabetic individuals under real-life conditions spent a considerable 
amount of time with blood glucose levels classified as ‘pre-diabetic’ or 
even diabetic. 
 
Mean glycemia and HbA1c show stronger and more consistent associations 
with CVD risk factors than fasting glucose or postprandial glucose levels 
or measures of GV in patients with diabetes.  
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De ADAG studie  
HbA1c is het percentage versuikerde rode bloedcellen en is een 
afspiegeling van de gemiddelde bloedsuiker van de afgelopen 2 a 3 
maanden. Tot voor kort was de HbA1c bepaling wereldwijd niet 
gestandaardiseerd. Door de ontwikkeling van een nieuwe IFCC-HbA1c 
referentie methode, die veel nauwkeuriger en specifieker het HbA1c meet 
en die nu het anker voor de HbA1c test wereldwijd is, werd de invoering 
van deze test met de nieuwe referentiewaarden heel belangrijk. Een 
internationale studie, de ADAG (de A1c Derived Average Glucose ) studie 
werd uitgevoerd, die de basis van dit doctoraatsproject is en wordt 
beschreven in hoofdstuk 2. De HbA1c studie ofwel ADAG studie is een 
internationale studie uitgevoerd in 10 verschillende centra over de wereld 
(2006-2008) waarin de relatie tussen de gemiddelde bloedsuikers over de 
afgelopen 3 maanden en het HbA1c aan het eind van die 3 maanden, is 
onderzocht in een diverse populatie. Dit werd gedaan om te kijken of 
HbA1c ook als geschatte gemiddelde bloed glucose gerapporteerd kon 
worden in dezelfde eenheden als de zelfgemeten glucose waarden door de 
patienten met een vingerprik. Verder hebben we onderzocht of factoren 
zoals leeftijd, geslacht, etniciteit en roken deze relatie beïnvloeden. In 
totaal hebben 507 deelnemers de onderzoeksperiode van 3 maanden 
waarin frequent glucose metingen werden gedaan, volbracht. 
 
De ADAG studie toonde een sterk lineair verband tussen HbA1c en 
gemiddelde bloed glucose bij patiënten met zowel type 1 als type 2 
diabetes mellitus (DM) (R2 = 0.84). Deze relatie werd al eerder beschreven 
in de Diabetes Control and Complications Trial (DCCT studie) (R = 0.82), 
en door Nathan (R = 0.90) maar alleen bij patiënten met T1DM diabetes. 
In de DCCT studie werden wel 1441 patiënten geïncludeerd maar deze 
patiënten maakten maar 1 keer per 3 maanden een 7-punt dag curve. 
Nathan daarintegen includeerde maar 22 patiënten met T1DM en 3 zonder 
diabetes waar echter wel een continue glucose registratie werd gedaan 
gedurende 3 maanden.  
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De ADAG studie was speciaal opgezet om de relatie tussen HbA1c en 
gemiddelde bloedglucose te onderzoeken, waarbij frequent bloed glucose 
waarden werden gemeten zowel door middel van het maken van een 
glucose dag curve m.b.v. een vingerprik als met behulp van continue 
glucose monitoring middels een sensor. Dit leverde gemiddeld 2700 
glucose waarden op ongeveer 52 dagen in een periode van 3 maanden op. 
Daarnaast werden 507 patiënten (268 T1DM, 159 T2DM) onderzocht 
maar ook gezonde vrijwilligers (n = 80) en bovendien verschillende 
etnische groepen.  
 
Het HbA1c werd in een centraal laboratorium gemeten met 4 verschillende 
methoden die goedgekeurd zijn door de DCCT. Dit suggereert een 
preciezere meting en verklaart waarom wij minder spreiding rondom de 
regressielijn en lagere waarden van de geschatte gemiddelde bloedglucose 
vonden dan in de DCCT studie.  
 
Leeftijd, geslacht en etnische verschillen  
De lineaire regressie vergelijking verschilde niet significant tussen de 
verschillende subgroepen gebaseerd op leeftijd, geslacht, type diabetes, 
etniciteit of roken.  
 
Leeftijd en geslacht: Een meta-analyse van data van de Framingham 
Offspring Study en the National Health and Nutrition Examination Survey 
toonde dat HbA1c waarden van personen zonder diabetes geleidelijk stegen 
met ongeveer 7 mmol/mol HbA1c (0.6%) tussen de leeftijd van 40 en 70 
jaar, wat de verandering in gemiddelde glucose weerspiegelt met de 
leeftijd. Andere studies bevestigden de positieve associatie tussen leeftijd 
en HbA1c in volwassenen. Faerch en Gulliford vonden beide iets hogere 
waarden van HbA1c bij mannen vergeleken met vrouwen, maar andere 
studies vonden geen geslachts gerelateerde verschillen in HbA1c. 
 
Etniciteit: De resultaten van de ADAG studie (P = 0.07) suggereerden dat 
de regressie lijn verschillend was voor de Afrikaans-Amerikanen zodat 
voor een gegeven waarde van HbA1c, de Afrikaans-Amerikanen een iets 
lagere gemiddelde bloedglucose zouden hebben. De groep Afrikaanse en 
Indiase mensen waren helaas onder vertegenwoordigd in de ADAG studie. 
Dit laatste kwam vooral omdat het Zuidoost Aziatische studiecentrum zich 
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terug getrokken heeft uit de studie vanwege technische moeilijkheden. De 
invloed van etniciteit op de gemiddelde bloedglucose-HbA1c relatie moet 
daarom verder onderzocht worden.  
 
Recent werden etnische verschillen in de relatie tussen HbA1c en bloed 
glucose beschreven. Ziemer vond hogere HbA1c waarden bij zwarte dan bij 
blanke mensen in het volledige spectrum van glycemie na correctie voor 
plasma glucose en andere factoren die correleren met HbA1c. Ook 
personen van Zuid-Aziatische origine hebben een hoger HbA1c dan blanke 
mensen onafhankelijk van nuchtere waarden en waarden na een glucose 
belasting test (OGTT). De resultaten van de Diabetes Prevention Program 
(3819 individuen ≥ 25 jaar met verminderde glucose tolerantie) tonen aan 
dat etniciteit een onafhankelijke factor is in het vaststellen van HbA1c: ‘na 
correctie voor glucose concentraties en een aantal andere factoren, waren 
gemiddelde HbA1c waarden 5.78% voor blanke, 5.93% voor Spanjaarden, 
6.00% voor Aziaten, 6.12% voor Amerikaans-Indiaanse, en 6.18% voor 
Afrikaans-Amerikanen (p < 0.001).  
 
Alhoewel de potentiële oorzaken voor etnische verschillen onbekend 
blijven, zijn mogelijke bijdragende factoren zoals verschil in overleving 
van rode bloedcellen, extra- en intra cellulaire glucose balans en niet 
glycemische genetische varianten van hemoglobine glycering nagegaan. 
Ook de manier waarop de gemiddelde bloedglucose was verkregen, bijv. 
glucose waarden voor versus na het eten zou de schatting van het 
gemiddelde bloedglucose hebben kunnen beïnvloedt en daarmee de 
vaststelling van de relatie met HbA1c. 
 
Totdat de oorzaken voor deze verschillen duidelijker zijn, is het 
vertrouwen op alleen HbA1c of dit zelfs gebruiken als voorkeurs criterium 
voor het stellen van de diagnose diabetes een potentieel gevaar voor 
systematische fouten en misclassificatie. HbA1c moet zorgvuldig gebruikt 
worden in combinatie met traditionele glucose criteria voor het screenen 
op en diagnosticeren van diabetes. 
 
Er is steeds meer literatuur die maten van glycemische controle in 
verschillende etnische groepen en de verschillen tussen deze groepen 
beschrijven. Een studie vond etnische verschillen in HbA1c en 1,5 
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AnhydroGlucitol (1,5AG) die niet konden worden toegeschreven aan 
gemiddelde bloedglucose. Deze data werpen vragen op over concordantie 
van zelf gemeten bloed glucose waarden, HbA1c en 1,5AG en stippen de 
behoefte aan om factoren die elk van deze parameters zouden kunnen 
beïnvloeden beter te begrijpen, voordat een betrouwbare vergelijking van 
deze maten tussen verschillende etnische groepen gemaakt kan worden. 
Natuurlijk kunnen deze resultaten niet vergeleken worden met de ADAG 
studie omdat deze studies primair niet ontworpen waren om de 
bloedglucose-HbA1c relatie en om betrouwbaar een gemiddelde 
bloedglucose vast te stellen.  
 
Tegenwoordig is HbA1c de marker van glycemische controle voor 
patiënten met diabetes, voornamelijk vanwege de sterk voorspellende 
relatie met lange termijn complicaties. Echter de ADAG studie en andere 
recente bevindingen suggereren het nut van het gebruik van meerdere 
maten van glycemie bijvoorbeeld 1,5AG en glucose variabiliteit (GV) om 
ons begrip van “overall” goede glycemische instelling te verbeteren in 
verschillende populaties.  
 
Roken en alcohol consumptie: In tenminste 3 studies is een negatieve 
associatie gevonden tussen alcohol consumptie en HbA1c. In tegenstelling 
tot Meyer, die deze bevindingen t.a.v. alcohol gebruik en HbA1c bij 
mannen zonder diabetes, in hun studie niet konden bevestigen. 
Verschillende studies hebben beschreven dat roken geassocieerd is met 
hogere HbA1c waarden, maar Koga vond geen associatie tussen roken en 
HbA1c. Glycotoxinen gevonden in sigaretten rook zouden een hogere mate 
van glycering van HbA kunnen induceren, of de relatieve weefsel hypoxie 
zou de verhoogde HbA1c waarden bij rokers kunnen verklaren.  
 
Beperkingen 
De ADAG studie heeft aan aantal tekortkomingen. In tegenstelling tot 
onze intentie en verwachting, waren sommige etnische groepen 
ondervertegenwoordigd, voornamelijk doordat een van de studie centra 
met een grote Aziatische populatie zich teruggetrokken heeft en werden er 
ook maar een beperkt aantal Afrikanen geïncludeerd.  
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Daarnaast was de schatting van de gemiddelde bloedsuiker gebaseerd op 2 
methoden: de continue glucose monitoring ofwel sensor en de zelf 
gemeten glucose waarden. Om deze metingen te combineren en een enkele 
geschatte glucose waarde te berekenen, moesten de metingen van de 
continue meting en de zelf gemeten glucose waarden gewogen worden 
naar het verschillend aantal metingen op een dag, echter de separate 
analyse naar de relatie tussen HbA1c en de zelfgemeten waarden danwel de 
continue gemeten waarden was niet significant verschillend.  
  
Verder zijn de resultaten alleen toepasbaar op deze populatie aangezien 
alleen patiënten met diabetes met stabiele regulatie zonder stoornissen of 
aandoeningen van de erytrocyten (rode bloedcellen) of rode bloedcel 
turnover werden onderzocht. 
 
Personen met aandoeningen die de levensduur van de erytrocyten konden 
aantasten en daardoor invloed zouden kunnen hebben op het HbA1c, 
werden geexcludeerd. Dit betrof zwangere vrouwen, personen met 
hematologische aandoeningen (bijv. bloedarmoede, hemoglobinopathieen, 
bloedverlies) en personen met ernstige nier- of leveraandoeningen. Er is 
over gesproken dat aanvullend onderzoek in deze groepen gedaan zou 
moeten worden, maar dit zou een meer complexe logistiek en studie 
protocol vergen. Glucose metingen zouden gepland moeten worden in 
verschillende stadia van de zwangerschap en bij specifieke hoogte van 
bloedarmoede en nierfunctie. Zo een onderzoek is uitdagend en niet 
haalbaar. In plaats daarvan zou nadruk moeten liggen op het feit dat het 
glyceringsproces (versuikeringsproces) afhankelijk is van de levensduur 
van de erytrocyten, onafhankelijk welke assay’s of meeteenheden worden 
gebruikt. 
 
Conclusies  
Wij concludeerden dat HbA1c waarden uitgedrukt kunnen worden in 
geschatte gemiddeld bloedglucose voor vrijwel alle patiënten met T1DM 
en T2DM en voor patiënten zonder diabetes. De gemiddelde bloedglucose-
HbA1c relatie voor het niet blanke ras en voor jonge patiënten zou verder 
onderzocht moeten worden.  
 
 
CHAPTER 10  
 222 
Implementatie van IFCC HbA1c test resultaten 
De belangrijke diabetes organisaties en de American Association for 
Clinical Chemistry (AACC) hebben consensus bereikt dat HbA1c 
gerapporteerd zou moeten worden in NGPSP HbA1c in % en in IFCC 
HbA1c in mmol HbA/mol Hb samen met geschatte gemiddelde 
bloedglucose in ofwel mmol/L danwel mg/dL. 
 
Tabel 1 geeft de door de National Glycohemoglobin Standardization 
Program (NGSP) gestandaardiseerde HbA1c waarden en de geschatte 
gemiddelde glucose (eAG) in mmol/L en mg/dL voor de verschillende 
gegeven IFCC-HbA1c waarden. 
 
Tabel 1: NGSP gestandaardiseerde HbA1c waarden en de geschatte 
gemiddelde bloedglucose (eAG) in mmol/L en mg/dL voor verschillende  
IFCC-HbA1c waarden.  
IFCC-HbA1c  NGSP-HbA1c  eAG  eAG  
(mmol/mol)   (%)   (mg/dL) (mmol/l) 
31    5    97  5.4 
42    6    126  7.0  
53    7    154  8.6  
64    8   183  10.2 
75   9    212  11.8 
86    10   240  13.4 
97   11   269  14.9 
108   12   298  16.5 
 
 
De uiteindelijke beslissing wat te rapporteren wordt landelijk gemaakt. 
Sommige landen hebben besloten om niet 3 verschillende waarden te 
rapporteren. Andere landen waren niet overtuigd van het voordeel om de 
geschatte gemiddelde glucose waarde te rapporteren met name niet 
vanwege de spreiding in gemiddelde bloedglucose voor een gegeven 
HbA1c. Inderdaad toont de regressie lijn van de ADAG studie een 
spreiding van gemiddelde bloedglucose voor individuen met dezelfde 
HbA1c waarde (Fig. 1).  
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Een HbA1c waarde van 6.0% correspondeert met een geschatte gemiddelde 
bloedglucose van 5.5 – 8.5 mmol/l (100–152 mg/dl), en een HbA1c waarde 
van 7.0% correspondeert met een geschatte gemiddelde bloedglucose van 
6.8 – 10.3 mmol/l (123–185 mg/dl) (95% betrouwbaarheidsinterval) [1]. 
 
 
Figuur 1: Lineaire relatie tussen geschatte gemiddelde glucose (eAG over 
3 maanden) en HbA1c aan het eind van de 3 maanden. 
 
In de Verenigde Staten adviseerde de Amerikaanse Diabetes Associatie en 
de AACC om NGSP HbA1c in % samen met de geschatte gemiddelde 
bloedglucose te rapporteren. De meeste landen rapporteren IFCC HbA1c  
in mmol HbA/mol Hb en de NGSP HbA1c in % en sommige landen zijn 
helemaal overgestapt op de IFCC HbA1c. Ondanks de verschillende 
getallen, zullen de gerapporteerde resultaten altijd terug te traceren zijn tot 
de verankerde IFCC assay via omrekenformules. (Tabel 2)  
De ADA, de International Diabetes Federation (IDF), de European 
Association for the Study of Diabetes (EASD) en de International Society 
Pediatric and Adolescent Diabetes (ISPAD) en ook andere associaties 
verstrekken richtlijnen voor patiënten zorg die direct verwijzen naar de 
DCCT uitgelijnde NGSP getallen. Deze richtlijnen zullen moeten worden 
aangepast zodat ze zowel NGSP als IFCC referentie waarden bevatten. 
 
Zoals eerder genoemd was het doel om HbA1c als geschatte gemiddelde 
bloedglucose, in de zelfde eenheden als de zelfgemeten bloedglucose 
waarden, te rapporteren om de interpretatie in de dagelijkse praktijk te 
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vergemakkelijken, maar dit is mislukt. Helaas is de wereldwijde 
standaardisatie en implementatie hoe de HbA1c test resultaten te 
rapporteren, niet succesvol geweest. Het rapporteren en implementeren 
van HbA1c van klinische data en research resultaten in het diabetes veld 
wereldwijd is meer gecompliceerd geworden maar de vergelijkbaarheid 
van de assay’s wereldwijd is verbeterd en ze zijn allemaal terug te traceren 
naar de verankerde IFCC assay.  
 
IFCC Netwerk als een NGSP anker   
Het IFCC netwerk is nu een secundair anker voor de NGSP. De stabiliteit 
van de relatie over langere tijd tussen de IFCC en NGSP zal continue 
gemonitord worden. Het NGSP certificatie proces zal niet veranderen en 
het IFCC Laboratorium Netwerk is vastgesteld. De lijst met huidige 
goedgekeurde en kandidaat IFCC Netwerk Laboratoria kan gevonden 
worden op: http://www.ifcchba1c.net/. Tabel 2 toont de 
omrekeningsfactoren voor IFCC vergeleken met elk van de aangewezen 
vergelijkingsmethode inclusief de NGSP.  
 
Tabel 2: Omrekeningsfactoren voor IFCC vergeleken met elk van de 
aangewezen vergelijkingsmethode inclusief de NGSP.    
Van IFCC naar vergelijkingsmethode Van vergelijkmethode naar IFCC  
NGSP (USA)  
NGSP = (0.09148*IFCC) + 2.152   IFCC = (10.93*NGSP) - 23.50 
   
JDS/JSCC (Japan) 
JDS = (0.09274*IFCC) +1 .724  IFCC = (10.78*JDS) - 18.59 
 
Mono-S (Zweden) 
Mono-S = (0.09890*IFCC) + 0.884 IFCC = (10.11*Mono-S) - 8.94  
 
 
Glucose Variabiliteit en HbA1c (Hoofdstuk 3) 
 
Glucose Variabiliteit 
De potentiële bijdrage van glucose schommelingen (glucose variabiliteit 
(GV)) of stijgingen in de bloedsuiker na het eten (postprandiale 
hyperglycemie (PPG)) aan het versuikeringsproces van de rode bloedcel 
(Hemoglobine glycerings proces) is nog steeds onduidelijk. Nuchtere 
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waarden en postprandiale excursies dragen bij aan de gemiddelde 
bloedglucose ofwel aan de totale glucose blootstelling en dus aan HbA1c. 
De specifieke vraag is of PPG en GV, separaat van de bijdrage aan het 
gemiddelde bloedglucose ook het glyceringsproces beïnvloeden en 
daarmee de relatie tussen gemiddelde bloedglucose en HbA1c. 
 
Vaststellen van Glucose Variabiliteit 
Er zijn verschillende methoden om GV te kwantificeren. In de ADAG 
studie hebben we verschillende variabiliteit maten berekend, zoals bijv. de 
amplitude van glycemische uitslagen, de Standaard Deviatie (SD) van alle 
bloed glucose waarden, en de omvang van de Amplitude van de 
Glycemische Excursies (MAGE) zoals beschreven door Service. 
Daarnaast verkregen we de Continue Overlappende Netto Glycemische 
Actie (CONGA) om GV te berekenen uit de glucose getallen van de 
sensor. De CONGA is gedefinieerd als de standaard deviatie van de 
verschillen, en meet de totale “binnen de dag variatie” van glucose 
metingen.  
 
Invloed van glucose variabiliteit op de gemiddelde bloedglucose-HbA1c 
relatie 
In hoofdstuk 3 hebben we de invloed van GV op de relatie tussen 
gemiddelde bloedglucose en HbA1c onderzocht. We vonden dat alle GV 
maten significant maar bescheiden deze relatie beïnvloedden. De 
variabiliteit maat SD toonde de sterkste invloed. Een hoge mate van GV 
(SD) was geassocieerd met een hoger HbA1c voor de gegeven gemiddelde 
bloedglucose, dit effect was meer uitgesproken bij hogere HbA1c waarden. 
Hoe dan ook de grootte van dit effect van GV was klein en alleen aan te 
tonen bij T1DM. Waarschijnlijk was de groep met T2DM patiënten te 
klein en de glucose variabiliteit te laag in deze groep om deze interactie 
aan te tonen.  
 
Onze resultaten liggen in een lijn met de resultaten van de DirectNet studie 
bij kinderen. Alhoewel de auteurs ook concludeerden dat HbA1c de 
gemiddelde bloedglucose over een bepaalde tijd reflecteert, vonden zij een 
substantieel grotere variatie tussen de individuen in de gemiddelde 
bloedglucose-HbA1c relatie dan in onze en Nathan’s studie bij 
volwassenen met T1DM. De DirecNet studie gebruikte een niet-
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gecentraliseerde HbA1c methode die relatief slecht correleerde met een 
high-performance liquid chromatografie (HPLC) methode, bovendien 
verrichtte zij in maar 67% van de studie periode een continue registratie 
(sensor), vergeleken met 97% in de 12-weken studie van Nathan. 
Daarnaast hadden deze kinderen een grote glucose variabiliteit waardoor 
de gemiddelde bloedglucose minder accuraat bepaald werd. Bij hoge GV 
kan het moeilijk zijn om de daadwerkelijk gemiddelde bloedglucose te 
bepalen, wat op zijn beurt de gemeten HbA1c waarde weer bepaalt,  omdat 
de timing van deze meting in relatie tot het HbA1c kritisch zal zijn.  
 
Korte perioden van hyperglycemie zouden gezien de langzame kinetiek 
van glycering, geen grote impact moeten hebben op HbA1c. Eerdere 
studies hebben onderzocht of de gemiddelde bloedglucose-HbA1c relatie 
beïnvloedt wordt door GV, maar vonden geen of weinig invloed. Echter 
deze studies maakten gebruik van weinig zelfgemeten bloedglucose 
waarden om gemiddelde bloedglucose en GV te bepalen in relatief kleine 
patiënten aantallen. Deze beperkingen tasten de precisie en accuraatheid 
van de schatting van gemiddelde bloedglucose en glycemische excursies 
aan. Continue glucose registratie geeft de mogelijkheid om glycemische 
excursies meer precies te registreren, inclusief de duur en frequentie van 
de excursies, en om verschillende maten van GV te berekenen.  
 
In het algemeen is GV hoger bij patiënten die slecht gereguleerd zijn en bij 
patiënten met T1DM dan bij patiënten met T2DM, wat waarschijnlijk 
toegeschreven kan worden aan insuline therapie en een hogere insuline 
gevoeligheid. Een hoge GV zou de glycering kunnen beïnvloeden doordat 
de rode bloedcel periodiek aan hoge bloedglucose wordt blootgesteld wat 
oxidatieve stress stimuleert en irreversibele glycering versnelt. Recent 
werd gespeculeerd dat zuurstof vrije radicalen de vorming van vroege 
eiwit glycering stimuleert. Zoals beweerd door Brownlee, zou 
hyperglycemie het onderliggende mechanisme kunnen zijn van 
toegenomen oxidatieve stress. 
 
Hoge GV en vooral post prandiale glucose excursies werden recent ook 
geassocieerd met oxidatieve stress bij T2DM. De activatie van oxidatieve 
stress, geschat door middel van de hoeveelheid uitgescheiden Isoprostane 
in de urine, correleerde hoog met de variabiliteit maat MAGE berekend uit 
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de sensor. Echter, Wentholt kon deze resultaten niet repliceren bij 
patiënten met T1DM. 
 
Recente gegevens suggereren dat ook hypoglycemie een belangrijke rol 
zou kunnen spelen bij vasculaire complicaties van diabetes. Hypoglycemie 
veroorzaakt ook oxidatieve stress, inflammatie, en endotheel dysfunctie. 
Oxidatieve stress wordt beschouwd als de belangrijke speler in de 
pathogenese van diabetische complicaties. Oxidatieve stress wordt 
geproduceerd tijdens hyperglycemie op mitochondriaal niveau, identiek 
als bij hypoglycemie. Daarom zou oxidatieve stress beschouwd kunnen 
worden als de onderliggende factor die hyperglycemie, hypoglycemie, en 
de vasculaire complicaties van diabetes aan elkaar linkt. Consistent met 
deze hypothese is het bewijs dat hyperglycemie en hypoglycemie beide 
endotheel dysfunctie en inflammatie veroorzaken door het genereren van 
oxidatieve stress. Endotheel dysfunctie en inflammatie zijn bekende 
pathogenetische factoren voor vasculaire ziekten, vooral bij patiënten met 
diabetes.  
 
Echter, Ceriello toonde aan dat de manier waarop herstel van 
hypoglycemie plaats vindt ook een effect zou kunnen hebben op 
cardiovasculair risico.  De schadelijke effecten van de voorafgaande 
hypoglycemie worden grotendeels opgevangen wanneer herstel van 
hypoglycemie resulteert in normoglycemie, terwijl endotheel functie, 
oxidatieve stress, en inflammatie verder verslechteren wanneer het herstel 
vanuit een hypoglycemie resulteert in hyperglycemie. 
 
De kracht van de ADAG studie is de grote precisie waarmee gemiddelde 
bloedglucose is gemeten in een grote groep van individuen met en zonder 
diabetes waarbij herhaaldelijke metingen werden verricht. De intensieve 
glucose monitoring met behulp van verschillende methoden maakte het 
ook mogelijk om op verschillende manieren postprandiale glucose te 
definiëren en leverde voldoende metingen op om betrouwbaar 
verschillende maten van GV te berekenen.  
 
Beperkingen 
MiniMed continue glucose monitor heeft de beperking dat glucose 
waarden onder 2.2 mmol/l of boven 22.2 mmol/l niet gemeten kunnen 
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worden. Omdat de participanten geselecteerd werden op het hebben van 
een stabiel HbA1c bij aanvang van de studie (gedefinieerd als een < 1% 
HbA1c verandering gedurende de 6 maanden voorafgaand aan de studie), 
en ook relatief stabiel bleven tijdens de studie zou de mate van glucose 
variabiliteit beperkt gebleven kunnen zijn in deze populatie vergeleken 
met de algemene populatie. Ondanks een stabiel HbA1c  was de mate van 
GV nog steeds aanzienlijk bij de deelnemers van de ADAG studie.  
 
Conclusies 
Bij hogere mate van GV verandert de relatie tussen HbA1c en gemiddelde 
bloedglucose bij patiënten met T1DM, wat resulteert in een hoger HbA1c 
voor de gegeven gemiddelde bloedglucose. Echter, de impact (rond een 
HbA1c streefwaarde van 7 %) valt erg mee. De potentiële invloed van	  GV 
op het glycerings proces, en HbA1c in het bijzonder, is bescheiden. Het 
mechanisme moet verder opgehelderd worden.   
 
 
Zijn bloedglucose concentraties de enige determinant 
van HbA1c ? (Hoofdstuk 4)  
 
Gemiddelde bloedglucose en HbA1c zijn nauw aan elkaar gerelateerd, 
maar inter-individuele variabiliteit, gekwantificeerd met Hemoglobine 
Glycering Index (HGI), bestaat en zou toe te schrijven kunnen zijn aan 
niet-glycemische factoren die glycering beïnvloeden. We hebben 
onderzocht of niet-glycemische factoren geassocieerd zijn met HGI.  
 
Vierenzeventig (14.6%) van de 507 personen hadden HbA1c waarden 
buiten de 80% voorspelling band van de HbA1c-gemiddelde bloedglucose 
relatie, 44 (8.7%) personen waren uitschieters naar boven met hoger dan 
voorspelde HbA1c waarden, en 30 (5.9%) personen waren uitschieters naar 
beneden met lager dan voorspelde HbA1c waarden.  
 
Maten van GV waren de belangrijkste determinanten van een hoge HGI. 
De GV maten SD, MAGE, CONGA4, AUC24 en fructosamine verklaarden 
de grootste fractie van de variantie van de uitschieter status voor de 
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uitschieters naar boven, maar niet voor de uitschieters naar beneden. Het 
kleine aantal in deze groep zou dit kunnen verklaren.  
 
Roken was de volgende variabele die de uitschieter status verklaarde. 
Zoals eerder beschreven is roken geassocieerd met hogere HbA1c waarden, 
maar andere vonden geen associatie tussen roken en HbA1c waarden. 
Roken zou de rode bloed cel turnover kunnen veranderen.  
 
Als laatste waren diabetes type, Apo-B spiegels en insuline therapie en 
cholesterolverlagende medicijnen geassocieerd met uitschieters naar 
boven. Echter deze factoren gecombineerd verklaarde maar 25% van de 
variantie in de HbA1c–gemiddelde bloedglucose relatie voor de uitschieters 
naar boven.  
De “niet-glucose variabele” diabetes type en insuline waren niet 
onafhankelijk geassocieerd met HGI. Roken, LDL, Apo-B en Apo-B/A1, 
waren onafhankelijk gerelateerd met hoge HGI.  
 
Fructosamine concentraties gemeten aan het begin van de studie (n = 507) 
waren significant gecorreleerd met HGI en uitschieter status. Dit 
suggereert dat patiënten met een hoge HGI en dus een hoger dan voorspeld 
HbA1c ook hogere fructosamine spiegels hebben. Deze bevinding 
ondersteunt eerdere suggesties dat de periode van glycemische 
blootstelling enige weken voor een HbA1c meting –zoals weerspiegelt door  
fructosamine- een disproportionele rol zou kunnen spelen in de HbA1c 
waarde. Als alternatief zou GV de mate van glycering in algemeen kunnen 
beïnvloeden, gemeten d.m.v. HbA1c of fructosamine. 
 
Zoals verwacht, had de groep patiënten met T1DM een hoger gemiddelde 
bloedglucose, HbA1c en GV waarden dan de groep met T2DM dan de 
groep zonder DM. Dit verklaart de grotere variantie in de relatie met hoger 
HGI. Kilpatrick vond dat HbA1c waarden tussen personen zonder diabetes 
aanzienlijk varieerden, terwijl waarden binnen de zelfde personen erg 
consistent zijn.  
 
Een potentiele niet bewezen verklaring voor deze biologische variabiliteit 
is het concept van snelle en langzame glyceerders, zoals beschreven door 
Hempe en door eerdere kleinere studies bij personen zonder en met DM.  
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Voor de meeste van deze studies zouden de discrepanties tussen HbA1c en 
gemiddelde bloedglucose toegeschreven kunnen worden aan een 
inaccurate schatting van de gemiddelde bloedglucose vanwege een 
insufficiënt aantal glucose metingen. 
De ADAG studie maakte gebruik van frequente metingen van 
bloedglucose gedurende de tijd, met frequente metingen op 52 van de 84 
dagen voorafgaand aan de HbA1c meting. HbA1c werd bepaald d.m.v. 4 
zeer nauwkeurige assay’s in een centraal laboratorium. Daarom zijn 
discrepanties in de gemiddelde bloedglucose-HbA1c relatie tussen 
individuen minder waarschijnlijk tgv fouten in de metingen van ofwel 
gemiddelde bloedglucose danwel HbA1c.  
 
Beperkingen 
Alhoewel de ADAG studie populatie was geselecteerd op factoren die niet 
met de meting van gemiddelde bloedglucose danwel met HbA1c 
interfereren of met de relatie tussen deze twee, werden factoren zoals 
etniciteit, leeftijd en geslacht, natuurlijk niet uitgesloten.  
 
Andere tekortkomingen van deze studie zijn de beperkingen in het 
verkrijgen van betrouwbare metingen buiten de grenzen van 2.2 en 22.2 
mmol/L bij het gebruik van de sensor en de variatie in de gemeten 
bloedglucose waarden met de Lifescan meter. Alhoewel het een van de 
grootste studies was die de relatie tussen HbA1c en gemiddelde 
bloedglucose onderzocht, hebben de relatieve kleine subpopulaties onze 
bevindingen beïnvloedt. Als laatste is de HGI niet onafhankelijk van het 
HbA1c, dus de gedocumenteerde associaties met HGI zouden kunnen 
worden beschaamd door HbA1c waarde op zichzelf. 
 
Conclusies 
Wij concludeerden dat hogere GV was geassocieerd met hogere HGI. 
Maten van GV (SD, MAGE en CONGA4) en AUC24 en fructosamine zijn 
sterk gecorreleerd met HGI en uitschieters naar boven. De GV maat SD en 
roken verklaarden de grootste fractie van de uitschieter status voor de 
uitschieters naar boven. Deze variabelen samen verklaren maar 13 % van 
de variantie in de HbA1c–gemiddelde bloedglucose relatie. Als laatste 
waren, diabetes type, Apo-B spiegels en insuline therapie en 
cholesterolverlagende behandeling geassocieerd met uitschieters naar 
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boven. Echter al deze factoren samen verklaarden maar 25% van de 
variantie in de gemiddelde bloedglucose-HbA1c relatie voor de uitschieters 
naar boven.   
 
 
1,5 AnhydroGlucitol (Hoofdstuk 5) 
 
Markers voor langere termijn glycemische controle, inclusief fructosamine 
en HbA1c, weerspiegelen gemiddelde glucose concentraties over 2 en 8 a 
10 weken respectievelijk, maar geven geen informatie over GV. Patiënten 
die goed gereguleerd zijn volgens volgens het HbA1c zouden nog steeds 
postprandiale hyperglycemie kunnen hebben. 
 
Plasma 1,5AG wordt uitgescheiden via de nier door competitieve remming 
van reabsorptie bij glucose waarden boven de nierdrempelwaarde (>10 
mmol/l) voor glucose. Eerdere studies hebben verlaagde 1,5AG spiegels 
laten zien in patiënten met hoge bloedglucose waarden (hyperglycemie). 
Daarom is 1,5AG voorgesteld als een marker voor glycemische excursies. 
We hebben onderzocht of 1,5AG gebruikt zou kunnen worden als een 
indicator van GV inclusief overall (postprandiale) hyperglycemische 
episodes in vooraf gedefinieerde HbA1c ranges. 
 
Conclusies 
Wij concludeerden dat de testprestaties van 1,5AG om hyperglycemische 
episodes aan te tonen in matig gereguleerde patiënten (HbA1c ≤ 64 
mmol/mol (8%)) matig goed was (AUC of ROC curve 0.73, p < 0.001). 
Maten van GV en hyperglycemische episodes correleerden significant en 
omgekeerd met 1,5AG bij HbA1c waarden ≤ 64 mmol/mol (8%) en tussen 
42 en 64 mmol/mol (6 - 8%). Het meten van 1,5AG naast HbA1c zou GV 
en postprandiale hyperglycemie aan kunnen tonen, vooral in patiënten met 
DM die matig gereguleerd zijn.  
 
Beperkingen 
De grootste beperking van deze studie was het feit dat alle variabelen 
werden gemeten op een tijdstip (een 48 uur periode) wat niet volledig de 
tijdsperiode dekt zoals gereflecteerd wordt door de verschillende gemeten 
parameters (HbA1c en 1,5AG). Omdat alleen participanten met relatief 
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stabiele glycemische controle in de studie werden geïncludeerd, 
veronderstelden we dat de GV maten en gemiddelde bloedglucose, 
bepaald op dit tijdstip, representatief zijn voor de periode die voorafgaat 
aan de meting. Ook konden we 1,5AG waarden niet corrigeren voor 
nierfunctie, maar participanten met ernstige nierinsufficiëntie werden 
geexcludeerd.  
 
1,5AG routinematig in de dagelijkse praktijk ? 
1,5AG zou gebruikt kunnen worden als een aanvullende tool om 
glycemische instelling te monitoren gedurende de afgelopen 2 a 3 weken 
voorafgaande aan de HbA1c meting. Dit zou patiënten kunnen motiveren 
om glycemische excursies te monitoren en betere glycemische instelling te 
bereiken. De keerzijde is de noodzaak van een extra bloedtest, aangezien 
op dit moment geen thuistes t voor 1,5AG beschikbaar is. 
 
De referentie waarde van 1,5AG is vastgesteld bij personen zonder 
diabetes en is vrij breed, wat een grote biologische variatie aangeeft in de 
populatie. Dit en ook het feit dat de 1,5AG concentratie onder invloed is 
van de hoogte van de gemiddelde bloedglucose en HbA1c, maakt de test 
minder betrouwbaar en minder makkelijk om te interpreteren. Patiënten 
kunnen eenvoudig hun glycemische instelling controleren door op 
relevante tijdstippen zelf controle te verrichten d.m.v. glucose metingen op 
de vingerprik en elke 3 maanden een HbA1c te laten meten.   
 
Helaas is 1,5AG niet bruikbaar bij zwangere vrouwen, een patiënten groep 
waar strakke glycemische controle extra belangrijk is, omdat de 
glomerulaire filtratie kan veranderen tijdens de zwangerschap. Abnormale 
waarden zijn ook beschreven bij individuen met een abnormale 
glomerulaire filtratie snelheid. Lage 1,5AG waarden zijn ook gevonden bij 
patiënten met terminaal nierfalen, dialyse patiënten, gevorderde lever 
cirrose en langdurig vasten. Meer studies zijn nodig om de klinische 
bruikbaarheid van 1,5AG vast te stellen, en in het bijzonder bij specifieke 
patiënten populaties zoals bijvoorbeeld zwangeren.  
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Associaties tussen verschillende glucose indices en 
HbA1c (Hoofdstuk 6) 
 
Vaststellen van glucose blootstelling  
Er bestaan diverse methoden om postprandiale glycemie of GV te 
kwantificeren, maar alleen een paar zijn met elkaar en met HbA1c 
vergeleken. Wij onderzochten de relatie tussen de meest gebruikte indices 
van GV, gemiddelde glucose, postprandiale glycemie en HbA1c door 
gebruik te maken van gedetailleerde glucose metingen verkregen onder 
normale levensomstandigheden in het ADAG studie cohort. Zoals we 
verwacht hadden, toonde onze analyse dat veel van deze glycemische 
indices sterk met elkaar gecorreleerd waren binnen elke categorie. 
Aanvullend bestudeerde we welke bloedglucose waarde(n) van de dag de 
sterkste voorspelling verleenden voor de gemiddelde bloedglucose, zoals 
gemeten met HbA1c, waarbij we speciaal focusten op de bijdrage van pre- 
en  postprandiale glucose aan gemiddelde bloedglucose.  
 
Indices van postprandiale glycemie en glucose variabiliteit 
Vooral indices van GV (CONGA, SD van de sensor of van de zelfgemeten 
glucose dag curven en de MAGE) waren sterk met elkaar gecorreleerd wat 
weergeeft dat deze berekende maten van variabiliteit bijna identieke 
informatie geven. MAGE is eerder beschreven als de gouden standaard om 
GV vast te stellen.  
 
Onze bevindingen tonen dat MAGE en CONGA of de ‘eenvoudige’ 
standaard deviatie (SD) informatie vangen over variabiliteit in zeer 
vergelijkbare mate, wat aangeeft dat de keuze gemaakt kan worden op 
basis van het gemak van de berekening of uit praktische overwegingen. De 
variabiliteit maten correleerden niet goed met de postprandiale metingen 
of met indexen van nuchtere of gemiddelde glycemie.  
 
De met de sensor gemeten postprandiale 2-uurs Area Under the Curve 
(AUC) volgend op een maaltijd correleerde erg goed met de postprandiale 
metingen m.b.v. de zelfcontroles met de vingerprik. Dit betekent dat de 
glucose excursie in de uren na een maaltijd betrouwbaar gevangen wordt 
met een routine vingerprik meting 90 minuten na een maaltijd. Beide 
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postprandiale metingen (d.m.v. een vingerprik of door een sensor) 
correleren matig met “overall” hyperglycemie zoals gemeten met de 
sensor (AUC >11.1 mmol/l), gemiddelde bloedglucose en HbA1c. 
 
Een ‘postprandiale stijging’ is in eerdere studies gebruikt om GV en 
postprandiale glucose vast te stellen, maar de definitie en rekenmethode 
verschilden nogal. Wanneer we de postprandiale stijging definieerden als 
het verschil tussen de pre-prandiaal waarde tot de hoogste postprandiale 
waarde in een 2-uurs window, toonde de index lage correlaties met 
postprandiale bloedglucose waarden (ρ= 0.45-0.51) en met indices van 
gemiddelde glycemie of hyperglycemie (ρ= 0.26-0.27). Van grote 
postprandiale stijgingen zou verwacht worden dat dat hoge GV reflecteert, 
echter de correlatie met de GV maten zijn niet sterk (ρ= van 0.41 (SMBG 
SD) tot 0.54 (CONGA4)). Daarom, lijken postprandiale glucose stijgingen 
niet een bevredigende manier om GV mee vast te stellen.   
 
Zoals verwacht correleerde HbA1c goed met gemiddelde bloedglucose van 
de sensor, de zelfgemeten bloedglucose met de vingerprik en de twee 
gecombineerd. Bij het verkennen van de bijdrage van de glucosespiegels 
van zelfgemeten glucose waarden op verschillende tijdstippen van de dag 
aan het HbA1c, hadden de glucose waarden voor de maaltijd een groter 
effect op HbA1c dan postprandiale glucosespiegels, vermoedelijk omdat ze 
meer lijken op de 24-uur glucose spiegels (en dus de lange termijn 
blootstelling aan glucose). 
 
Dit resultaat was hetzelfde vóór en na inclusie van de nachtelijke 
bloedglucose index in het regressiemodel. Het leidde verrassenderwijs 
alleen tot een kleine toename van het aandeel in HbA1c variatie. 
 
Het frequent geciteerde artikel van Monnier concludeerde dat  
postprandiale glucose spiegels het meeste bijdragen aan HbA1c waarden bij  
patiënten met een HbA1c < 8.5%, terwijl nuchtere glucose spiegels het 
meeste bijdragen bij patiënten met een HbA1c > 8.5%.  
De berekeningen die deze conclusie ondersteunen werden alleen gebaseerd 
op AUC metingen verkregen van maaltijd-perioden, en dus hielden ze 
geen rekening met de bijdrage van blootstelling aan glucose buiten de 
maaltijden om aan het HbA1c.  
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Monnier definieerde postprandiale glycemie als de AUC boven ieders 
individuele nuchtere waarde, terwijl preprandiale glycemie werd 
gedefinieerd als de AUC tussen 6.1 mmol/l (110 mg/dl) en de gemeten 
nuchtere bloedglucose voor elk individue. Deze benadering introduceert 
bias wanneer de associatie tussen deze 2 indexen en HbA1c onderzocht 
wordt. Individuen met HbA1c waarden van 8.5% zullen sterk de neiging 
hebben om hogere nuchtere bloedglucose waarden te hebben. Hun 
postprandiale AUC waarden zullen daarom vals verlaagd zijn omdat alleen 
excursie boven deze hoge individuele nuchter waarden beschouwd worden 
als postprandiale glucose blootstelling. Tegelijkertijd verschaft Monnier’s 
definitie hogere preprandiale AUC in dezelfde groep, en dus introduceert 
hij hiermee het gerapporteerde effect. Dit methodologisch probleem zou 
kunnen verklaren waarom Monnier’s resultaten verschillen van onze 
bevindingen en van die van anderen.   
 
De vermeende rol van GV en postprandiale glucose als risicofactoren voor 
het ontwikkelen van diabetische complicaties zijn gebaseerd op 1) studies 
die een associatie rapporteren tussen buitensporige postprandiale glucose 
spiegels en factoren die zouden kunnen lijden tot de ontwikkeling van 
diabetische complicaties, 2) epidemiologische studies die glucosewaarden 
2 uur na een glucose belasting test associeerden met toegenomen 
mortaliteit en cardiovasculaire ziekten, en 3) een paar klinische studies in 
erg specifieke subgroepen (bijv. zwangere vrouwen en individuen met een 
verminderde glucose tolerantie of patiënten met T2DM na een 
doorgemaakt infarct), die het probleem hebben aangepakt met 
verschillende methoden en die tegenstrijdige resultaten hebben 
opgeleverd. De rol van postprandiale glucose en GV als risicofactoren 
moet verder onderzocht worden en inzicht in de verschillen en 
overeenkomsten tussen de verschillende metingen van postprandiale  
glucose, overall hyperglycemie en GV is belangrijk.  
 
Nuchtere bloedglucose spiegels waren alleen matig gecorreleerd met 
indexen van hyperglycemie en gemiddelde of postprandiale glucose 
spiegels. 
 
De glucose metingen in de ADAG studie waren intensief en niet bruikbaar 
in de dagelijkse praktijk. Metingen van nuchtere, goed getimede 
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postprandiale glucose waarden en HbA1c zijn veel makkelijker inzetbaar in 
de klinische praktijk.  
 
Sensor versus zelfgemeten bloedglucose waarden met de vingerprik 
Conventionele zelfgemeten bloedglucose waarden zijn goed bekend en 
worden regelmatig gebruikt door de meeste patiënten. Een continue 
registratie (sensor) heeft het voordeel van uitgebreide bloedglucose 
gegevens verzameling en heeft een duidelijke educatieve kracht, maar 
vereist ook aanzienlijke extra middelen, met name van personeel en door 
educatieve eisen. Dit maakt dat de sensor duurder is in het gebruik in de 
dagelijkse praktijk maar ook in een research setting. Deze extra middelen 
zouden kosten effectief kunnen zijn als een betere glycemische instelling 
het doel is, maar het gebruik van de sensor lijkt niet nodig te zijn om de 
mate van GV en postprandiale variabiliteit vast te stelen in situaties waar 
frequente zelf controle plaats kan vinden d.m.v. zelfgemeten bloedglucose.  
 
Beperkingen 
Het feit dat participanten een stabiel HbA1c (< 1% HbA1c verandering in de 
6 maanden voorafgaand aan de studie) hadden, zou geleid kunnen hebben 
tot een onderschatting van GV. Echter, er werden hoge waarden van GV 
gevonden ondanks stabiele waarden van HbA1c. Zelfs al hebben patiënten 
met T1DM en T2DM verschillende glucose patronen door een 
verschillende pathofysiologie, het mechanisme van glycering van 
hemoglobine is waarschijnlijk hetzelfde. Daarom hebben we de 
glycemische indexen berekend voor de gecombineerde groep.   
 
Conclusies 
Er wordt nog steeds gediscussieerd over het belang van glucose excursies 
en postprandiale glycemie in de dagelijkse controle van diabetes en risico 
management. Verschillende indices die op verschillende manieren 
gemeten en berekend zijn, correleren goed binnen elke categorie 
(variabiliteit, postprandiaal, gemiddelde indices). Variabiliteit indices 
correleerden zwak met de andere categorieën wat aangeeft dat deze maten 
andere informatie verschaffen. Echter, indices van postprandiale, 
gemiddelde “overall” hyperglycemie correleren matig tussen de 
categorieën. 
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Onze bevindingen bevestigen dat nuchtere glucose geen goede indicator is 
van algemene glycemie. Het gemiddelde van alle preprandiale waarden 
heeft een sterkere relatie met HbA1c, zowel bij patiënten met T1DM en 
T2DM, vergeleken met de postprandiaal glucose waarden. 
 
Glucose variabiliteit in de klinische praktijk  
Artsen moeten GV zowel kwalitatief als kwantitatief begrijpen en ernaar 
streven om de variabiliteit te verminderen voordat je probeert om het 
gemiddelde niveau van de bloedglucose te verlagen. Dit klinkt intuïtief 
logisch en kan wiskundig worden aangetoond. Als het gemiddelde 
glucosegehalte 5,6 mmol/L (100 mg/dl) is, maar de SD is 2,2 mmol/L (40 
mg/dL), dan kan men voorspellen dat er een onaanvaardbaar hoog aantal 
ernstige hypoglycemieen zou optreden, hoewel de gemiddelde glucose in 
het normale bereik ligt.  
 
Dit geldt voor bloedglucose zoals gemeten met zelfcontroles op de 
vingerprik, laboratorium metingen van veneuze monsters en interstitiële 
glucose zoals gemeten door de continue registratie. Bij de titratie van 
basale insuline, is het essentieel om de tussen- de dag (binnen-subject) 
variabiliteit te kennen van de nuchtere plasmaglucose om de streef 
glucosewaarde goed in te stellen zodat het risico op hypoglykemie 
aanvaardbaar is. Helaas zijn deze schattingen van GV zelden verkregen. 
GV dient ook als een facet van de kwaliteit van de glycemische controle, 
nog een reden om GV kwantificeren. Epidemiologische en preklinische 
studies suggereren dat GV bijdraagt aan het risico van complicaties bij 
diabetes. Deze hypothese blijft controversieel en zal een actief gebied van 
onderzoek blijven. 
 
De drie bovenstaande overwegingen, de eis van een goede controle, de 
wens om de kwaliteit van de glycemische controle te evalueren, en de 
plausibele link naar complicaties, vormen een belangrijke impuls om 
methode om GV te kwantificeren, te ontwikkelen, te testen en toe te 
passen. Om de arts te helpen bij de interpretatie van GV maten, moeten we 
''normaal waarden'' of ''referentie waarden'' hebben. Gegevens verkregen 
bij individuen zonder diabetes, zoals gerapporteerd door Mazze en Zhou, 
kunnen helpen bij het opzetten van een baseline. Echter, deze waarden 
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liggen zo ver van wat wordt waargenomen bij patiënten met diabetes dat 
zij slechts weinig relevant zijn. 
 
We moeten in staat zijn om de waargenomen variabiliteit te beoordelen in 
een grote populatie (of populaties) van de mensen met diabetes (T1DM en 
T2DM). Omdat de meeste maten van GV nauw verwant zijn aan 
gemiddelde glucose en HbA1c waarden, moeten criteria worden 
ontwikkeld voor meerdere ranges van de HbA1c-waarden. 
 
Verschillende groepen hebben computerprogramma's ontwikkeld om GV 
te berekenen. Deze omvatten methoden voor het berekenen van MAGE, 
software zogenaamde ''Gly-culator'' en spreadsheets om onder andere SD's 
te berekenen. Het doel was een standaardisatie te introduceren om daarmee 
het risico van fouten in de berekeningen te reduceren. 
 
Momenteel is er een overvloed aan maten van GV, en het aantal blijft 
groeien. We moeten ervoor zorgen dat deze parameters klinisch bruikbaar 
worden, door het verstrekken van referentiegebieden voor bepaalde 
categorieën patiënten (gedefinieerd door type diabetes, soort therapie, de 
mate van glycemische controle door de ''gouden standaard'' HbA1c). 
Datareductie moet volledig worden geautomatiseerd, of de glucose data nu 
worden gegenereerd uit zelfmetingen, continue glucose monitoring, of uit 
ziekenhuis-gebaseerde systemen.  
 
 
Real life glycemische profielen bij individuen zonder 
diabetes (Hoofdstuk 7)  
 
Glucose profielen verkregen bij gezonde personen onder real-life 
omstandigheden kunnen dienen als een benchmark voor studies bij 
patiënten met hyperglycemie. Het huidige begrip van normoglycemia is 
grotendeels gebaseerd op studies van populaties zonder diabetes, met een 
beperkt aantal glucose metingen per individu in experimentele 
omstandigheden. Real-life glycemische profielen van gezonde individuen 
zijn niet direct beschikbaar. 
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In de ADAG studie werden real-life glycemische profielen verkregen, 
waaronder postprandiale glucose waarden van 80 personen zonder 
diabetes. Het doel was om inzicht te krijgen in glycemische variabiliteit bij 
individuen zonder diabetes en om te onderzoeken of orale glucose 
tolerantie test (OGTT) drempels voor verminderde glucosetolerantie (IGT) 
en diabetes in het echte leven werden overschreden. De mediane tijd van 
de continue glucose monitoring (over een periode van 3 maanden) was 
230 uur per persoon. Dit bood gedetailleerde informatie over glucose 
profielen onder reële omstandigheden, verschillende mogelijkheden om 
postprandiale glucose te definiëren, en voldoende metingen voor het 
betrouwbaar beoordelen van kenmerken van GV (SD). 
 
We vonden dat bijna alle personen (93%) zonder diabetes de IGT drempel 
van 7,8 mmol/l op een bepaald punt van de dag overschreden en zij 
brachten een mediaan van 26 minuten (range 0 min - 6 uur 52 min) per 
dag boven dit niveau door. Acht personen (10%) verbleven al meer dan 2 
uur in het IGT bereik. Een op de tien bereikte glucose spiegels van (11,1 
mmol/l) wat diagnostisch is voor het stellen van de diagnose diabetes. 
Deze bevindingen suggereren dat glucosespiegels bij personen zonder 
diabetes vaak in het IGT bereik zitten en dat een aanzienlijk deel op nog 
hogere niveaus komt.  
 
Dit wijst erop dat, hoewel de gecontroleerde individuen zonder diabetes in 
de ADAG studie, geselecteerd op basis van een zeer lage nuchtere bloed 
glucose, een deel van de blootstelling aan matig verhoogde 
glucosewaarden uit het zicht bleef, toen we individuen classificeerden op 
basis op geïsoleerde glucose metingen en HbA1c. Eerdere kleinere studies 
suggereren vergelijkbare patronen, zij het in meer homogene populaties. 
 
Glucose en HbA1c-waarden van personen zonder diabetes en patiënten met 
verminderde glucose tolerantie of diabetes zijn onderdeel van een 
continuüm, er zijn geen strikte afkappunten, maar het is een glijdende 
schaal. 
 
Tijdens een gestandaardiseerde glucose belasting test (OGTT) is het 
bekend dat glucose waarden de concentratie van 7,8 mmol/l kunnen 
overschrijden bij personen met een normale glucosetolerantie. Echter, 
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aangezien de 75g glucose bij de OGTT een extreem vloeibare glucose 
belasting is in vergelijking met een gemiddelde gemengde maaltijd, vinden 
we dat onze resultaten op basis van real-life monitoring belangrijke 
aanvullende informatie oplevert.  
 
Beperkingen 
Een beperking van de ADAG studie bij het onderzoeken van individuen 
zonder diabetes is de afwezigheid van OGTTs bij de screening om 
diabetes met zekerheid uit te sluiten of patiënten te classificeren als het 
hebben van verminderde glucose tolerantie. Echter, ons exclusie criterium 
van een nuchtere glucose <5,4 mmol/l is zeer specifiek voor het uitsluiten 
van diabetes. 
 
Bovendien werd het exclusie criterium van een HbA1c >6,5% in de ADAG 
studie recent voorgesteld als nieuw diagnosticum voor diabetes. Het  
gemiddelde HbA1c voor individuen zonder DM in onze studie was 
aanzienlijk lager: 5,2% (SD 0.3). Bovendien zou het interessant geweest 
zijn om de oorzaken van glucose schommelingen te analyseren, dit hebben 
we echter niet gedaan. 
 
 
HbA1c en gemiddelde bloedglucose tonen sterkere 
associaties met risicofactoren voor hart- en vaatziekten 
dan postprandiale glycemie of glucose variabiliteit bij 
patiënten met diabetes (Hoofdstuk 8) 
 
Beoordeling van de blootstelling aan glucose 
Gesuggereerd werd dat verhoogde glucose excursies en postprandiale 
hyperglycemie unieke risicofactoren zijn van cardiovasculaire ziekten 
(CVD) en mortaliteit bij patiënten met diabetes mellitus. Een groot deel 
van het bewijs is gebaseerd op een 2-uur glucose waarde na orale 
glucosetolerantietest in epidemiologische studies. Behandelingsschema's 
en richtlijnen focussen steeds meer op postprandiale glucose controle als 
extra doel naast de gemiddelde glucose controle. 
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Echter, direct bewijs voor een extra effect van het reguleren van 
postprandiale glucose - bovenop het effect van lagere gemiddelde 
glucosewaarden - op relevante diabetische eindpunten is beperkt. 
Slechts enkele studies hebben deze hypothese direct getest of vergeleken 
naast het effect met dat van de totale blootstelling aan glucose (HbA1c) en 
hebben aangetoond dat postprandiale glucose spiegels en/of GV 
onafhankelijke mechanismen zijn. Een enkele gerandomiseerde studie 
vergeleek de effecten van twee insulinesecretagogen met verschillende 
effecten op postprandiale glucose, en hebben gevonden dat de controle van 
postprandiale hyperglycemie tot een vermindering van intima-media dikte 
bij patiënten met T2DM leidt in vergelijking met de controlegroep. 
Therapie die leidt tot lagere postprandiale glucose spiegels werd 
geassocieerd met significante reducties in de concentraties van de 
ontstekingsfactoren IL6 en hs-CRP. Een recente gerandomiseerde 
klinische studie bij patiënten met T2DM en CVD was geen voorstander 
van een extra voordeel van het mikken op controle van postprandiale 
glucose op latere CVD events. Echter, in deze studie zou het verschil het 
tussen de 2 postprandiale glucose interventie groepen te klein kunnen zijn 
om dit effect aan te tonen. 
 
We onderzochten de associatie tussen de verschillende indices van  
glycemie gemeten tijdens elke-dag-activiteiten en metabole CVD 
risicofactoren (lipiden, hs-C-reactief proteïne, bloeddruk). Om de 
risicofactoren van hart- en vaatziekten te correleren aan de blootstelling 
aan glucose, moesten we categorieën van algemeen gebruikte indices van 
glycemische variabiliteit, gemiddelde en postprandiale glycemie 
definiëren. Zoals we verwacht hadden, bleek uit onze analyse dat veel van 
deze glycemische indices sterk gecorreleerd waren binnen elke categorie. 
In onze studie toonden indices van GV geen significante associaties met 
cardiovasculaire risicofactoren. GV en postprandiale hyperglycemie waren 
niet sterker geassocieerd met bekende metabole CVD risicofactoren dan de 
maten van de gemiddelde glucose. Dit suggereert dat de impact van 
postprandiale glucose op cardiovasculair risico waarschijnlijk gevangen 
wordt door de bepaling van de gemiddelde bloedglucose of HbA1c. 
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Verschillende epidemiologische studies die een verband tussen post-
OGTT hyperglycemie en verhoogde CVD en mortaliteit aantonen, hebben 
geen rekening gehouden met een gemiddelde glucose meting (bijvoorbeeld 
door HbA1c). Bovendien, de grondige meting van glycemie onder reële 
omstandigheden in de ADAG studie geeft een betrouwbaardere index van 
dag tot dag blootstelling dan de gebruikelijke eenmalige meting van 
glucose spiegels na een OGTT. Bovendien liet intensieve glucose 
monitoring met diverse methodes het toe om op verschillende manieren 
postprandiale glucose te definiëren en leverde het voldoende metingen op 
om de verschillende functies van glycemie zoals GV betrouwbaar te 
beoordelen. 
Van GV is het niet aangetoond dat het geassocieerd is met het ontwikkelen 
van complicaties in T1DM. In de DCCT bleek GV (van zeven punt 
glucose dag curve) geen factor te zijn in het ontwikkelen van micro-
vasculaire complicaties en pre- en postprandiale glucose waarden droegen 
evenveel bij aan complicaties van de kleine vaten. 
Het CVD risicofactoren die we hebben gekozen, zijn goed gevalideerde of 
"traditionele" risicofactoren van hart en vaat ziekten (lipiden en de 
bloeddruk) en een indicator van low-grade ontsteking (hs-CRP). We 
hebben nagedacht over de mogelijke impact van de behandeling door het 
verlagen van deze risicofactoren op onze bevindingen.  Het uitsluiten van 
deelnemers met lipiden verlagende of anti-hypertensie behandeling, 
veranderde de resultaten niet wezenlijk.  
 
De associaties tussen de berekende glycemische indexen en CVD 
risicofactoren werden onderzocht in individuele lineaire regressiemodellen 
gecorrigeerd voor leeftijd, geslacht, en het type diabetes. We overwogen 
het gebruik van multivariate modellen, die zowel gemiddelde als 
postprandiale glycemie bevatten. We kozen dit model niet omdat 
gemiddelde bloedglucose en HbA1c nauw verwant zijn aan de maaltijd 
gerelateerde glucose waarden en bij dergelijke analyses zouden kleine 
schommelingen te grote invloed hebben 
 
Om een vergelijking van de associaties te vergemakkelijken, werden 
potentieel verklarende glycemische variabelen gestandaardiseerd in de 
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studie populatie standaarddeviatie (SD). Omdat onze data cross-sectioneel 
zijn en wij geen informatie over CVD uitkomsten hebben, hebben wij 
rekening gehouden met manieren om het risico van hart- en vaatziekten te 
schatten als een continue uitkomst. Een gerenommeerde, reproduceerbare 
risicoscore zoals de UKPDS risicoscore zou een manier geweest zijn om 
dit te doen. Aangezien geen gegevens over boezemfibrilleren en 
diabetesduur  beschikbaar waren, beide factoren zijn opgenomen in de 
UKPDS risico score, kon dit risicoanalyse instrument niet worden 
gebruikt. Daarom werd een gecombineerde Z-score berekend uit de 
gestandaardiseerde cardiovasculaire risicofactoren. Deze Z-score is 
gebaseerd op de verdeling in de huidige studie populatie 
(gestandaardiseerd door SD), daarom zijn de resultaten niet vergelijkbaar 
met andere populaties. Echter, het gebruik van deze score gaf ons een 
index voor een gecombineerd cardiovasculaire risico voor elk individu. 
 
Onze resultaten ondersteunen niet een unieke rol van postprandiale 
hyperglycemie in cardiovasculaire ziekten. Monitoring van postprandiale 
glucose en GV kan belangrijk zijn bij het aanpassen van de behandeling 
om goede glycemische controle te bereiken en dagelijkse excursies 
waaronder hypoglykemie te voorkomen, maar onze resultaten suggereren 
dat interventies om het risico op cardiovasculaire ziekten te verminderen, 
het beste zijn gericht op het beheersen van gemiddelde glucose en HbA1c. 
 
Beperkingen 
De belangrijkste beperking van de studie in deze context is het cross-
sectionele karakter. Hoewel het een zeer hoge resolutie heeft, is de glucose 
controle op korte termijn, en zijn de uitkomsten cardiovasculaire ziekten 
risicofactoren in plaats van werkelijke gebeurtenissen van cardiovasculaire 
ziekten. Daarom kan deze studie geen directe conclusies trekken over de 
impact van postprandiale glucose spiegels of GV op cardiovasculaire 
eindpunten. Echter, onze resultaten wijzen erop dat indien er een 
dergelijke effect bestaat, het onwaarschijnlijk is dat het gemedieerd wordt 
door mechanismen (risicofactoren) onderzocht in onze studie. 
Bovendien hadden de deelnemers een stabiel HbA1c bij aanvang 
(gedefinieerd als <1% verandering in HbA1c tijdens de 6 maanden 
voorafgaand aan het onderzoek), en relatief stabiel tijdens het onderzoek. 
Hierdoor zou GV beperkt geweest kunnen zijn bij de patiënten met 
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diabetes. Echter, hoge waarden van GV werden gezien bij onze mensen 
ondanks stabiele HbA1c waarden. 
 
 
Conclusies 
Gemiddelde glycemie en HbA1c tonen consistente associaties met 
risicofactoren voor hart- en vaatziekten op een sterker niveau dan nuchtere 
glucose en de meeste maten van postprandiale glucose en GV. In onze 
studie, kunnen de eerder waargenomen associaties tussen GV en 
postprandiale glucose en gebeurtenissen van hart- en vaatziekten niet 
worden verklaard door een associatie met bekende metabole risicofactoren 
voor hart- en vaat ziekten. 
 
 
Toekomstperspectieven 
 
Het NGSP certificatie proces zal zorgen voor standaardisatie en het IFCC 
Laboratorium Netwerk zal blijven dienen als een tweede anker voor de 
NGSP. De rapportage van HbA1c testresultaten aan artsen, patiënten en in 
de wetenschappelijke literatuur zal echter variëren tussen landen en 
regio's. Wetenschappelijke rapportage zal geleidelijk veranderen in de SI-
eenheden (mmol/mol), terwijl artsen en patiënten DCCT of geschatte 
gemiddelde glucose waarden zullen blijven gebruiken. 
 
HbA1c zal steeds meer worden gebruikt voor diagnostische doeleinden en 
in de eerste lijn en in de opkomende landen. Deze toegenomen vraag heeft 
geleid tot een grotere vraag naar nieuwe en goedkopere HbA1c 
testsystemen. Deze hogere kosten, in vergelijking met de glucose test, 
strepen weg tegen gebruiksgemak (geen vasten vereist) en mogelijk minder 
personele kosten als de glucose tolerantie test niet nodig zal zijn. 
 
Glucose variabiliteit zal de aandacht van diabetes onderzoekers blijven 
vragen. De vragen die moeten worden aangepakt zijn onder meer: wat is 
de beste maatstaf van glucose variabiliteit in het dagelijks leven? Hoe GV 
te definiëren voor verschillende patiëntengroepen en voor verschillende 
niveaus van de glycemische controle? Hoe dit te implementeren in de 
Nederlandse Samenvatting  
 
 245 
dagelijkse klinische praktijk? Nieuwe technologie voor continue glucose 
monitoring hebben geleid tot de beschikbaarheid van grote aantallen 
bloedglucosewaarden. Nu hebben we software nodig om klinisch 
betekenisvolle, dat wil zeggen bruikbare informatie te extraheren uit deze 
rijke databronnen. 
 
Een andere gebied van aandacht blijft de rol van glucose variabiliteit en 
oxidatieve stress, en de vermoedelijke relatie met de ontwikkeling van 
diabetes gerelateerde complicaties. Een beter begrip van de rol van 
oxidatieve stress en geavanceerde glycerings eindproducten (AGE) in de 
pathofysiologie van complicaties moet worden verkregen. De nadruk zal 
verschuiven van postprandiale glucose naar alle aspecten van glucose 
variabiliteit. 
 
1.5AG werd gepropageerd als klinisch relevante informatie voor 
patiënten. Nieuwe assay systemen zullen ontwikkeld worden voor 
thuisgebruik. Dit zal patiënten hopelijk ondersteunen om een stabielere 
glycemische controle te bereiken en een goede controle te houden. Dit 
moet in goed gecontroleerde studies worden vastgesteld. 
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Conclusies 
 
De algemene conclusies van dit proefschrift zijn: 
 
De ADAG studie toonde een eenvoudige lineaire relatie tussen 
gemiddelde glucose en HbA1c in een klinisch relevante bereik van glucose 
controle bij patiënten met T1DM en T2DM. Factoren die van invloed zijn 
op deze relatie zijn; ras/etniciteit, roken, hoge glucose variabiliteit, 
veranderde erythropoiese, veranderde erytrocyten levensduur, 
zwangerschap, nierfalen, bloeding, bloedtransfusie en 
hemoglobinopathieën. 
 
HbA1c kan in een geschatte gemiddelde bloedglucose worden 
weergegeven met een standaarddeviatie van 0,87 mmol/l. Het wereldwijde 
gebruik van geschatte gemiddelde bloedglucose in de klinische praktijk is 
mislukt. 
 
De wereldwijde standaardisatie hoe HbA1c testresultaten te rapporteren is 
niet succesvol gebleken. De vergelijkbaarheid van de wereldwijde test is 
verbeterd, maar de rapportage en interpretatie van HbA1c in klinische 
gegevens en onderzoeksresultaten op het gebied van diabetes wereldwijd 
is ingewikkelder geworden. 
 
We vonden dat alle glucose variabiliteit maten bescheiden, maar 
significante, invloed hebben op de MBG-HbA1c relatie. 
 
Hogere glucose variabiliteit werd geassocieerd met hogere HGI. Maten 
van glucose variabiliteit (SD, MAGE en CONGA4) en fructosamine zijn 
sterk gecorreleerd met HGI en hoge outlier-status. 
 
De glucose variabiliteit maat SD en roken verklaarden de grootste fractie 
van uitschieter status voor de hoge uitschieters. Deze variabelen samen 
verklaren slechts ongeveer 13% van de variantie in de gemiddelde 
bloedglucose-HbA1c relatie. 
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1,5AG zou naast HbA1c glucose variabiliteit en postprandiale 
hyperglycemie kunnen identificeren, vooral bij matig gecontroleerde 
diabetes patiënten. 
 
In het algemeen waren berekeningen op basis van de continue glucose 
registratie niet meer informatief dan op basis van frequente zelfgemeten 7-
punt dag curve. 
 
Indices van glucose variabiliteit correleren niet sterk met indices van 
nuchtere, postprandiallle of totale hyperglycemie. 
 
Het gemiddelde van alle pre-prandiale glucosewaarden had een grotere 
impact op HbA1c dan postprandiale glucosewaarden bij patiënten met 
T1DM en T2DM. 
 
Personen zonder diabetes zitten onder real-life omstandigheden een 
aanzienlijke hoeveelheid van de tijd met hun bloedsuikerspiegels op 
waarden geclassificeerd als 'pre diabetes' of zelfs diabetes. 
 
Bij patiënten met diabetes tonen gemiddelde glycemie en HbA1c een 
sterkere en consistentere associatie met risicofactoren voor hart- en 
vaatziekten dan nuchtere glucose of postprandiale glucosewaarden of 
maten van glucose variabiliteit. 
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Dankwoord 
 
Ik ben me ervan bewust dat zonder de steun en medewerking van vele 
mensen dit proefschrift niet tot stand had kunnen komen. Een aantal 
mensen in het bijzonder wil ik graag persoonlijk bedanken. 
 
Mijn promotoren prof.dr. R.J. Heine en prof.dr. M. Diamant. Beste Rob, 
hoezo major life events? In de afgelopen jaren hebben wij samen meerdere 
life-events het hoofd weten te bieden. Het houdt je wel jong, scherp en 
draagt bij aan je ontwikkeling! Wat ben ik blij dat ik voor jou heb mogen 
werken. Jij hield altijd de hoofdlijnen in de gaten en gaf altijd positieve 
feedback. Altijd een supersnelle correctie van een manuscript en een 
efficiënte bespreking waardoor ik weer weken vooruit kon met mijn 
project. Zelfs toen de afstand letterlijk groot geworden was tussen ons, 
was je toch ook weer heel dichtbij en betrokken zowel bij mijn proefschrift 
als bij mij als persoon en privé. In Lissabon zei ik gekscherend tegen jou 
dat ik dan wel graag jouw laatste promovenda wilde zijn, toch wel iets 
speciaals, maar dat raadde je me af, omdat mijn tegenkandidaat ook zo 
geheel zijn eigen tempo trok. Dankzij jouw positieve en stimulerende 
begeleiding is me dat op de valreep toch nog gelukt! Bedankt voor alles! 
Prof.dr. M. Diamant, beste Michaela, wat ben jij toch een bijzonder mens. 
Toen Rob naar Amerika vertrokken was sprong jij moeiteloos op de 
rijdende trein, maar ook toen deze trein wel erg lang op verschillende 
perrons stil was komen te staan en behoorlijk wat vertraging opliep was jij 
degene die hem weer aan het rijden kreeg. Ik heb veel bewondering voor 
jouw werk en kwaliteiten en ben dankbaar dat ik voor je heb mogen 
werken en voor alles wat je voor me gedaan hebt.  
 
Prof. dr. D. Nathan, dear David, thank you very much that you wanted to 
be study chair together with Rob for the ADAG study. Thank you very 
much for all the revisions of manuscripts and your support at the 
symposium at the EASD in Amsterdam. 
 
De leden van de lees c.q. promotie commissie: Dr. ir. R.J. Slingerland 
(Isala Klinieken), Dr. P.H. Geelhoed-Duijvestijn (Medisch Centrum 
Haaglanden), prof.dr. B.H.R. Wolffenbuttel (UMCG), prof.dr. M.A. 
Blankenstein (VUmc), prof.dr. H.J.G. Bilo (UMCG en Isala Klinieken), 
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Dr. E.H. Serne (VUmc), prof.dr. J.B.L. Hoekstra (AMC) veel dank voor 
het bestuderen van mijn proefschrift. 
 
Mijn opleiders, dr. J.J.M. van Meyel, prof.dr. J.M. van der Meer, prof.dr. 
C.D.A. Steehouwer, prof.dr. S. Danner, prof.dr. M. Kramer, prof.dr. C. 
Netelenbos, prof.dr. P. Lips, allen hartelijk dank voor alles wat ik in de 
loop der jaren geleerd heb. 
 
Mijn studie begeleider dr. S. Simsek, beste Suat, onze samenwerking was 
van korte duur, maar niet minder bijzonder. We hebben vele uren samen 
steriel gestaan en pompen gespoeld en weer gevuld. Als het vullen van de 
pomp niet lukte dan had jij een oplossing en als jij even uit je concentratie 
was dan had ik de 8 pagina’s lange handleiding paraat voor de volgende 
stap. Uiteindelijk bleek jij mijn concurrent bij de sollicitatie procedure in 
Alkmaar, maar ik denk dat we beide op onze plek terecht zijn gekomen. 
 
Dear Rikke, in a very early timeframe you and Charlotte came to 
Amsterdam to meet and  discuss the study protocol and to collaborate. 
From the beginning we had a good contact and yes we collaborated! I was 
quite busy with the bloodsamples and the barcode for these samples. At 
the start of the inclusion period you were the leading person as I was at 
home confronted with a major life-event. To handle the glucose values 
measured with the CGMS and to calculate the glucose variability 
parameters we had a lot of support from Bendix. During the rest of this 
project we met often at congresses, to do rehearsals and to support each 
other with oral presentations en poster presentations, we organised study 
meetings, had to sign agreements and you came several times to 
Amsterdam (EASD 2007). Furthermore I enjoyed the meetings in 
Copenhagen (EASD 2006) and at the Steno Diabetes Center very much 
(specially the very healthy and fresh lunches!). Thanks for meeting you, 
your support and everything else. 
 
Lieve Ada, wat hebben wij veel lief en leed gedeeld samen, en wat hebben 
wij prettig samen gewerkt, ik heb ook veel praktische dingen van je 
geleerd. Je ging zelfs mee op congres naar München voor de gezelligheid 
en mental support. Eigenlijk hadden we Kaapstad op de agenda gezet maar 
ja toen hadden we nog niet genoeg data te presenteren. We hebben tot op 
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de dag van vandaag nog steeds leuk contact, ook al zien we elkaar minder 
vaak. Elk jaar verheug ik me er weer op als je bij ons langs komt in de 
caravan tijdens de vakantie op het strand in Egmond aan Zee. Hopelijk zie 
ik je volgend seizoen daar weer en zo niet dan organiseren we gewoon iets 
anders. 
 
Beste Kor, Erna en Robbert. Zonder de HbA1c bepalingen gedaan in jullie 
laboratorium in Zwolle, zou deze studie niet geslaagd zijn. Wat een hoop 
monsters allen voorzien van een barcode moesten verscheept worden naar 
jullie lab, daarnaast werd uit elk monster op 4 verschillende apparaten een 
HbA1c gemeten. Erna jij haalde direct de verouderde monsters van een 
Indiaas studie center eruit. Inmiddels is Kor met pensioen, is Erna als 
laborant ook al gepromoveerd op HbA1c (ontzettend knap van je!) en kom 
ik Robbert op 30 september weer tegen! 
 
Beste kamergenoten, ooit met Pim in ‘de kelder’ begonnen, jij was in mijn 
ogen een heel ervaren dokter en bovendien reeds gepromoveerd! De kelder 
is inmiddels allang gesloopt en jij bent alweer weg uit het VU medisch 
centrum. Daarna naar de 7de verdieping op de poli samen met alle andere 
die ook Endocrinoloog wilde worden, zoals Eric Duschek, Marieke van 
Es, Boris Kanen, Sofie Mijnhout, en later Noortje Rabelink, Elin Seebus 
en Richard IJzerman. Sofie jij zei wel eens tegen mij dat ik net een 
secretaresse leek als ik de gehele vloeroppervlakte van de kamer nodig had 
om alle uitgeprinte lab etiketten, elk met een unieke barcode, voor alle 
bloedmonsters van alle studie centra, moest ordenen en opsturen. Ik heb 
echter nog nooit een secretaresse met haar post op de grond zien zitten! 
 
Beste medepromovendi, en dat waren er heel veel. Mathijs Bunck, Luuk 
Rijzewijk, Maarten Tushuizen, Eelco van Duinkerken, Nynke van der Zijl, 
Sigridur, Larissa van Goolen, Daniel van Raalte, Mariska van Vliet, 
Renate van Genugten, Aletta Wessels. Soms ben ik wel eens jaloers op 
jullie geweest dat jullie 5 dagen van de week met jullie proefschrift bezig 
konden zijn, zonder afgeleid te worden door een opleiding of parttime 
baan daarnaast, zonder het runnen van een gezin. Een aantal van jullie 
heeft net als ik in het laatste traject van de promotie kinderen gekregen en 
of een nieuwe baan aanvaard. Ik heb stuk voor stuk bewondering voor 
jullie en jullie mooie “boekjes”. Even apart wil ik stilstaan bij Annemarie 
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Simonis, oud kamergenoot en als kinderarts bijna aan het eind van haar 
carrière nog even gepromoveerd op de tweeling studie! We hebben veel 
ervaringen zowel privé als proefschrift gerelateerd gedeeld, en we delen 
bovendien het uit zijn kluiten gewassen dorp waar we nu beiden wonen. Ik 
zag jou gemiddeld 1 a 2 keer per week op onze kamer er viel dan altijd 
veel bij te praten, je onderzoek kostte veel tijd en je proefschrift vorderde 
langzaam maar ineens was het klaar. Dank voor alles wat we samen 
hebben gedeeld en ik kom binnenkort weer eens een bakkie bij je doen! 
 
Beste Joop en Piet, wat is statistiek toch een moeilijk vak, zonder jullie 
geduldige uitleg, volgeschreven side boards en adviezen en hulp zou het 
nooit gelukt zijn. Helaas kwam ik Piet en zijn vrouw Jenneke destijds 
bijna wekelijks tegen in de poligangen van het VUmc. Joop heb ik zelfs na 
zijn pensioen nog gestalkt met statistiek vragen  om artikelen gepubliceerd 
te krijgen. 
 
De mensen van het lab. Beste Babs, dank voor de snelle en degelijke hulp 
van jou en het lab om alle 1,5AG bepalingen voor deze studie te doen. 
Ook dank aan jou supervisors Rien Blankenstein en Anneke Bouman, die 
dit project hebben gesteund. Het was voor jou een project om deze 
bepaling in het lab op te zetten, maar naar ik heb begrepen moest je de 
leverancier ook nog het een en ander hierover uitleggen. 
 
Beste “maten” bedankt dat jullie wel vertrouwen in mij hadden als jonge 
klare in de maatschap. In Alkmaar dorsten ze het niet aan met mij als 
alleenstaande moeder. Gelukkig maar want ik voel me helemaal op mijn 
plek bij jullie in het Apeldoornse. Bedankt ook dat jullie mij in de 
gelegenheid hebben gesteld om mijn proefschrift af te kunnen ronden, 
naast het opstarten van een drukke perifere praktijk en alle ballen in de 
lucht te kunnen houden ook in het laatste traject van mijn proefschrift! 
 
Lieve Ma (en ook nog steeds een beetje Pa) wat hebben jullie ons altijd 
gesteund in onze ontwikkeling, of het nu ging om opleiding, sporten of 
wat dan ook. Helaas heeft Pa vanaf mijn VWO diploma dit allemaal niet 
meer mee mogen maken. Toch denk ik dat hij de laatste bijna 30 jaar af en 
toe vanaf boven op zijn gemak en op afstand heeft gevolgd en ik weet 
zeker dat hij zonder meer heel trots zou zijn geweest op zijn kinderen. Wat 
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er uiteindelijk van ons terecht is gekomen is dus grotendeels aan jou te 
danken Ma. Bedankt voor al je steun in zowel goede als minder goede 
tijden. Wanneer gaan we weer shoppen? 
 
Lieve Robin en Frederique, Bart en Carolien. Jullie leven zo bewust. 
Super! Het leven hangt aan een zijden draadje, dat hebben jullie aan den 
lijve ondervonden Bart en Carolien. Gelukkig ben je er goed doorheen 
gekomen en gaat het inmiddels weer goed met je Carolien. Geniet van 
elkaar, van jullie kids en het gezin. Helaas zien we elkaar iets minder 
frequent maar het contact is er niet minder goed om. Bedankt dat jullie 
altijd voor me klaar staan. 
 
Lieve Job, Olivier en Jytte, promoveren is zwaarder dan 3 kinderen op de 
wereld zetten! Maar wat zou ik zonder jullie moeten? Het is een hele 
verantwoordelijkheid maar ook een leuke uitdaging om jullie op te voeden 
tot een paar evenwichtige, gelukkige en ontwikkelde mensen, zeker als je 
af en toe het gevoel hebt er alleen voor te staan. Naast een drukke baan is 
het soms moeilijk om voldoende tijd en aandacht voor jullie te vinden. 
Alle ballen in de lucht houden is geen gemakkelijke opgaaf, helaas voor 
jullie is een bal kapot gevallen en toch gaat het leven in een andere vorm 
gewoon door. De bal dyslexie (soms denk ik dat jullie het van mij hebben) 
is ook voor jullie Job en Olivier een zware bal om in de lucht te houden. 
Maar zoals dit boekje laat zien geldt nog altijd de aanhouder wint, en ik 
weet zeker dat deze vlieger ook voor jullie opgaat!  
 
Dear Yannick, thanks for your never ending support, the positive input 
you give to our family, the way you help me to raise my kids, the nice 
lunches and the nice dinner you make for us (or do I have to say 
desserts?). Without your support I could not do my job nor finishing my 
PhD. I am so sorry to say that I was not alway’s connected that well the 
last very busy period, but I hope to find more time now! Thank you very 
much and I hope you would like to stay a bit longer with us! 
 
Verder dank aan alle andere die ik hier niet heb genoemd, met name aan 
de patiënten en gezonde vrijwilligers die mee hebben gedaan aan deze 
studie. Als ik dan toch nog iemand vergeten ben dan komt dat omdat ik dit 
dankwoord op een zondag s’ nachts om 01.30 uur geschreven heb!
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Curriculum Vitae 
 
De auteur van dit proefschrift werd geboren op 17 mei 1966 te 
Amsterdam. In 1984 behaalde zij het VWO diploma aan het 
Haarlemmermeer Lyceum te Badhoevedorp. In dat zelfde jaar begon zij 
aan de opleiding Fysiotherapie aan de Stichting Academie Fysiotherapie 
Amsterdam en studeerde in 1989 af.  
Na 4 keer uitgeloot te zijn voor Medicijnen, lootte zij eindelijk in 1988 in 
voor de studie Geneeskunde aan de Universiteit van Amsterdam. In 1992 
werd het doctoraal- en in 1995 het artsexamen afgelegd. Van mei 1995 tot 
januari 1997 werkte zij als AGNIO Interne Geneeskunde in Ziekenhuis 
Hilversum (dr. F. van Kersen). Van 1997 tot 2000 volgde zij de opleiding 
tot Internist in het Lucas Andreas Ziekenhuis te Amsterdam (opleider dr. 
J.J.M. van Meyel). Vanaf 2000 tot 2003 werkte zij in het Vrije Universiteit 
Medisch Centrum (opleiders prof. dr. J.M. van der Meer en prof. dr. 
C.D.A. Steehouwer, prof. dr. S. Danner) en in oktober 2003 behaalde zij 
haar Internisten diploma. Van oktober 2003 tot jan 2005 werkte zij op de 
afdeling Diabetologie onder prof. R.J. Heine aan haar promotieonderzoek 
met als onderwerp: A randomized clinical trial to assess efficacy, cost-
effectiveness and impact on quality of life of continuous intraperitoneal 
insulin infusion versus intensive insulin therapy in poorly controlled type 1 
diabetes patients. Tijdens dit onderzoek werd helaas de productie van de 
implanteerbare pomp tijdelijk stop gezet. In deze periode werd met spoed 
een onderzoeks protocol geschreven worden over de relatie van HbA1c met 
de gemiddelde bloedsuiker ivm met de wereldwijde invoering van de 
nieuwe IFCC-HbA1c meetmethode. Hiermee was in 2006 een aanzet tot 
het huidige proefschrift ontstaan. Later bleek de productie van de  
implanteerbare pomp helemaal stop gezet te worden i.v.m hoge productie 
kosten en een fusie binnen het bedrijf. 
De afronding van de opleiding Endocrinologie (opleiders prof dr. C. 
Netelenbos en prof. dr. P.T.A. Lips) vond plaats in november 2006. 
Sindsdien is zij verbonden gebleven aan de afdeling 
Endocrinologie/Diabetologie in het VUmc tot medio 2009. In deze periode 
heeft de promovenda naast wetenschappelijk onderzoek gewerkt voor het 
college ter beoordeling van geneesmiddelen. Tijdens het promotie traject 
aanvaardde haar promotor prof. dr. R.J. Heine een baan in de Verenigde 
Staten, via email contact en teleconferentie bleef hij de sturende en 
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drijfende kracht voor dit promotieonderzoek. In deze periode werd prof. 
dr. M. Diamant intensief betrokken bij dit promotieonderzoek en heeft zij 
een beslissende rol gespeeld in het afronden van dit proefschrift. Tijdens 
het hele traject heeft de promovenda in augustus 2009 een baan als 
Internist in een perifere maatschap aanvaard en is zij tegenwoordig 
werkzaam als Internist-Endocrinoloog in de maatschap van het Gelre 
Ziekenhuis in Apeldoorn. 
Naast deze activiteiten heeft de auteur van dit proefschrift  samen met 
Marcel van der Meulen het gedeelde ouderschap over hun drie kinderen; 
Job (1999), Olivier (2001) en Jytte (2003). 
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Abbreviations 
 
α  alfa  
AACC  American Association for Clinical Chemistry 
ADA  American Diabetes Association 
ADAG  A1c derived Average Glucose 
APO  Apolipoproteine 
AUC  Area Under the Curve 
AUC >180  Area Under the Curve above 180 mg/dl 
AUCpp  Area Under the Curve post prandial 
β  beta 
BG  Blood Glucose 
BMI  Body Mass Index 
BV  Biological Variation 
CGM  Continuous Glucose Monitoring 
CGMS  Continuous Glucose Monitoring System 
CI  Confidence Interval 
CONGA Continuous Net Glycemic Action 
CV  Coefficient of Variation 
CVD  Cardio Vascular Disease 
DCCT  Diabetes Control And Complications Trial 
DCMs  Designated Comparison Methods 
DNA  DeoxyNucleosisAcid 
DM  Diabetes Mellites 
eAG  estimated Average Glucose 
EASD  European Association for the Study of Diabetes 
EDIC Epidemiology of Diabetes Interventions and 
Complications 
FBG  Fasting Blood Glucose 
FDA  Food and Drug Administration 
FPG  Fasting Plasma Glucose 
GHb  Glycohemoglobin 
GLUT-1 Glucose Transporter-1 
GV  Glucose Variability 
Hb  Hemoglobin 
HbA  Hemoglobin A 
HbA1c   Hemoglobin A1c  
HGI  Hemoglobin Glycation Index 
HPLC  High Performance Liquid Chromatografie 
IDF  International Diabetes Federation 
IFCC  International Federation of Clinical Chemistry 
IGT  Impaired Glucose Tolerance 
ISPAD International Society Pedriatic and Adolescent Diabetes 
LDL  Low Density Lipoproteine 
MAGE  Magnitude of Average Glucose Excursions 
Max  Maximum 
MBG  Mean Blood Glucose 
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Min   Minimum 
n  number 
Neg  Negative 
NGSP  National Glycohemoglobin Standardization Program 
NCCLP  National Committee for Clinical Laboratory Standards 
OGTT  Oral Glucose Tolerance Test 
Pos  Positive 
PPG  Post Prandial Glucose 
ROC  Receiver Operating Curve 
ROS  Reactive Oxygen Species 
SD  Standard Deviation 
SE  Standard deviation of the Error 
Sig  Significant 
SMBG  Self Monitoring Blood Glucose 
T1DM  Type 1 diabetes mellites 
T2DM  Type 2 diabetes mellites 
UKPDS United Kingdom Prospective Diabetes Study 
U.S.  United States 
1,5AG  1,5 AnhydroGlucitol 
 
 
